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ABSTRACT	
The key role of p53 as a tumour suppressor is widely acknowledged and based on many 
observa-ons that p53 suppresses oncogene-mediated transforma-on of rodent fibroblasts and 
is the most frequently mutated gene in human cancers. However, the p53 family of 
transcrip-on factors is evolu-onarily very ancient and already found in primordial metazoans 
where it acts as a pivotal coordinator of repara-ve responses to cellular stress, cell and DNA 
damage (“the Guardian of the Genome”). The best guess is that the tumour suppressor 
func-ons of p53, principally induc-on of cell death and senescence, are later addi-ons that 
serve to rein in rogue soma-c cells. The extent to which the immediate stress response and 
tumour suppression func-ons of p53 augment or antagonise each other is hotly debated, not 
the least because of occasional studies that indicate a paradoxical posi-ve selec-ve reten-on of 
p53 in some early stage cancers, sugges-ng that p53 func-on is indeed in some way beneficial 
for nascent tumours. Such inherent antagonis-cally pleiotropic proper-es make classical 
gene-c analysis of p53 func-on complicated – as does the confounding presence in the 
mammalian genome of at least two addi-onal paralogues of p53, p63 and p73 whose func-ons 
par-ally overlap. Therefore, to address the poten-ally dis-nct func-ons of p53 in development, 
maintenance and repair of normal adult -ssues and in tumour suppression, I have built a 
unique, temporally switchable mouse model in which p53 func-on may be reversibly toggled 
between wild type and null states at will in vivo. I show that acute systemic repression of p53 in 
adult mice elicits no overt symptoms or soma-c pathologies. However, spontaneous tumours 
emerged in the same cellular compartments and with a similar latency to those observed in 
germline p53-null mice. Detailed analyses of -ssues and tumours have yet to be conducted. 
Temporal dissec-on of p53’s func-ons at different stages of chemically-induced skin cancer 
revealed a window during the ini-a-on stage where p53 reten-on promoted early 
carcinogenesis (skin papillomas) while loss of p53 promoted the development of later 
squamous carcinomas. The ability to rapidly and reversibly switch p53 func-onal status and to 
iden-fy windows of p53 pro-tumourigenic and tumour suppressive func-on will provide new 
insights into the diverse and perhaps antagonis-c roles of p53 in development, -ssue 
homeostasis, cancer and ageing. 
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INTRODUCTION 
I.1	Cancer	as	a	disease	
I.1.1	Historical	perspective	
 Cancer has been documented since an2quity. Papyri from 1600 BC contain descrip2ons 
of breast cancer and a procedure to remove it by cauterisa2on (American Cancer Society 2009). 
Hippocrates, a physician from the Age of Pericles of Classical Greece, named the disease 
Karkinos (Greek word for crab in reference to the cross surface of a tumour that appears “with 
vein stretched on all sides as the animal the crab has feet”. Our current word “cancer” derives 
from this. Since the last century, we have acquired a deeper understanding of cancer in terms of 
its pathologies, causes and molecular mechanisms. However, the disease remains incurable for 
many pa2ents and remains the second leading cause of mortality - aNer cardiovascular diseases 
- in the world, accoun2ng for one in six deaths. In the UK, one in every two people will 
eventually develop some form of cancer (Cancer Research UK 2019). 
I.1.2	Cancers	are	genetic	diseases	
 Cancer is not a single disease but a collec2ve of gene2c diseases that share the feature 
of abnormal, uncontrollable propaga2on and expansion of the defec2ve cancer cells. Cancers 
are probably all gene2c by origin, involving rela2vely subtle abnormali2es in regula2on and/or 
func2on of key growth-regulatory genes that arise by muta2ons that accumulate in soma2c 
cells over 2me. These DNA muta2ons frequently corrupt the amino acid sequences of specific 
gene products (though some are known to affect non-coding RNA such as Long Non-coding 
RNAs (Do & Kim 2018)), altering the encoded protein’s structure and how it interacts with other 
macromolecules that control its func2on and regula2on. Other oncogenic muta2ons directly 
inac2vate genes by frameshiN or nonsense muta2ons in their coding sequences. Furthermore, 
muta2ons of transcrip2onal regulatory cis-elements can lead to altera2on in expression of the 
genes. While some muta2ons precociously ac2vate signalling pathways that promote 
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prolifera2on of cells (oncogenes), others inhibits pathways that restricts cells from prolifera2on 
or promotes cell death and differen2a2on (tumour suppressor genes). Accumula2on of such 
muta2ons confers on (pre-)cancer cells an enhanced propensity to survive and/or proliferate 
promiscuously, thereby eroding their dependence upon their original designated soma2c 
niches. Such rogue clones are thenceforth subject to various selec2ve pressures that limit 
uncontrolled prolifera2on within their local soma2c environments. In this way, incipient cancer 
clones gradually accumulate combina2ons of muta2ons that drive their evolu2on into 
malignant cancer cells. Such malignant cells expand uncontrollably and compete in organs for 
space occupancy and resources such as supply of nutrients and oxygen. Their outgrowth also 
blocks ducts and vessels, compromising architecture and func2on of the organ in which the 
tumour resides. Cancer cells may also spread and invade other parts of the body, developing 
into secondary tumours (metastasis) that are not always operable. Eventually the tumour-
occupied organs or even the whole system fails, resul2ng in the pa2ent’s death.  
  
I.1.3	Existing	therapeutic	options	
 Nowadays, there are mul2ple treatment op2ons for cancers. Surgical removal of the 
primary tumour mass remains the most effec2ve one - it can eliminate and cure some types of 
cancers - but is only effec2ve at the earliest stages of malignant outgrowth of solid tumours, 
before they have metastasised. Other treatment op2ons such as chemotherapy, radiotherapy, 
targeted therapy and immunotherapy can be applied more systemically but are less effec2ve at 
curing the disease and oNen elicit more severe side-effects, although they do allow disease 
management and prolong survival of pa2ents. The challenge of trea2ng cancers is mul2fold. 
First, the diverse pathologies of different types of cancer and varia2ons amongst individual 
pa2ents, each of whom have dis2nct gene2c makeups. Second, biological signaling pathways 
exhibit both robustness and redundancy, making it difficult to target individual oncogenic 
processes effec2vely. As a consequence, even similar types of cancer can be driven by 
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substan2ally different underlying molecular mechanisms in different pa2ents. As a result, there 
are almost no general treatments for all cancers and individual pa2ents likely respond 
differently to the same treatment (even for the same type of cancer). Exis2ng therapies 
targe2ng specific oncogenic signalling pathways may eliminate some (even most) cancer cells 
but some cancer cells survive, adapt, evolve and re-wire, regenera2ng tumours that are no 
longer sensi2ve to the ini2ally effec2ve therapy, and the pa2ent relapses. 
I.1.4	Therapeutic	challenges	
 These current challenges in curing human cancers could, however, perhaps be overcome 
by ra2onal design of therapies that target the non-redundant “nodes” at which all oncogenic 
signalling pathways converge (e.g. inhibi2on of the pleiotropic oncogenic transcrip2on factor c-
MYC or reac2va2on of intrinsic tumour suppressors, such as p53 and its agen2ve pathways). 
The idea behind this is that cancers are aberrantly ac2vated variants of normal developmental 
or regenera2ve soma2c programmes and therefore share common underlying mechanisms that 
drive or inhibit them. In this unorthodox view of cancer, the apparent, diverse differences 
between individual cancers arise because most oncogenic muta2ons arise in the robust, 
redundant upstream signal networks that drive the underlying common cancer engines. Indeed, 
mul2ple studies have tested this hypothesis in mouse models in the past two decades and 
proved the validity of this, at least in principle. Thus, Soucek et al. demonstrated that systemic 
repression of c-Myc by a dominant nega2ve mutant induced general regression of Ras-driven 
lung tumours within one week by blocking prolifera2on and inducing apoptosis specifically in 
the cancer cells (Soucek et al. 2008). Follow-up studies expanded the applicability of the no2on 
that c-Myc is a shared signalling node upon which cancer cells vitally depend to other types of 
murine cancer (Sodir et al. 2011; Soucek et al. 2011). Similarly, other studies demonstrated in 
mouse models that carefully 2med restora2on of the tumour suppressor p53 results in 
regression of tumours, though to different extents in different tumour types and via different 
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pathways, such as senescence versus apoptosis (Mar2ns et al. 2006; Xue et al. 2007; Ventura et 
al. 2007; Junnla et al. 2010; Feldser et al. 2010). A more thorough and comprehensive 
understanding of the biology of these shared oncogenic and tumour suppressive pathways, as 
well as the underlying mechanisms by which they operate, awaits further analysis in order to 
determine its applicability to human cancer pa2ents. 
I.2	Tumorigenesis,	oncogenes	and	tumour	suppressors	
 Tumourigenesis describes the process by which cancers arise and evolve to macroscopic 
size. The process is thought to involve the same general processes as macroscopic evolu2on – 
random gene2c diversifica2on through muta2on followed by selec2on for increased fecundity. 
However, in cancer, the process is confined to soma2c cell clones, the selec2ve pressures are 
those that normally limit untoward expansion of soma2c cells and remain only par2ally 
understood, and the ul2mate impact of such excessive soma2c cell growth is ironically 
detrimental to the survival of the host. It is axioma2c that this oncogenic evolu2onary process 
does not take place in normal 2ssues, mainly because normal soma2c cells are under strict 
restraints that limit their growth, propaga2on and survival to discrete soma2c organ niches. It is 
these soma2c restraints, most notably the inhibitory ac2ons of key tumour suppressors such as 
p53, that serve as the selec2ve pressures that shape the evolu2on of incipient cancer clones. 
Such is the basic mechanism underlying the evolu2on of cancer cells. 
 DNA muta2on, an inescapable consequence of the intrinsic chemical reac2vity of nucleic 
acids, become relevant to tumourigenesis when they result either in ac2va2on of oncogenes or 
inac2va2on of tumour suppressor genes. Classically, oncogenes are opera2onally defined as 
genes whose mutagenic ac2va2on drives precocious expansion of soma2c cell clones. The 
normal (non-mutated) proto-oncogene counterparts of oncogenes are typically (although not 
exclusively) involved in promo2ng prolifera2on or survival of soma2c cells in response to 
mitogenic growth and survival factors during development and in maintenance and repair of 
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adult 2ssues. A more inclusive defini2on of an oncogene also includes genes that, while not 
necessarily themselves mutated, nonetheless transduce the pro-prolifera2ve/pro-survival 
signals from upstream ac2vated oncogenes. A good example of this lager class is the 
transcrip2on factor Myc. Myc is seldom directly mutated in human cancers, at least in their 
early stages. However, due to its normal role as the non-redundant link connec2ng diverse 
upstream mitogenic signals to the disparate downstream transcrip2onal effector programmes 
that implement soma2c cell prolifera2on, it serves as an obligate  conduit for many, perhaps all, 
upstream oncogenic muta2ons. Thus, MYC, expression is frequently deregulated in human 
cancers due to relentless upstream oncogenic signals channelled by RTK-Ras, Wnt-β-catenin or 
Notch (Soucek & Evan 2010). 
 However, acquisi2on of oncogenic ac2vi2es, or the abnormal prolifera2ve ac2vi2es they 
elicit, are under constant scru2ny and restraint imposed by so-called tumour suppressors. The 
term tumour suppressor is rather misleading since few or none of these appear to have evolved 
to suppress tumourigenesis: virtually all are evolu2onarily ancient and present in unicellular 
organisms and short-lived invertebrates in which cancer is, respec2vely, either a meaningless 
concept or unlikely to be a significant source of morbidity. Rather, tumour suppressor genes 
appear to have evolved originally as intrinsic checks, antagonists or agenuators of the signals 
and processes that drive prolifera2on of normal cells. Hence, their roles as suppressors of 
cancer appear to be either exapted consequences or subsequent re-purposing of their 
primordial func2ons. In adult vertebrates, soma2c cell prolifera2on is restricted to a few 
con2nuously renewing 2ssues and to regenera2on following injury or pathogen damage. In 
adult vertebrate 2ssues, the majority of cells have differen2ated into a quiescent state that 
performs specialised niche func2ons to maintain systemic homeostasis. Certain sub-popula2ons 
of soma2c cells in most 2ssues, stem cells, do retain a certain capacity to proliferate and 
replenish organs as cells gradually diminish in the 2ssue from wear and tear or damage. 
However, these are under 2ght control. Maintenance of the overall balance between 
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prolifera2ve poten2al in development and systemic homeostasis aNerwards is a primary 
func2on for many tumour suppressor genes. Nonetheless, the fact that various tumour 
suppressors are frequently inac2vated in human cancers agests to their indisputable 
importance in stalling genesis and evolu2on of cancer cells  
 p53, in par2cular, has been acknowledged as a pivotal tumour suppressor since the late 
80s/early 90s when studies confirmed the protein’s capacity to suppress oncogene-mediated 
transforma2on of mouse fibroblasts (Eliyahu et al. 1989; Finlay et al. 1989) and iden2fied 
frequent muta2ons of the TP53 gene in diverse human cancers (Baker 1989; Nigro et al. 1989). 
These early studies were soon reinforced by the signature phenotype of germline p53-knockout 
mice, which revealed a mostly normal physiology but with dras2cally increased suscep2bility to 
spontaneous tumourigenesis, principally lymphoma (Donehower et al. 1992). 
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I.3	The	p53	protein	
I.3.1	Structure	and	function	of	the	p53	protein	
Before introducing the p53 signaling networks, I will first discuss current knowledge of p53 
protein structure and func2ons. The human p53 protein is a 393 amino acid-long transcrip2on 
factor (390 in the mouse analog) whose sequence may be divided into six structural/func2onal 
domains - two N-terminal Trans-ac2va2on domains (TADI and TADII), followed by a proline-rich 
region, a core DNA-binding domain (DBD), an oligomerisa2on domain (OD), and a regulatory 
domain at the C-terminus (CTD) (Figure I.1). Also present is a nuclear localisa2on signal within 
the OD. The N-terminal TADI (amino acid 1 - 42) and TADII (amino acid 43 - 63) interact 
independently as well as coopera2vely with a variety of proteins that are each involved in 
different aspects of transcrip2on control, such as histone modifica2on and transcrip2onal 
ini2a2on, and which determine target gene preference (Lemon & Tjian 2000). For instance, 
TAD1 interacts with the transcrip2on components TAF6 and chroma2n modifier PRMT1 (Thut et 
al. 1995; An et al. 2004), while TAD2 interacts with the chroma2n modifier GCN5 and DNA 
metabolism proteins PC4 and RPA (Gamper & Roeder 2008; Rajagopalan et al. 2009). Both TAD1 
and TAD2 interact with the nega2ve p53 regulators MDM2 and MDMX. The requirement for 
transac2va2on ac2vity from the two TADs is not the same for all target genes. TADI is solely 
required for transac2va2on of certain canonical p53 target genes, including CDKN1A, PUMA and 
NOXA, but is dispensable for transcrip2onal ac2va2on of other targets such as ABHD4, BAX and 
SIDT2. TAD2 appears to be par2cularly important for the tumour suppressive ac2vity of p53 (Raj 
& Agardi 2017). 
 The proline-rich region (amino acids 64-92) plays a cri2cal and specific role in ac2va2on 
of apoptosis and related processes such as reac2ve oxygen species produc2on through 
induc2on of the PIG3 gene yet appears dispensable for transac2va2on of other key p53 targets, 
such as CDKN1A and MDM2 (Walker & Levine 1996; Sakamuro et al. 1997; Venot et al. 1998; 
Zhu et al. 1999; Flag et al. 2000; Bap2ste et al. 2002; Lee et al. 2010). 
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 The core DBD (amino acid 102-292), as its name suggests, mediates p53 sequence-
specific DNA binding and is essen2al for the protein’s func2on as a transcrip2on factor 
(Pavle2ch et al. 1993; Wang et al. 1993). Its well-conserved loop-sheet-helix mo2f of the 
domain interacts with residues in the DNA major groove and the principal muta2onal hot-spot 
for the many p53-inac2va2ng muta2ons found in cancers. Such muta2ons alter, or en2rely 
abrogate, the sequence-specific binding capacity of p53, underscoring the significance of this 
domain for the protein’s tumour-related func2ons (Cho et al. 1994).  
 The C-terminal OD (amino acid 307-355) mediates tetramerisa2on of the p53 protein. 
Though monomeric p53 protein monomer can bind to DNA, tetramerisa2on increases the DNA 
binding affinity of p53 some 10-100 fold (Balagurumoorthy et al. 1995). Tetrameric p53 also 
interacts with various other proteins more efficiently – for example, caesein kinase 2 (Götz et al. 
1999) and the adenovirus E4orf6 protein (Delphin et al. 1997). 
 The function of the CTD (amino acid 356 - 393) remains the most controversial amongst the 
domains. First described as a negative regulator of sequence-specific binding to DNA (Anderson et al. 
1997; Ayed et al. 2001; Hupp et al. 1992; Hupp & Lane 1994; Jayaraman & Prives 1995), the CTD has since 
been shown to promote p53 binding to chromatin (Espinosa & Emerson 2001) and its linear diffusion 
along the DNA molecule (McKinney et al. 2004; Tafvizi et al. 2011). A study recently published by Laptenko 
et al. supports the notion that the p53 CTD is indeed an important determinant of sequence-specific 
binding by the DBD to DNA that enhances the stability of the p53-DNA complex (Laptenko et al. 2015). 
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Figure I.1 Functional domains of the p53 protein. TADI: transactivation domain one, amino acids 1 - 42; TADII: 
transactivation domain two, amino acids 43 - 63; Pro-rich: proline-rich region, amino acids 64 - 92; DBD: core 
DNA-binding domain, amino acids 102 - 292; OD: oligomerisation domain, amino acids 307 - 355; NLS: nuclear 
localisation signal, amino acids 316 - 325; CTD: C-terminal regulatory domain, amino acids 356 - 393.
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I.3.2	Regulation	of	p53	by	post-translational	modiFications	
 The intracellular level of p53, along with its various func2ons, are in the main, if not 
en2rely, regulated by post-transla2onal modifica2ons (PTMs) at different amino acid residues 
throughout the protein. A major class of such modifica2ons is phosphoryla2on at serine and 
threonine residues, many of which are important modulators of p53 ac2vity. For example, 
phosphoryla2on of serine-15, threonine-18 and serine-20 block binding of MDM2. MDM2 is an 
E3 ubiqui2n ligase that acts as a pivotal nega2ve regulator of p53 stability: hence 
phosphoryla2on at serine-15, threonine-18 and serine-20 stabilises p53 and leads to its rapid 
accumula2on (Shieh et al. 1997; Bögger et al. 1999; Chehab et al. 1999; Craig et al. 1999; 
Dumaz & Meek 1999; Unger et al. n.d.; Sakaguchi et al. 2000; Dumaz et al. 2001; Schon et al. 
2002). The same phosphoryla2on event also promote interac2on of p53 with p300/CBP, 
thereby enhancing p53 transac2va2on ac2vity (Lambert et al. 1998; Dumaz & Meek 1999; 
Dornan et al. 2003; Finlan & Hupp 2004).  
 Another important class of PTMs of p53 is ubiqui2na2on, the process by which single or 
mul2ple ubiqui2n units are added to target lysine residues. Thus, (poly-)ubiqui2na2on of the six 
lysine residues at the C-terminus of p53 by MDM2 targets p53 for proteasomal degrada2on and 
is essen2al to maintain low levels of p53 in unstressed or undamaged cells (Horn & Vousden 
2007). Mono-ubiqui2na2on of one of these lysine residues also promotes nuclear export of p53 
(Li et al. 2003; Nie et al. 2007), though the func2onal implica2on of this remains unclear.  
 Many p53 lysine residues subject to ubiqui2na2on, such as the six C-terminal lysine 
residues discussed above, can also be acetylated by the p300/CBP complex (Carter & Vousden 
2009), thereby enhancing p53’s binding to specific sequences of DNA and transac2va2on of 
associated target genes (Grossman 2001). As acetylated lysine residues cannot be ubiqui2nated, 
this suggests that compe22on between the two PTMs for the same lysine residues is cri2cal for 
determining p53 stability and transcrip2onal ac2vity (Ito et al. 2002; Le Cam et al. 2006). 
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 Other PTMs such as SUMOyla2on (conjuga2on of the small ubiqui2n-like modifier) and 
methyla2on are also observed on some lysine residues of p53, though their biological relevance 
is not well defined (Carter & Vousden 2009). However, it is clear from such analyses that p53 
protein is heavily regulated by PTMs and that these modifica2ons are cri2cal determinants of 
the protein’s stability, level and func2on.
I.3.3	Isoforms	of	p53	mRNA	and	protein	
 It has been reported that the human TP53 mRNA is expressed in some nine isoforms 
through a combina2on of alterna2ve usage of two transcrip2on start site and alterna2ve 
splicing, while a total of twelve p53 protein isoforms is translated from these mRNA isoforms 
due to further varia2on introduced by usage of internal ribosomal entry sites in some mRNA 
isoforms (Joruiz & Bourdon 2016). As these isoforms have been iden2fied in different cellular 
contexts and condi2ons, inves2gators have agempted to draw inferences as to differen2al 
func2onality of these many isoforms. However, evidence to support such differen2al isoform 
func2on is scarce and to date the only reasonably firm conclusion is that the balance of p53 
isoform expression might define p53’s post-damage/-infec2on downstream responses (Bourdon 
et al. 2005; Joruiz & Bourdon 2016). For example, systemic cons2tu2ve expression at high-level 
of a shortened isoform of p53, named p44 (translated from an mRNA lacking exons 1-3), from a 
randomly inserted transgene in mice led to ageing phenotypes and shortened lifespan (Maier et 
al. 2004). The inves2gators speculated that such systemic overexpression of p44 leads to 
prolifera2on deficit, cellular senescence and organismal ageing to aberrant insulin-like growth 
factor (IGF) signalling. However, several caveats weaken this study. First, while it is formally 
possible that this p53 isoform exists in a physiological senng with the speculated func2ons, 
there is no evidence that it is normally expressed at the level required to elicit its phenotypic 
impact. Also, there remains the possibility that the p44 isoform transgene has disrupted some 
endogenous genes. 
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 The Evan Laboratory recently generated a mouse model in which a full-length mouse 
Trp53 mRNA construct (with preserva2on of intron 4) was knocked into the ubiquitously and 
cons2tu2vely expressed Rosa26 locus. The ectopic allele of Trp53, R26-p53, was shown to be 
expressed at levels similar to that of the endogenous Trp53 alleles in all 2ssues in vivo and in 
derived embryonic fibroblasts in vitro. Furthermore, the p53 protein expressed from the ectopic 
allele exhibited iden2cal func2onality to that expressed from the endogenous alleles in terms of 
p53 transcrip2on ac2vi2es. Importantly, animals carrying two R26-p53 alleles but no 
endogenous Trp53 appeared iden2cal phenotypically to Trp53 wild type mice in all aspects 
examined; all developmental and physiological abnormality exhibited by the germline p53-null 
mice, including sensi2vity to whole body irradia2on, were rescued by the ectopic R26-p53 
alleles (unpublished data). As the R26-p53 allele likely expresses only one isoform of mRNA and 
protein, it challenges the speculated importance of mRNA/protein isoforms on biology of p53. 
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I.4	p53	tumour	suppression	
 2019 marks the 40th year of p53’s discovery, with more than 100,000 hits returning from 
a search of p53 on PubMed. Nonetheless, it appears we are s2ll only beginning to glimpse the 
physiological and pathological func2ons of p53. This is perhaps unsurprising considering the 
en2re research field took a decade-long early detour aNer mistakenly classifying p53 as a proto-
oncogene! The paradigm was corrected some 30 years ago: even so, our understanding of p53 
remains patchy. 
I.4.1	The	discovery	of	p53	
 p53 was originally iden2fied in 1979 by several laboratories as a protein interac2ng with 
the oncogenic SV40 viral large T-an2gen in SV40-infected cells (Lane & Crawford 1979; Linzer & 
Levine 1979). As the protein level of p53 appeared to be regulated by large T-an2gen in these 
cells, it was presumed that the protein was oncogenic and played a part in SV40 LT-mediated 
transforma2on (Linzer et al. 1979). Shortly thereaNer, p53 cDNA clones were successfully 
isolated from tumour cells and were shown to be capable of transforming normal rodent 
fibroblasts together with dominant oncogenes such as RasV12 (Eliyahu et al. 1984; Jenkins, 
Rudge, Redmond, et al. 1984; Jenkins, Rudge & Currie 1984; Eliyahu et al. 1985). This, again, 
supported the no2on that p53 was an oncogenic protein.  Around the same 2me, Maltzman 
and Czyzyk showed that p53 protein expression level was induced by DNA damage (Maltzman & 
Czyzyk 1984), providing the first hint as to the actual func2on of the protein, as determined in 
the early 90s. 
I.4.2	p53	is	a	tumour	suppressor	
 The turning point for the paradigm of p53 as an oncoprotein came in 1989 when two 
reports showed that wild type p53 cDNA transfected and expressed is capable of suppressing 
oncogene-mediated transforma2on of rodent fibroblasts cells in vitro while the mutant versions 
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- which indeed had been cloned instead of the wild type in the previous reports in 1984 - 
transform the cells (Eliyahu et al. 1989; Finlay et al. 1989). This was further supported by the 
iden2fica2on of point muta2ons in the p53 gene in both human and mouse cancers as well as in 
cancer cell lines (Baker et al. 1989; Hollstein et al. 1991; Wolf & Roger 1984; Ben David et al. 
1988; Mowat et al. 1985; Wolf & Roger 1985). Furthermore, it was shown that inheritance of 
mutant a TP53 allele is the underlying cause of Li-Fraumeni syndrome, which predisposes 
pa2ents to early (before 30-year old) development of cancer (Malkin et al. 1990; Srivastava et 
al. 1990). Finally, Donehower et al. showed in 1992 that germline p53-knockout mice were 
viable and fer2le but developed spontaneous tumours at an average age of 20 weeks (earliest 
12 weeks) (Donehower et al. 1992). Together, these findings firmly established the paradigm of 
p53 as a tumour suppressor. 
 In the 90s, research on p53 took off and yielded some founda2onal understanding of 
p53’s cellular func2ons. First, several studies reported that p53 protein is induced by DNA 
damage signals and, when so ac2vated, stops cell-cycle progression and triggers apoptosis 
(Yonish-Rouach et al. 1991; Hall et al. 1993; Lowe, Schmig, et al. 1993; Lowe, Ruley, et al. 1993). 
Based on the hints that p53 protein binds to DNA at a specific consensus sequence (Bargonen 
et al. 1991; Kern et al. 1991; El-Deiry et al. 1992), Kastan et al. established that p53 is a 
transcrip2on factor inducible by ATM kinase (back then only known as a ataxia-telangiectasia 
gene product) upon DNA damage signals and directly induces transcrip2on of the growth arrest 
and DNA damage protein 45 (GADD45) by binding to its coding gene (Kastan et al. 1992). It was 
at around this 2me that p53 was dubbed the 2tle “guardian of the genome”, a hypothesis 
centralising p53-mediated DNA damage response as its principal mechanism of tumour 
suppression (Lane 1992). The Guardian of the Genome hypothesis soon turned to dogma. 
 The next few years saw the progressive unveiling of p53’s agendant pathways as well as 
the mechanisms that regulate its ac2vity. In 1993, El-Deiry et al. discovered that p53 directly 
induces expression of the CDKN1A gene, which encodes p21Cip1 (alterna2vely p21Waf1), a potent 
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inhibitor of the cyclin-dependent kinases whose ac2vi2es are necessary for cell cycle 
progression. This linked p53 ac2va2on directly to cell cycle arrest (El-Deiry 1993). Next, the gene 
encoding the E3 ubiqui2n ligase MDM2 was revealed as a direct target of p53 while the MDM2 
protein was shown to be a key mediator of p53 degrada2on (Momand et al. 1992; Barak et al. 
1993; Wu et al. 1993). This placed p53 and MDM2 in a direct nega2ve feedback loop – p53 
induces MDM2, which inhibits p53. Further inves2ga2on showed that MDM2 is absolutely and 
con2nuously required to keep p53’s protein level low in the absence of upstream p53-ac2va2ng 
signals (Barak et al. 1993; Wu et al. 1993; Kubbutat et al. 1997; Haupt et al. 1997; Momand et 
al. 1992). Germline knockouts of MDM2 were embryonically lethal in early gesta2on but this 
lethality was rescued by co-dele2on of p53 (de Oca Luna et al. 1995; Jones et al. 1995; Table 
I.1).  
 Other important milestones in our understanding of p53 biology include uncovering the 
diverse upstream signalling pathways that transduce various stress and damage insults, 
including DNA damage and oncogene ac2va2on, to regula2on of the p53 protein. Three reports 
published between 1997-2000 established that upon DNA damage signals protein kinases ATM, 
Chk1 and Chk2 phosphorylate p53 at mul2ple sites, disrup2ng the Mdm2-p53 complex and 
releasing p53 from its nega2ve regula2on by Mdm2, thereby triggering rapid p53 accumula2on 
(Siliciano et al. 1997; Canman et al. 1998). 
 Then the protein ARF (also named p14ARF in human and p19Arf in mouse), encoded by 
the INK4ARF gene, was shown to bind and ubiqui2nate MDM2, causing its dissocia2on from 
p53 and subsequent degrada2on by the proteosome pathway. p53 released from MDM2 is no 
longer ubiqui2nated and degraded and thus is accumulated to high level (Quelle et al. 1995; 
Kamijo et al. 1997; Zhang et al. 1998; Kamijo et al. 1998; Pomerantz et al. 1998). Remarkably, 
Zindy et al. demonstrated in mouse embryonic fibroblasts that Myc induces p19Arf and thereby 
triggers p53-dependent apoptosis (Zindy et al. 1998). The ability of ARF to survey oncogenic 
signals was further confirmed by a report in which the inves2gators visualise p19Arf expression 
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in vivo in mice by replacing the first exon of the mouse endogenous gene with a GFP-expressing 
open reading frame (ORF). It was shown that oncogenic signals such as ectopic overexpression 
of Ras and Myc s2mulate p19Arf expression (Zindy et al. 2003). Together, these data showed that 
the p53 network has evolved a dedicated faculty with which to detect and eliminate cells that 
exhibit aberrant oncogenic signals, persistent and obligate agributes of (proto-)cancer cells.  
 16
Year Discovery Reference
1979 - p53 interacts with the oncogenic SV40 viral Large T-an2gen and so characterised as an oncogene.
Lane & Crawford 1979; Linzer & 
Levine 1979; Linzer et al. 1979
1984 - 1985
- p53 can transform rodent fibroblasts together with 
some oncogenes. 
- p53 is inducible by DNA damage.
Eliyahu et al. 1984; Jenkins, Rudge, 
Redmond, et al. 1984; Jenkins, Rudge 
& Currie 1984;  
Eliyahu et al. 1985; Maltzman & 
Czyzyk 1984
1989
- Correct cloning of WT p53 which was confirmed to 
suppress transforma2on of cells by oncogene; thus 
confirming p53 func2on as tumour suppressor.
Eliyahu et al. 1989; Finlay et al. 1989
1990 - Inheritance of one allele of TP53 is the underlying cause of Li-Fraumeni syndrome.
Malkin et al. 1990; Srivastava et al. 
1990
1992
- Germline p53-knockout mice are born viable and 
fer2le but develop spontaneous tumours at young 
age
Donehower et al. 1992
1991 - 1993
- Ac2vated by DNA damage, p53 stops cell-cycle 
progression and triggers apoptosis. 
- p53 consensus sequence.
Yonish-Rouach et al. 1991; Hall et al. 
1993; Lowe, Schmig, et al. 1993; 
Lowe, Ruley, et al. 1993 
Bargonen et al. 1991; Kern et al. 
1991; El-Deiry et al. 1992
1992 - 1993, 
1995
- p53 is a transcrip2on factor ac2vated by ATM kinase 
upon DNA damage and induces transcrip2on of 
GADD45. 
- Dabbed the name “The Guardian of the Genome”. 
- MDM2-p53 nega2ve feedback loop. 
- CDKN1A as a p53 target gene and link to cell cycle 
arrest. 
- Germline knockout of MDM2 is embronically lethal.
Kastan et al. 1992 
Lane 1992 
Momand et al 1992; Barak et al. 
1993; Wu et al. 1993 
El-Deiry 1993 
de Oca Luna et al. 1995; Jones et al. 
1995
1997 - 1998
- DNA damage signal is relayed to p53 from ATM kinase 
via Chk1 and Chk2 kinases that phosphorylate p53 at 
mul2ple sites, disrup2ng MDM2 binding and 
inhibi2on.
Siliciano et al. 1997; Canman et al. 
1998
1995, 1997, 
1998, 2003
- ARF protein frees p53 from MDM2 and allows p53’s 
accumula2on in response to oncogenic Myc signal 
and triggers apoptosis.
Quelle et al. 1995, Kamijo et al. 1997, 
Zhang et al. 1998, Kamijo et al. 1998; 
Pomerantz et al. 1998, Zindy et al. 
1998, Zindy et al. 2003
Table I.1 Milestones in p53 research that establishes its role in DNA damage response and as a 
tumour suppressor.
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I.4.3	Mechanisms	of	p53	tumour	suppression	
 The extent to which the p53 DNA damage response versus ARF-p53 oncogenic signalling 
contribute to p53’s tumour suppressive nature has long been hotly debated. In keeping with 
Lane’s “guardian of the genome” no2on (Lane 1992), many reports have argued that p53 
inhibits tumorigenesis by sensing episodic or ongoing DNA damage in evolving tumour cells and 
direc2ng affected cells to senescence or apoptosis. For example, two reports published in 2005 
noted a correla2on between the ac2va2on of the ATM-Chk2-p53 apoptosis pathway in different 
human early (pre-invasive) cancerous lesions and frequent muta2ons and/or inac2va2on of this 
pathway in lesions of later stages. Based on such observa2ons, the authors speculated that the 
ATM-Chk2-p53-mediated DNA damage response is the principal axis of p53-mediated tumour 
suppression (Bartkova et al. 2005; Gorgoulis et al. 2005). This view, however, was challenged by 
Christophorou et al. who, using a reversibly switchable p53 mouse model showed that the p53-
mediated response to DNA damage inflicted by whole body irradia2on is irrelevant for 
suppression of lymphoma induced by the irradia2on: rather, the tumour suppressive effect of 
p53 was en2rely dependent on ARF (Christophorou et al. 2006). A complementary study 
showed that oncogenic signals sensed and relayed by ARF to p53 are alone essen2al for the 
extra protec2on against induced cancers conferred by an extra germline copy of p53 (Efeyan et 
al. 2006). ARF appears to have evolved specifically to monitor oncogenic signalling. In addi2on, 
however, ARF is reported to direct p53-independent func2ons, such as the sumoyla2on and 
nega2ve regula2on of MDM2 and nucleophosmin (NPM or B23 is a nuclear protein involved in 
ribosome biogenesis) (Tago et al. 2005), perhaps sugges2ng that its original evolu2on trajectory 
was independent of p53. Given the evidence sugges2ng that p53 family proteins may ini2ally 
have evolved to regulate aspects of damage/stress sensing during development (discussed 
below in SecGon I.5.1), it seems plausible that p53 and ARF evolved independently and their 
roles then later converged to poten2ate the emerging necessity to rein in rogue soma2c cells in 
larger, longer-lived organisms.   
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While sufficiently effec2ve in preven2ng tumorigenesis through reproduc2ve age, ARF-
p53-mediated tumour suppression is not without its shortcomings. Thus, two reports published 
respec2vely in 2007 and 2008 demonstrated that ARF suppresses tumourigenesis by sensing 
aberrantly high levels of growth signals in cells. The problem being that aberrantly persistent 
growth signals are the underlying cause of oncogenesis whereas eleva2on of signals is an 
indirect byproduct of the muta2ons that commonly cause signal deregula2on: elevated 
oncogenic signaling flux is a “frequent but not unfailing correlate of the true agribute” of 
oncogenesis (Sarkisian et al. 2007; Murphy et al. 2008; Junnla & Evan 2009). Such subop2mal 
design for tumour suppression appears peculiar - why has the system not evolved to ensure 
more accurate surveillance of rogue cells driven by oncogenic signalling? Possibly, the ARF-
mediated sensing system that has evolved is adequate to suppress cancer through reproduc2ve 
age, aNer which it is evolu2onarily irrelevant? Alterna2vely, perhaps ARF evolved ini2ally not for 
surveillance of tumourigenesis but some other, currently obscure, func2on? Answers to these 
ques2ons are sure to offer addi2onal fundamental insights to how p53 suppresses cancers.
I.4.4	Exploring	p53-based	cancer	therapies	
 Despite our incomplete understanding of p53-mediated tumour suppression, it is clear 
that restora2on of p53 in late stage p53-nega2ve murine cancers is remarkably effec2ve at 
elimina2ng exis2ng tumours, as indicated by several reports published through 2006-2010. The 
rapid elimina2on of tumours, by apoptosis or senescence, upon restora2on of p53 in different 
murine cancer models formally illustrated the therapeu2c feasibility of restoring wild type p53 
in tumours in which endogenous p53 is mutated or inac2vated. Importantly, such observa2ons 
confirmed that p53-ac2va2ng signals persist in tumours that have evolved in the absence of p53 
and that the downstream p53-dependent tumour suppressive pathways remain func2onal in 
such cells (Mar2ns et al. 2006; Ventura et al. 2007; Xue et al. 2007; Junnla et al. 2010; Feldser 
et al. 2010). Nonetheless, the differen2al responses of tumours at different stages of their 
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progression - early stage tumours were largely unresponsive to p53 restora2on whereas later 
stage lesions underwent profound regression - indicated that addi2onal factors need to be 
considered when implemen2ng p53-based therapy. Provoca2vely, there is also evidence that 
reten2on of p53 confers selec2ve advantages on early stage tumours (see below). 
 A parallel approach to exploring the mechanisms underlying p53’s tumour suppressive 
nature is to enhance the general ac2vi2es of p53, i.e. increasing p53-mediated tumour 
surveillance. Tyner et al. showed that a mutant p53 lacking its N-terminus conferred augmented 
tumour suppression in mice when co-expressed with wild type p53, although such animals also 
exhibited features of premature ageing (Tyner et al. 2002). The authors agributed these 
observa2ons to increased baseline p53 ac2vity of the mutant. While such results are intriguing 
in the sense that p53 ac2vity may possibly be fine-tuned pharmacologically to provide 
enhanced tumour suppression, it remains unclear whether the observed phenotypes were 
indeed a result of increased p53 ac2vity, as the authors claimed. A copy of the mutant allele by 
itself failed to match wild type p53 in terms of suppression of spontaneous tumourigenesis. 
Moreover, it was later realised that the Tyner mutant mouse also had some 24 other 
endogenous genes inadvertently deleted (Gentry & Venkatachalam 2005). Nonetheless, an 
elegant study by Garcia-Cao et al. showed that increasing p53 ac2vi2es by adding an extra 
transgenic copy of Trp53 driven at rela2vely normal na2ve levels of transcrip2on (a “super p53” 
mouse) did confer extra protec2on against induced tumours without leading to premature 
ageing (Garcia-Cao 2002). The difference in terms of the ageing phenotype in the two studies is 
explicable by the argument that the augmented p53 ac2vi2es in the “super p53” model 
remained subject to normal factors that regulate p53, such as by Mdm2 and ARF while the 
structurally altered Tyner mutant p53 might not be so regulatable. Remarkably, a follow up 
study combining “super p53” with the p19Arf-knockout model showed that the extra protec2on 
bestowed on by the addi2onal Trp53 allele is en2rely dependent on oncogenic ac2va2on 
through ARF (as discussed above), underscoring the importance of the ARF-p53 axis for p53’s 
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tumour suppressive ac2vi2es (Efeyan et al. 2006). This same idea of enhancing p53-mediated 
tumour suppression by cons2tu2vely enhancing p53 ac2vity was explored in a different way in 
mice by another approach - using a hypomorphic mutant of the p53 inhibitor MDM2 (Mendrysa 
et al. 2006). This also showed enhance protec2on against tumours, but without associated 
premature ageing. Taken together, these findings confirm the validity of augmen2ng p53’s level 
and ac2vi2es as a preven2ve therapeu2c approach. 
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model GeneGc modificaGon Phenotype* Reference
p53 KO Trp53 gene dele2on Increased tumour suscep2bility Downhower  et al. 1992
p53m  Trp53 exon 1 to 6 dele2on Premature ageing phenotype Tyner et al. 2002
Super p53 An extra, ectopic copy of Trp53 gene Increased tumour resistance
García-Cao et al. 
2002
p19Arf KO Ink4Arf dele2on Increased tumour suscep2bility Kamigo et al. 1997
Mdm2 KO Mdm2 gene dele2on Embryonic lethality rescuable by p53 KO
Luna et al. 1995;  
Jones et al. 1995
Hypomorphic 
Mdm2 Reduced expression of Mdm2
Anemia and increased 
radiosensi2vity rescuable by p53 KO
Mendrysa et al. 
2003
p53Flox
Cognate sequence of Cre 
recombinase flanking exon 2 to 
11
Trp53 exon 2 to 11 dele2on in the 
presence of Cre
Ventura et al. 
2007
p53ER
In-frame fusion of estrogen 
receptor sequence to 3’ of 
Trp53
p53ER func2ons like wild type in the 
presence of tamoxifen ligand. 
Otherwise is null.
Christophorou  
et al. 2005
TRE.shp53 cDNA of shRNA to Trp53 added to genome as transgene 
The shRNA is expressed in the 
presence of tetracycline ligand and 
transcrip2on ac2vator rtTA
Xue et al. 2010
Table I.2 Summary of some mouse geneGc models of p53. *Only the phenotype of homozygous 
animals are described here.
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I.5	Non-tumour	suppressive	functions	of	p53	
 Since being dubbed as the “guardian of the genome” by David Lane (1992), p53 has 
been viewed by most primarily as a tumour suppressor that uses the DNA-damage response as 
its principal sensing mechanism. However, such a hypothesis is not logically plausible from an 
evolu2onary point of view given the evolu2onary age of p53 (and its siblings p63 and p73). 
There is emerging evidence sugges2ng p53’s func2onal involvement in diverse development 
and physiological processes in addi2on to DNA damage response – notably, metabolism and 
autophagy and a wide variety of responses to injury (Antoniades et al. 1994) and infec2on (Siegl 
et al. 2014). 
I.5.1	Ancient	function	of	p53	-	what	has	it	evolved	to	do?		
 p53 and/or its siblings p63 and p73 are evolu2onarily ancient and their common 
ancestor is found, together with their MDM2 controllers, across a wide diversity of simple 
eukaryo2c lifeforms, including choanoflagellates, cnidaria and Placozoa, many of which are the 
simplest animals with no evident differen2ated lineages (Chen et al. 2017; Rutkowski et al. 
2010; Pankow & Bamberger 2007; Lane et al. 2010). Such evolu2onary evidence suggests that 
p53 evolved ini2ally as a transcrip2onal integrator of responses to stress/damage/
developmental signals rather than for its evolu2onarily rela2vely recent role of tumour 
suppression. The common ancestor gene of the p53/p63/p73 family more closely resembles 
p63 and p73 than p53 itself. It seems plausible that this ancestral gene func2oned principally to 
preserve the integrity of gamete genomes by elimina2ng defec2ve germ cells, a func2on 
conserved (mostly in p63 and p73) in higher eukaryo2c lifeforms such as invertebrates and 
vertebrates (Suh et al. 2006; Belyi et al. 2010). Presumably, in more complex organisms p53 
inherited this primordial germline func2on and extended it to the elimina2on of aberrant 
soma2c cells whose uncontrolled clonal outgrowth would fatally corrupt embryonic and adult 
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2ssue func2on. This role would be especially important in 2ssues with high rates of cell division 
and, hence, high rates of intrinsic DNA damage (Takimoto & El-Deiry 2001; Aranda-Anzaldo & 
Dent 2003). 
 Func2onal analyses of the Drosophila melanogaster p53 homologue, Dmp53, have 
yielded further insights into the gene’s likely evolu2onary trajectory. Germline dele2on of 
Dmp53, like that of Trp53 dele2on in mouse, is not embryonic lethal but generates offspring 
with reduced viability and fer2lity (Lee et al. 2003; Bauer et al. 2005). However, in contrast to 
Trp53-null mice Drosophila do not develop cancers whether Dmp53 has or has not been 
deleted, even aNer irradia2on. This suggests that Dmp53 does not act as a conven2onal tumour 
suppressor in the fruit fly (Bauer et al. 2005). Of course, this could be an indirect secondary 
consequence of the fruit fly developmental programme – its short lifespan and limited cell 
prolifera2on in adults would greatly limit the chances of soma2c cells arising with the 
compound ensemble of interac2ng muta2ons necessary for malignant outgrowth. Nonetheless, 
Dmp53 remains essen2al for inducing apoptosis in response to genotoxic stress. However, it 
appears to be dispensable for cell cycle arrest in response to genotoxic injury. This could 
indicate that the apopto2c func2on of p53 predates its cell cycle arrest func2on (Kondo 1998; 
Sogame et al. 2003). On the other hand, protostomes like arthropods have undergone extensive 
lateral evolu2onary diversifica2on since splinng from their deuterostome cousins. Hence, traits 
that differ between insects and vertebrates are as likely to reflect horizontal specialisa2on as 
they are chronological sequence. 
I.5.2	Developmental	functions	of	p53	
 As discussed above, it seems plausible that p53 has evolved to facilitate certain 
processes in embryonic development and adult 2ssue maintenance – either a dedicated 
developmental role for p53 itself or perhaps through func2onal overlap with the ac2vi2es of 
p63 and/or p73. Such puta2ve physiological func2ons of p53 have, of course, been 
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overshadowed by the ini2al reports on germline p53-null mice that indicated no demonstrable 
phenotype other than greatly increased tumour rates and radio-resistance (Donehower et al. 
1992; Clarke et al. 1993; Lowe et al. 1993). However, subsequent reports detailed a variety of 
developmental deficits in p53-null mice, albeit with variable penetrance. These included a range 
of developmental defects that cause occasional miscarriage or persist to adulthood such as 
neural tube closure defects leading to exencephaly and craniofacial abnormali2es (Armstrong et 
al. 1995; Kaufman et al. 1997), and abnormali2es in lung, urinary tract and kidney as well as 
dwarfism (Tateossian et al. 2015; Saifudeen et al. 2009; Baatout et al. 2002). Trp53-/- female 
mice are also less fecund due to lack of expression of Lif1, the p53-dependent gene encoding 
Leukaemia Inhibitory Factor, a cytokine cri2cal for embryo implanta2on (Hu et al. 2007). 
Importantly, the variable penetrance developmental phenotypes observed in Trp53-/- mice 
probably fail to reflect the complete scope of p53’s involvement in these complex 
developmental processes due to some degree of compensa2on by the closely related and 
func2onally degenerate p63 and p73 (Jain & Barton 2018), both of which have been shown to 
play more direct, prominent roles in mouse development than p53 (Mills et al. 1999; Yang et al. 
1999; Yang et al. 2000). 
I.5.3	p53	plays	a	key	role	in	somatic	stem	cell	maintenance		
 More recent studies have shown the involvement of p53 in soma2c stem cell 
homeostasis, including the regula2on of haematopoie2c cell fates, renewal and differen2a2on 
of mammary stem cells and repression of hepa2c stem cells (Liu et al. 2009; Bondar & 
Medzhitov 2010; Colaluca et al. 2008; Tosoni et al. 2015; Tschaharganeh et al. 2014). p53 also 
plays key roles in various signalling pathways that, respec2vely, regulate pluripotency and 
induce differen2a2on. For instance, p53 is required to maintain the balance of DNA methyla2on 
that is important in preserving mouse embryonic stem cell homogeneity in vitro (Tovy et al. 
2017). Notably, p53 is reported to induce mouse embryonic stem cell differen2a2on by 
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repressing expression of Nanog (a homeobox transcrip2onal factor that maintains embryonic 
stem cell pluripotency by suppressing cell fate determina2on factors; (Lin et al. 2005)), while 
Wang et al. demonstrated a specific role for p53 and its family members in modula2ng 
mesendoderm differen2a2on of mouse embryonic stem cells by coordina2ng Wnt and Nodal 
signalling (Wang et al. 2017). 
I.5.4	p53	and	cellular	stresses	-	metabolism,	hypoxia	and	autophagy	
 Discoveries of the direct p53 target genes TIGAR (TP53-induced glycolysis and apoptosis 
regulator) and DRAM (damage-regulated autophagy modulator) in 2006 established the first 
links between p53 and cellular metabolism. p53’s role in metabolism mirrors that of its DNA 
damage responses: in the presence of mild and transient metabolic stresses, redox imbalance or 
hypoxia, p53 facilitates responses that protect cells and allows them to cope with the insults, so 
promo2ng cell survival. However, if the insult persists or the damage inflicted cannot be 
resolved, p53 switches its role to promote cell death or, possibly, irreversible arrest (i.e. cellular 
senescence) (Humpton & Vousden 2016). Thus, when a cell is subject to a transient glucose 
scarcity, AMPK (AMP-ac2vated protein kinase) acts through p53 to facilitate metabolic cell-cycle 
arrest (Jones et al. 2005). p53 transac2vates TIGAR, which in turn facilitates metabolic 
reprogramming by reducing the glycoly2c rate and increasing oxida2ve phosphoryla2on. In 
concert, p53 also directly adjusts expression of glycoly2c enzymes accordingly. The net outcome 
is priori2sa2on of metabolic pathways that sustain survival of cells over counterproduc2ve 
expenditure through prolifera2on-related pathways (Humpton & Vousden 2016). 
 Another common source of stress in cells is increased reac2ve oxygen species (ROS). 
Following a mild increase in ROS, p53 protects cells by media2ng ROS detoxifica2on. Upon 
induc2on by upstream signals, p53 increases TIGAR expression, which promotes produc2on of 
NADPH (which helps with ROS removal) via the pentose phosphate pathway and induces 
expression of an2oxidant genes, such as aldehyde dehydrogenase 4 (ALDH4) that reduces 
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intracellular ROS level (Yoon et al. 2004). On the other hand, Fitzgerald et al. showed that upon 
irradia2on, p53-dependent expression of CDKN1A in a human cancer cell line increased the ROS 
level and led to more senescence (Fitzgerald et al. 2015). Although it has been shown in 
haemotopoie2c stem cells (HSC) that p53 is induced by thioredoxin-interac2ng protein (TXNIP) - 
a ROS sensor - upon mild ROS stress, how p53 is induced in other contexts is s2ll not known 
(Jung et al. 2013; Budanov 2011). 
 p53 func2ons analogously during hypoxia. When hypoxic stress is mild and transient, 
p53 protects by helping cells to cope with the stress and to survive (Alarcón et al. 1999; Li et al. 
2004; Feng et al. 2011). However, in cells undergoing a severe lack of oxygen (anoxia), p53 
ac2va2on correlates with cell death. However, no consistently proven mechanis2c rela2onship 
is known that links hypoxia sensors (such as HIF1 complex) and p53. Consequently, the p53 
response to severe hypoxia may well be an indirect consequence of oxygen depriva2on – 
perhaps via DNA damage (Hammond et al. 2002; Pan et al. 2004).  
 p53 also plays an important role in autophagy, the cellular catabolic process that 
recycles intracellular components such as macro-molecules and organelles to facilitate survival 
of cells. Autophagy is an important transient survival mechanism in circumstances such as 
nutrient deficiency as it allows ra2oning and re-alloca2on of resources. Given p53’s role in 
media2ng metabolic stresses, as discussed, it is not unsurprising that p53 is also an ac2vator of 
autophagy through direct transac2va2on of autophagy-related genes such as DRAM (Crighton 
et al. 2006). Interes2ngly, p53 is also known to induced other autophagy genes such as Ulk1 and 
Atg7 upon DNA double strand breaks amongst other DNA damage response genes (Kenzelmann 
Broz et al. 2013).
 Nonetheless, although it is becoming clear that p53 plays a pivotal func2on as a 
coordinator of responses to stress in the soma, some fundamentally important ques2ons 
remain unanswered: what are the upstream ac2vators of p53 when subject to such diverse 
forms of insult? Since p53 is a but single protein yet facilitates differen2al signalling of so many 
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diverse effector pathways, how is each type of insult coded so as to be relayed by p53 to trigger 
the most effec2ve response? For example, is it facilitated by different sets of phosphoryla2on, 
acetyla2on and/or ubiqui2na2on on p53? Or by different parallel modulatory signals? Different 
chroma2n accessibility? What governs the thresholds at which p53 func2on shiNs from 
protec2ve to apopto2c? Is there a common threshold for all the stresses or dis2nct thresholds 
for each? Answers to these ques2ons, along with many more, are central to craNing a 
comprehensive func2onal picture of p53 biology.
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I.6	Questions	to	address	regarding	p53	biology	and	experimental	approach	
I.6.1	Importance	of	p53	in	adulthood	physiology	
 While its developmental roles have been fairly well characterised, p53’s importance in 
adulthood physiology is not well established, despite numerous published studies that implicate 
p53 in a wide range of physiological processes. And given the existence of the closely related 
and func2onally overlapping p53-family members p63 and p73, how essen2al and/or non-
redundant is p53 in the maintenance of adult 2ssues and organs in the face of injury, insults and 
infec2on? Such ques2ons might be effec2vely addressed by acutely and reversibly repressing 
p53’s expression and ac2vi2es in adulthood. For example, acute repression of p53 in adult mice 
would uncover any possible roles for endogenous p53 in its basal, non-ac2vated state, 
par2cularly in 2ssues known to express low level of p53 most of the 2me. More sustained p53 
suppression might reveal its role in maintaining 2ssues homeostasis, including any role in 
governing stem cell prolifera2on, differen2a2on and survival. 
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I.6.2	Clarifying	th30e	paradigm	of	p53	tumour	suppression	
 The discussions in SecGon I.5 call into ques2on p53’s role in tumourigenesis. While the 
ARF-p53 pathway is tumour suppressive, it appears to be an “improvised” evolu2onary 
adapta2on rather than a primordial evolved func2on of p53. Indeed, as discussed earlier, the 
tumour suppression func2on of p53 therefore appears sub-op2mally “designed” since it fails to 
detect the actual cause of tumourigenesis – the aberrant persistence of growth signals – but 
instead senses the supraphysiologically high signal flux generated by the most frequent 
oncogenic muta2ons, such as amplifica2on or promoter hijacking (Murphy et al. 2008). 
Moreover, despite being the most frequently mutated gene in human cancers, TP53 is oNen not 
completely inac2vated or deleted like other prominent tumour suppressors such as RB and APC 
in human cancers; instead, missense muta2ons are common that, while abroga2ng aspects of 
p53 func2on nonetheless preserve other aspects of its func2onality (Fodde 2002; Du & Searle 
2009; Aranda-Anzaldo & Dent 2007). These observa2ons suggest p53 may not solely play the 
part of suppressor of tumourigenesis but might also contribute to genesis and evolu2on of 
cancer cells via its other, non-tumour suppressive func2ons, for example those media2ng 
protec2ve responses to injury or stress. It seems plausible that these protec2ve p53 func2ons 
would be selec2vely retained, at least in early stages of tumourigenesis un2l the point where 
addi2onal oncogenic muta2ons drive oncogenic signals to the level where they breach the ARF-
p53 detec2on threshold. This unorthodox no2on is consistent with observa2ons that 
inac2va2on of TP53 appears to arise (i.e. be posi2vely selected) only rela2vely late in most 
human cancers, and is supported by a remarkable and counterintui2ve study in the early 90s in 
which inves2gators compared the early development of chemically induced skin cancer in 
germline p53-null versus WT mice. Unexpectedly, they noted that an absence of p53 
significantly impedes the oncogenic process by greatly reducing the incidence of papillomas 
(Figure I.2) (Kemp et al. 1993). At the 2me, this observa2on was perplexing and contrary to the 
deeply rooted paradigm of p53 as a potent tumour suppressor. However, a role for p53 in 
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protec2ng early stage cancers is en2rely consistent with these observa2ons. Undoubtedly, 
further careful tes2ng of the hypothesis, for example by suppressing p53 ac2vi2es in early 
stages of tumourigenesis, will yield an essen2al understanding of the dynamic roles p53 plays in 
different phases of carcinogenesis.
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Figure I.2 Rate of papilloma genesis in p53 wild type (Trp53+/+), hemizygous (Trp53+/-) and null (Trp53-/-) 
mice. Note that only the number of papillomas was ploged; once a papilloma evolved to later stage 
carcinoma, it was not included. The curve for p53-null mice stops at 18 weeks because either all papillomas 
had converted to carcinomas or the animal succumbed to spontaneous tumours (Figure from Kemp et al. 
1993).
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I.6.3	Aims	of	the	project	and	experimental	approaches	
 The two main ques2ons regarding p53’s physiological and tumourigenic roles to address 
in this thesis are: 
(1) What are the immediate consequences, if any, of acute blockade of p53 func2on in adult 
mice – both systemically and 2ssue-by-2ssue? Does prolonged suppression of p53 
func2ons in adult mice impact maintenance of 2ssue homeostasis? 
(2) Does p53 confer any advantages to the genesis and/or early stage development of 
chemically induced skin cancer? What aspects of p53’s func2ons are involved? 
  
 The experiments designed to address these ques2ons are illustrated in Figure I.3 below. 
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Figure I.3 SchemaGc diagrams of experiments to address quesGons regarding p53’s funcGons in (a) 
physiological processes and (b) at different stages of tumourigenesis.
Repress p53 funcGons 
at different stages
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I.6.4	In	vivo	models	to	be	used	
 To efficiently address the ques2ons regarding p53’s physiological func2ons and its roles 
in tumourigenesis, an in vivo switchable model of p53 is required and it must fulfil several 
prerequisites:   
(1) Rapidly and reversibly switchable repression of all endogenous Trp53 alleles. This permits 
dissec2on of physiological and tumourigenic func2ons of p53 in its na2ve contexts with 
precise temporal resolu2on.  
(2) Minimal impact exerted by the implemented repression system on the normal expression 
and regula2on of Trp53 and so when the repression system is not in use the animals 
behave exactly as wild type. It also permits normal development of experimental animals 
without poten2al compensa2on from other genes such as Trp63 and Trp73. 
 Although exis2ng gene2c mouse models of p53 employing different switchable 
molecular technologies such as Cre recombinase-mediated gene excision and ligand-ac2vatable 
estrogen receptor protein domain are available, none fulfils the posted criteria due to their 
caveats and limita2ons (discussed in details in Chapter 1 SecGon 1.1). Hence, it is necessary to 
develop a novel, improved reversibly switchable system of p53 to address the important 
ques2ons regarding p53’s func2ons in physiological processes and tumorigenesis. 
 The chemically induced skin cancer model of skin squamous cells carcinoma (Abel et al. 
2009) used in the Kemp study (1993) will also be used here too as the induced skin cancer 
develop with a well-defined, visually assessable progression, providing an ideal perform for 
temporal dissec2on of p53’s func2ons at different stages. 
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M.1	Molecular	cloning	and	DNA	manipulation	
M.1.1	PCR	ampli;ication,	restriction	digestion	and	ligation	of	DNA	
 PCR was used to amplify DNA fragments throughout the cloning process using Q5 High-
Fidelity DNA Polymerase (NEB). General PCR composiGon and reacGon cycles recommended by 
the manufacturer are summarised in Tables M.1a and M.1b respecGvely. Colony-PCRs used for 
screening plasmid constructs in E. coli using the same reacGon condiGons were carried out with 
Taq Polymerase (NEB) following the manufacturer’s instrucGons (not shown). Table M.1c shows 
the primers used in all PCR reacGons in this thesis. 
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Table M.1a General PCR reac;on composi;on
Reagent Volume
DNA template (Plasmid to be verified) 0.5 μl
10x ExTaq Buffer (Thermo ScienGfic) 5 μl
2.5 mM dNTP (Thermo ScienGfic) 4 μl 
Primer 1 (depends on gene to be amplified) 2 μl
Primer 2 (depends on gene to be amplified) 2 μl
Q5 or Taq DNA Polymerase 0.25 μl
MiliQ water To 50 μl
Table M.1b General PCR reac;on cycle
Step Temperature Dura;on
1 95oC 3 minutes
2 95oC 25 seconds
Repeats 29 ;mes3 T oC (Depend on primer melGng temperature) * 25 seconds
4 72oC t minutes #
4 72oC 5 minutes
5 10oC 2 minutes
* T = ~2 oC lower than the Tm of the primer with a lower Tm 
#  t depends on size of fragment to be amplified; generally 60 second/1000 bp. 
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Table M.1c List of PCR primers used
Direc;on Primer sequence Descrip;on Tm (OC) 
Forward 5'-CTTCCTACAGATCCTTCTGT-3'
BAC verification PCR 1. Figure 1.6. 
54.9
Reverse 5'-GTAGTGTTGCTTGCCTGT-3' 56.2
Forward 5'-TTCTGACCTCTGCATGTC-3'
BAC verification PCR 2. Figure 1.6. 
57.1
Reverse 5'-CCCAAGTAAAAAGTTGGA-3' 55
Forward 5'-CTAGGGAAACAAGCTCGT-3'
BAC verification PCR 3. Figure 1.6. 
57
Reverse 5'-CGACAGTCTTGTAATCTCAA-3' 55.3
Forward 5'-TTAGCTAATGAGGGGAAA-3'
BAC verification PCR 4. Figure 1.6. 
54.8
Reverse 5'-GCTTTGTGCATGTTATT-3' 51.4
Forward 5'-AAAAAA-GTCGAC-TAGGCACACTGACATGCCTA-3'
To clone 200 bp homology sequence upstream of the 
10 kbp fragment into the DTA3 vector. Figure 1.7.
62
Reverse 5'-TTTTTT-AGATCT-GTTGTTTGAGACAGGGTTTC-3' 58.6
Forward 5'-AAAAAA-AGATCT-GCTTACATATGACCCTGCAC-3'
To clone 200 bp homology sequence downstream of 
the 10 kbp fragment into the DTA3 vector. Figure 1.7.
59.6
Reverse 5'-TTTTTT-GGTACC-TCAACTGTAGCAGCAGGTTA-3' 58.7
Forward 5'-AAAAAA-GTCGAC-GCTTCACAGTAAGACCCTGT-3'
To clone 200 bp homology sequence upstream of the 
10 kbp fragment into the DTA4 vector. Figure 1.7.
58.4
Reverse 5'-TTTTTT-AGATCT-GTTTGTTTTGAGATGGGGTC-3' 60.8
Forward 5'-AAAAAA-AGATCT-CCCTTTCAGATAGATACCGG-3'
To clone 200 bp homology sequence downstream of 
the 10 kbp fragment into the DTA4 vector. Figure 1.7.
60
Reverse 5'-TTTTTT-GGTACC-GGCAGGTGAATGACTCTTTAT-3' 59.6
Forward 5'-AAAAAA-GTCGAC-ATAAGATCGTCTCAAAGGCG-3'
To clone 200 bp homology sequence upstream of the 
10 kbp fragment into the DTA5 vector. Figure 1.7.
60.8
Reverse 5'-TTTTTT-AGATCT-ATCATTTGTCACACCCAAGT-3' 59.3
Forward 5'-AAAAAA-AGATCT-CCCAGAACCCACTTCTTATA-3'
To clone 200 bp homology sequence downstream of 
the 10 kbp fragment into the DTA5 vector. Figure 1.7.
58.1
Reverse 5'-TTTTTT-GGTACC-GAGGTAGGCTCTTCCTTATC-3' 56.1
Forward 5’-TGCTTTCCCTCAAGACAGATTCTCTAAGTAGCCCTGGCTGT CCTAGAACTGGACCCATGG-TCGAGTTTACCACTCCCT-3' To add homology sequences of 60 bp upstream and 
downstream of insertion site C3 to the two ends of 
the TRE-LoxP-Neo-LoxP cassette. Figure 1.9. 
57.1
Reverse 5’-TTAATCTCAGCACTCTGGGGGAAGAAGCAGGCAGATGTGT GAGTTCCAGGCAAACATGGA-ATAACTTCGTATAGCATACATT-3
51.6
Forward 5’-CTGCAAGTCCCCGCCTCCATTTCTTGCCCTCAACCCACGGA AGGACTTGCCCTTACTTGT-TCGAGTTTACCACTCCCT-3' To add homology sequences of 60 bp upstream and 
downstream of insertion site C4 to the two ends of 
the TRE-LoxP-Neo-LoxP cassette. Figure 1.9. 
57.1
Reverse 5’-AAAGTCCCAATCCCAGCAACCCCCGCGAGACTCCTGGCACA AAGCTGGATAGTCGCCATA-ATAACTTCGTATAGCATACATT-3'
51.6
Forward 5’-TTGGCGGGCGGGATGAACGGGAGTGTATATGTCAGATGCTG TAGTGAGGGTAGCTGATGA-TCGAGTTTACCACTCCCT-3' To add homology sequences of 60 bp upstream and 
downstream of insertion site C5 to the two ends of 
the TRE-LoxP-Neo-LoxP cassette. Figure 1.9. 
57.1
Reverse 5’-CCCTATATGCTCTACTTTGCAGGTGCATGACAGTGAGGCTCG TCGGTCCTAACATCATCA-ATAACTTCGTATAGCATACATT-3'
51.6
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Table M.1c List of PCR primers used (con;nued)
Direc;on Primer sequence Descrip;on Tm (OC) 
Forward 5’-GACCCTATCTCAAAATAAAGCAAAA-3’
Amplifying 5’ junction of TRE-LoxP-Neo-LoxP 
cassette insertion at C3. Figure 1.11.
62.5
Reverse 5'-CGTCCTGCAGTTCATTCA-3' 64.1
Forward 5'-TTCTTTTTGTCAAGACCGAC-3'
Amplifying 3’ junction of TRE-LoxP-Neo-LoxP 
cassette insertion at C3. Figure 1.11.
59.3
Reverse 5’-TGAAAGGTTGCAAGTGGTAAGT-3’ 62.4
Forward 5'-TAGCTGGATAGGAAAGAGCA-3'
Amplifying 5’ junction of TRE-LoxP-Neo-LoxP 
cassette insertion at C4. Figure 1.11.
59.2
Reverse 5'-CGTCCTGCAGTTCATTCA-3' 64.1
Forward 5'-TTCTTTTTGTCAAGACCGAC-3'
Amplifying 3’ junction of TRE-LoxP-Neo-LoxP 
cassette insertion at C4. Figure 1.11.
59.3
Reverse 5'-GTTTTATGGATGCAAACGGA-3' 62.2
Forward 5'-GGTAGCGACTACAGTTAGGG-3'
Amplifying 5’ junction of TRE-LoxP-Neo-LoxP 
cassette insertion at C5. Figure 1.11.
57.9
Reverse 5'-CGTCCTGCAGTTCATTCA-3' 64.1
Forward 5'-TTCTTTTTGTCAAGACCGAC-3'
Amplifying 3’ junction of TRE-LoxP-Neo-LoxP 
cassette insertion at C5. Figure 1.11.
59.3
Reverse 5'-ATCTCATCCAGGAACGGAA-3' 62.1
Forward 5’-GAATTCGATATCAAGCTTATCGATACCG TCGAC-ATCAGCCATCTCTAAACCGG-3' To amplify the first fragment of the TRE-LoxP-Neo-
LoxP cassette-inserted DTA3 vector for Gibson 
assemble. Section 1.3.
62.3
Reverse 5'-TCGTCCTGCAGTTCATTCAG-3' 64.1
Forward 5'-CGGTTCTTTTTGTCAAGACC-3' To amplify the second fragment of the TRE-LoxP-
Neo-LoxP cassette-inserted DTA3 vector for Gibson 
assemble. Section 1.3.
64.1
Reverse 5’-CCCTCACTAAAGGGAACAAAAGCTGGG TACC-ATTGCTTTAGGTTCGGCTTA-3'
60.3
Forward 5’-GAATTCGATATCAAGCTTATCGATACCGT 
CGAC-ATATGCATTTGCACACTGCC-3' To amplify the first fragment of the TRE-LoxP-Neo-LoxP cassette-inserted DTA4 vector for Gibson 
assemble. Section 1.3.
63.5
Reverse 5'-TCGTCCTGCAGTTCATTCAG-3' 64.1
Forward 5'-CGGTTCTTTTTGTCAAGACC-3' To amplify the second fragment of the TRE-LoxP-
Neo-LoxP cassette-inserted DTA4 vector for Gibson 
assemble. Section 1.3.
61.1
Reverse 5’-CCCTCACTAAAGGGAACAAAAGCTGGGT 
ACC-CTTTCTCTAAGGAACCATCG-3'
58
Forward 5’-GAATTCGATATCAAGCTTATCGATACCGTC 
GAC-CACAGTTTTCACTTGCAGGG-3' To amplify the first fragment of the TRE-LoxP-Neo-LoxP cassette-inserted DTA5 vector for Gibson 
assemble. Section 1.3.
63.3
Reverse 5'-TCGTCCTGCAGTTCATTCAG-3' 64.1
Forward 5'-CGGTTCTTTTTGTCAAGACC-3' To amplify the second fragment of the TRE-LoxP-
Neo-LoxP cassette-inserted DTA5 vector for Gibson 
assemble. Section 1.3.
61.1
Reverse 5’-CCCTCACTAAAGGGAACAAAAGCTGGGTA 
CC-GCGCGTACTCAGTGTGATAA-3'
61.5
Forward 5'-GGAACACAAAGGTCCTTGTG-3'
To clone DNA probe 3.3 for southern blot from 
wildtype mouse genomic DNA. 
62
Reverse 5'-GTCTGGCCTTATCTTGGTCA-3' 61.7
METHODS AND MATERIALS 
 RestricGon enzyme digesGons were carried out following the manufacturer’s instrucGons 
(NEB). The general reacGon composiGon and condiGons are summarised in Table M.2. 
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Table M.1c List of PCR primers used (con;nued)
Direc;on Primer sequence Descrip;on Tm (OC) 
Forward 5'-GACCACAGTGTCCAGACCAT-3'
To clone DNA probe 7.8 for southern blot from 
wildtype mouse genomic DNA.
62.6
Reverse 5'-AAAGGATTGCGAAAAAGGAC-3' 61.9
Forward 5’-GACCCTATCTCAAAATAAAGCAAAA-3’ Amplifying across the whole insertion at C3; also 
used for PCR genotyping for TRE3-inserted mice. 
Figure 1.17, Figure 1.22, Figure 2.1.
62.5
Reverse 5’-TGAAAGGTTGCAAGTGGTAAGT-3’ 62.4
Forward 5'-TAGCTGGATAGGAAAGAGCA-3' Amplifying across the whole insertion at C4; also 
used for PCR genotyping for TRE4-inserted mice. 
Figure 1.17, Figure 1.22, Figure 2.1.
59.2
Reverse 5'-GTTTTATGGATGCAAACGGA-3' 62.2
Forward 5'-GGTAGCGACTACAGTTAGGG-3' Amplifying across the whole insertion at C5; also 
used for PCR genotyping for TRE5-inserted mice. 
Figure 1.17, Figure 1.22, Figure 2.1.
57.9
Reverse 5'-ATCTCATCCAGGAACGGAA-3' 62.1
Table M.2 General reac;on condi;ons for restric;on enzyme diges;on
Reagent Volume
DNA to be digested x μl (0.5 - 1 μg) *
10x NEBuffer 5 μl (which one to use depends on enzyme)
RestricGon enzyme 1 - 4 μl (depending on enzyme)
Sterilized water To 50 μl
Total reacGon volume 50 μl
IncubaGon temperature 37oC (25oC for ApaI)
IncubaGon Time 1 hour
* value of x depends of DNA concentraGon
METHODS AND MATERIALS 
 DNA ligaGon reacGons were carried out following the manufacturer’s instrucGons (NEB) 
as summarised in Table M.3 below. 
M.1.2	BAC	preparation	and	veri;ication	
 The BAC preparaGon and verificaGon methods used were modified from the online 
protocol provided by Dr. Douglas Mortlock (hgp://kingsley.stanford.edu/Lab%20Protocols-
WEB%202003/Molecular%20Biology/BAC%20modificaGon%20protocol.htm). A 2ml overnight 
culture was collected in an eppendorf tube and pelleted by centrifugaGon for 1 minute at 20000 
x g. The pellet was resuspended in 250 μl of resuspension buffer (1x TE buffer pH8, 10mM Tris-
HCl containing 1mM EDTA added with 100 µg/mL RNase A). 250 μl of lysis buffer (200 mM 
NaOH, 1%SDS) was added to lyse the cells for 2-3 mins. 350 μl of neutralisaGon buffer (3 M 
potassium acetate, pH5.5) was added followed by vigorous mixing. The mix was then 
centrifuged for 10 min at 20000 x g. The supernatant was transferred to a tube containing 550 
μl of isopropanol and centrifuged for 15min at 20000 x g. The supernatant was discarded and 
the pellet washed with 70% ethanol. Aner briefly air drying, the pellet was resuspended in 30 μl 
of water. 
 PCRs that amplify four short regions across the p53 promoter and intron sequence in the 
BAC were used to verify the BAC. The four pairs of primers are listed in Table M.1c. 
Table M.3 Composi;on and condi;on of liga;on reac;on 
Reagent
DNA vector backbone 50 ng
Insert (wildtype or mutant c-myc genes) 3x backbone (molar radio)
10x T4 DNA Ligase buffer (NEB) 2 μl 
T4 DNA Ligase (NEB) 1 μl
MiliQ Water To 20 μl
Total reacGon mixture volume 20 μl
IncubaGon temperature 25oC
IncubaGon Gme 15 minutes
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M.1.3	Preparing	electro-competent	EL350,	electroporation	and	recombineering		
of	DNA	in	EL350	
 The protocol used was modified from the online protocol provided by Dr. Douglas 
Mortlock (hgp://kingsley.stanford.edu/Lab%20Protocols-WEB%202003/Molecular%20Biology/
BAC%20modificaGon%20protocol.htm). 
 EL350, a strain of bacteria that harbour heat-inducible expression of recombinase (at 
42oC), was grown in 2 mL overnight in Luria-Bertani (LB) broth with appropriate anGbioGcs at 
32oC. A 50 mL culture was inoculated using 1 mL of the overnight culture unGl the OD at 600 nm 
reaches 0.4-0.6. Recombinase acGvity was induced by incubaGon with constant swirling at 42oC 
for 10-15 mins and then chilled on ice for 15 mins. A negaGve control for recombineering that 
was not incubated at 42oC was also included. The bacteria were collected by centrifugaGon for 
10 mins at 2680 x g. The supernatant was discarded and 30 ml cold water (pre-chilled overnight 
at 4oC fridge) was added to re-suspend the pellet by mixing the tube on ice. The bacterial pellet 
was washed twice more and the final bacterial pellet re-suspended in 1 mL of water and 
transferred to a pre-chilled eppendorf tube. The bacteria were collected by centrifuge for 5 
mins at 2680 x g at 4oC . The supernatant was discarded and the bacteria re-suspended in 200 μl 
of cold sterilised water, which was used for 4 transformaGons. 
 DNA diluted in water was added to a pre-chilled eppendorf tube containing 50 μL of 
electro-competent bacteria and mixed by gentle pipepng up and down. The mixture was 
transferred to a pre-chilled 1mm cuvege and an electric pulse delivered (volts = 1.8, capacitance 
= 25uFD and resistance = 200 Ohms). The electroporaGon mixture was removed by adding 500 
μL of LB to the cuvege and transferred to an eppendorf tube. The tube was shaken at 32oC for 1 
hour and the bacteria plated onto LB agar plates containing appropriate anGbioGcs. 
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M.1.4	Gibson	Assembly	
 Gibson Assembly reacGons were carried out following the manufacturer’s instrucGons 
(NEB), summarised in Table M.4 below. 
 The DNA vector to be recombineered was suspended in water and electroporated 
into electro-competent EL350 E. coli that carried the heat-inducible recombinase gene. 
Following recovery, the bacteria were then plated on LB agar plates containing 
appropriate anGbioGcs for selecGon. 
M.1.5	Antibiotics	used	in	molecular	cloning	
 AnGbioGcs used to select posiGve clones were detailed in Table M.5 below.  
Table M.4 Composi;on and condi;on of Gibson Assembly
DNA fragment 1 0.02 - 0.5 pmols
DNA fragment 2 0.02 - 0.5 pmols
Gibson Assembly Master Mix (2X) 10 μl 
Deionised H2O To 20 μl
Total reacGon mixture volume 20 μl
IncubaGon at 50OC Up to 60 minutes
Table M.5 List of an;bio;cs
Name Working concentra;on
Ampicillin 100 μg/mL
Chloramphenicol 10 μg/mL (in ethanol)
Kanamycin 50 μg/mL
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M.2.	Mouse	embryonic	stem	cells	(mESCs)	culture	and	targeting	
M.2.1	Culture	of	mESCs	
 Wild-type mouse embryonic stem cells (mESCs) were cultured on gelaGn-coated Gssue 
culture dishes in 2I/LIF medium in a 37oC, 5% CO2 and 0.1% oxygen environment as described 
(Silva et al. 2008). For maintenance, cells were normally passaged every two days by 
trypsinizaGon. When necessary, doxycycline was added to the growth medium to a final 
concentraGon of 1 mg/mL for various duraGons as indicated in the results. 
 For transfecGon with DTA targeGng vectors, mESCs were cultured on an extra layer of 
mitomycin C-treated, i.e. mitoGcally inacGvated feeder cells (mouse embryonic fibroblasts) 
grown on the gelaGn-coated plate (mitomycin C concentraGon = 10 μg/mL; 2 hours at 37OC).  
M.2.2	DNA	electroporation	into	mESCs	
 E14 mESCs were grown to 60% confluence in a 6-well plate, recovered by trypsinizaGon 
and resuspended in 800 μL of DMEM containing 40 μg of the DTA targeGng vector linearised by 
NotI restricGon enzyme digesGon (NEB). The cells were then electrophorated using a BioRad 
GenePulser Xcell electroporaGon machine (0.96 kV, 10 μF) and transferred to 9.2 mL of pre-
warmed 2I/LIF medium followed by seeding onto ten 10-cm gelaGn-coated dishes with a layer 
of the inacGvated feeder cells menGoned in M.2.1 (1 mL per dish). AnGbioGc selecGon was 
added one day aner seeding and conGnued unGl resistant colonies arose (or non-transfected 
cells all died). 
M.2.3	Isolation	of	antibiotic-resistant	clones	of	mESCs	
 AnGbioGc-resistant colonies (in the form of embryoid bodies) were picked with a 10 μL 
pipege Gp, dissociated into single cells by treatment with trypsin (0.05% with 0.02% EDTA, 37 
OC, 5 minutes) and then seeded into gelaGn-coated 96-well plates. 96 colonies were picked for 
each transfecGon. Medium was changed one day later and the cells passaged by 1:4 diluGon 
41
METHODS AND MATERIALS 
into four 96-well plates. When confluent, the medium of three of the four duplicate 96-well 
plates was changed to freezing medium (70% Glasgow Minimum EssenGal Medium (GMEM), 
20% serum, 10% DMSO) and the plates frozen and stored in a -80 OC freezer for later thawing 
aner verificaGon of correct targeGng. The remaining plate was used to prepare genomic DNA 
(gDNA) for southern blot verificaGon of correct targeGng.  
M.2.4	Preparation	of	mESCs	for	blastocyst	injection	
 Correctly targeted clones of mouse embryonic stem cells were thawed and expanded 
into 6-well plates. The cells were trypsinized and resuspended in 200 μL of injecGon medium 
(N2B27 medium with 0.1M HEPES). Blastocyst injecGon was carried by the core facility of the 
Cambridge Stem Cell InsGtute. 
M.2.5	Lipofectamine	transfection	of	mESCs	
 Lipofectamine 2000 transfecGon reagent (ThermoFisher ScienGfic Cat. no.: 11668030) 
was used to introduce the Cre-expressing DNA vector pCAG-Cre (a gin from Connie Cepko; 
Addgene plasmid #13775; hgp://n2t.net/addgene:13775; RRID:Addgene_13775; (Matsuda & 
Cepko 2007)) and rtTS-expressing DNA vector following the manufacturer’s instrucGons. While 
the expression of Cre from pCAG-Cre was only transiently required and hence no permanent 
integraGon of the plasmid into the mESCs genome, persistent rtTS expression was required in 
the mESCs and so the cells were selected with puromycin (working concentraGon = 1 µg/mL) for 
stable integraGon of the linearised pPCAGIPCAG plasmid into the genome. 
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M.2.6	mESCs	culture	media	composition	
M.3	Primary	mouse	embryonic	;ibroblasts	(MEFs)	culture		
 Mouse embryonic fibroblasts (MEFs) of various desired genotypes were prepared from 
13 d.p.c. (day post-coitum) embryos as described (Jozefczuk et al. 2012). Cells were passaged 
and maintained in Dulbecco's minimal essenGal medium supplemented with 10% BGS, 5% 
glucose and 2 mM Glutamine (DMEM; Sigma-Aldrich) at 37oC and 5% CO2. For maintenance, 
cells were normally passaged every two days by standard trypsinizaGon. When necessary, 
doxycycline was added to the growth medium to a final concentraGon of 1 mg/mL for different 
periods of Gme as indicated in the results. 
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mESCs freezing medium 2x 1x
GMEM w/ serum 40% 70%
Extra Serum (FBS) 40% 20%
DMSO 20% 10%
2I/LIF
N2B27 200 mL
PD03 (to 1 μM) 20 μL (10 μL of stock/100 mL)
Chiron (to 3 μM) 60 μL (30 μL of stock/100 mL)
Mouse LIF (for mESC) 200 μL (stock = 1000x)
N2B27 (base for 2I/LIF)
DMEM/F12 500 mL
Neurobasal medium 500 mL
N2 (need to match batch with B27) 5 mL
B27 (need to match batch with N2) 10 mL
Glutamine 10 mL
2-Mercaptoethanol 1.1 mL
METHODS AND MATERIALS 
M.4	Southern	blot		
 Genomic DNA (gDNA) was harvested from cells grown in culture or mouse Gssues 
extracted using tail lysis buffer (50 mM TRIS, 50 mM EDTA, 0.5% SDS) followed by ethanol 
precipitaGon. 4 μg of gDNA was digested overnight at 37 OC with the desired restricGon 
enzymes, separated by agarose gel (0.8% agarose) electrophoresis (70 volt, 8 hours) and 
transferred onto Hybond C membranes.  50 ng of DNA probes 3.3 or 7.8 prepared by PCR and 
radioacGvely labelled with 32P using the Random Primed DNA Labelling Kit (Roche, Cat. No. 11 
004 760 001) were used to anneal to the 5’ and 3’ ends of the targeted inserted DNA. Table M.5 
shows the sequences of the DNA probes 3.3 and 7.8. 
 The radioacGvely hybridised membranes were sequenGally washed with a series of 
buffers with increasing stringency (2x to 0.2x saline-sodium citrate buffer plus 0.1% SDS; 1x 
saline-sodium citrate buffer = 150 mM sodium chloride, 15 mM trisodium citrate, pH7) and then 
exposed to X-ray film for 10 days in -80oC freezer and then developed with an AFP Mini-Med 90 
automated developer. 
 The radioacGvely hybridised membranes were washed with a series of washing buffers 
of decreasing concentraGons (saline-sodium citrate buffer 1x = 150 mM sodium chloride, 15 
mM trisodium citrate, pH7; 0.1% SDS) and then visualised by X-ray film exposure in a light-
sealed cassege. The X-ray films were exposed to the membrane for 10 days in -80oC freezer (the 
low temperature intensified the signals) and then developed. 
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Table M.5 Sequences of southern blot probes
Probe 3.3 5’-GGAACACAAAGGTCCTTGTGTCTACAGGTAAAAACCCTATTCTTCCATCCAGAAAGCTAGG 
AATTGAAGTGATTAATAGTCCTGTGATCTGTTATCTGCTGGGCTAAGCCATACCAAGTTCCTTC
AACCAGGGCCAGAGGTGGCTAGTACTCTAAATGAGCCTTACAGACAGGGGCTCCCCAAGCT
CCCACAGCCAGGACCTGAGATACCTAATAGTCTAAATGACCTTCACATCATCTGTATGGCCAGG
GGCTTCCCCAGGCTCCCACAACCAGGACTACAAGTGGCTAATATCCCAAACGACCTCTATAGC
ATCTGTATGACCAAGATAAGGCCAGAC-3’
Probe 7.8 5’-GACCACAGTGTCCAGACCATACATAGAGGGAGTTCAAGGTCATCCTTCCCTGGGTAGTTGT 
AAGCTGACTTGAGATAAATGAGAGTGTCTTCAAAAACAGAGAAAGAGTACAAAAGTTAACAT
TGGCAAACCAGAGCCTACTGGCCTTTCTCCTGATGGGTAAATGAGGACGTCTCGATGGCCCG
TGCCTTTAATGCTAACACTCTTGGGATGCTGAGGTAACTTGGGCTACTTAGCAAGACCTTGTC
TCAGAAAGGCAAACAGCTGGAGATATGGCTTGGAGTAGATTATTTCACCTGGCAAACATGAT
ACCCTTGGTTTAAATCCTGAGACCACAAAAAACAGGTTAAACCCAGCTTGACCAAGTGCCAT
TGGTCCATGGATTGCTGTATTGGAATCAAACAGAAATCTATGTCATTCACAGCAGTAACCTCCT
GGGAATACTTCAAGAGACGGAGAAAGGGCGACTGACTGTGCCCTCCGTCCTTTTTCGCAATC
CTTT-3’
Underlined are the annealing sequences to which the primers used to amplified the probes from 
wildtype mouse gDNA by PCRs.
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M.5	RNA	extraction	and	qPCR	analysis	
 Messenger RNA was extracted from cells or frozen mouse Gssues using Trizol reagent 
following the manufacturer’s protocol (ThermoFisher ScienGfic, Cat no. 15596018). 
Complementary DNA (cDNA) was synthesized from the extracted mRNA (1 mg of mRNA used 
per reacGon) by reverse transcripGon using the High-Capacity cDNA Reverse TranscripGon Kit 
following the manufacturer’s protocol (Applied BiosystemTM, Cat no. 4368814). The synthesized 
cDNA was diluted 1:5 and then analysed by real Gme PCR (qPCR) using SYBRTM Green Master 
Mix (Applied Biosystem, Cat no. 4367659) and the QuantStudio™ 5 Real-Time PCR System 
(Applied Biosystem, Cat no. A28140). Table M.6a outlines the general condiGons of the qPCRs 
and Table M.6b lists the details of the qPCR primers used in this thesis. 
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Table M.6a General qPCR reac;on cycle
Step Temperature Dura;on
1 50oC 2 minutes
2 95oC 10 minutes
3 95oC 15 seconds
Repeats 39 ;mes
4* 61 oC 30 seconds
5 95oC 15 seconds
Melt curve stage4 60oC 1 minute
5 95oC 15 seconds
*Annealing plus amplificaGon step, primers are designed to have an annealing temperature of 60oC.
METHODS AND MATERIALS 
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Table M.6b List of qPCR primers used
Direc;on Primer sequence* Target
Forward 5'-ATGCCCATGCTACAGAGGAG-3'
Mouse endogenous Trp53
Reverse 5'-AGACTGGCCCTTCTTGGTCT-3'
Forward 5’-ACTTCGTGCAAGAAATGCTGAAT-3’
Mouse endogenous Tbp
Reverse 5’-CAGTTGTCCGTGGCTCTCTTATT-3’
Forward 5’-GGCCTGGAACTAATCATATGTG-3’
Mouse Rosa26rtTS knockin allele
Reverse 5’-CGAGTAAAGAGCACAGCCAC-3’
Forward 5’-TAGCAAACTGGTGCTCAAGG-3’
Mouse endogenous Bax
Reverse 5’-TCTTGGATCCAGACAAGCAG-3’
Forward 5’-GACGACCTCAACGCACAGTA-3’
Mouse endogenous Puma
Reverse 5’-CTAATTGGGCTCCATCTCG-3’
Forward 5’-CCTGGTGATGTCCACCTG-3’
Mouse endogenous Cdkn1a
Reverse 5’-CATGAGCGCATCGCAATC-3’
Forward 5'-CTTCCAGTGAGTTGAGTCCT-3'
Mouse endogenous Wrap53α
Reverse 5'-TTGCAACCTTTCAAGAAGTT-3'
Forward 5’-GATGATGGTTCGCCTCTT-3’
Mouse endogenous Wrap53β
Reverse 5’-AGTAGATGCGCTGATTAGTGGT-3’
*All primers were designed to have a uniform annealing temperature of 60OC at which the PCR programme was run.
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M.6	Protein	extraction	and	Western	blot	
 Cell lysates were prepared either from cultured cells or frozen mouse Gssues using RIPA 
buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1% sodium 
deoxycholate, 0.1% SDS) supplemented with protease inhibitors (Roche, Cat. no. 11836153001; 
1 tablet/10 mL of 1x RIPA). Following sonicaGon and centrifugaGon to remove genomic DNA, 
total protein concentraGon was determined using the BCA protein assay following the 
manufacturer’s protocol (Thermo ScienGficTM PierceTM BCATM, Cat. no. 10678484).  
 Lysates were supplemented with 0.01% bromophenol blue as a loading dye and 1 mM 
DTT, heated to 95oC for 3 minutes and 10 - 30 μg of total protein loaded onto SDS-12% 
polyacrylamide denaturing gels. Proteins were separated by electrophoresis (120 volt, 120 
minutes)  and then transferred to PVDF membranes by electroblopng in NuPAGE transfer buffer 
(Invitrogen) at 30v for 60 minutes. Non-specific protein binding to the membranes was blocked 
by incubaGon in 5% (w/v) bovine serum albumin in TBS-T (20 mM Tris and 150 mM NaCl, pH7.6, 
0.1% Tween 20) for 1 hour at room temperature. The membrane was then incubated for 1 hour 
each in primary and secondary anGbodies with washing three Gmes in TBST in between. 
Primary anGbodies used in the Western blots in this thesis are listed in Table M.7. Aner blopng 
with secondary anGbody the membranes were treated with ECL chemiluminescent substrate 
(Thermo ScienGfic) followed by exposure to X-ray. Films were developed and fixed using an AFP 
Mini-Med 90 automated developer. 
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Table M.7 An;bodies used in Western blots
An;body Source Target Primary/Secondary
Host 
species Clone
Concentra;on 
used
1C12 Cell 
Signaling
Mouse p53 
protein 1
O Mouse Monocolonal 1: 1000
AC15 Santa Cruz Biotech.
Mouse β-AcGn 
protein 1
O Mouse Monoclonal 1:5000
D16H11 Cell Signaling
Mouse Gapdh 
protein 1
O Rabbit Monoclonal 1:1000
A4416 Sigma Mouse IgG 2O-HRP Goat Polyclonal 1:10000
A0545 Sigma Rabbit IgG 2O-HRP Goat Polyclonal 1:10000
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M.7	Mice	
M.7.1	Genetic	backgrounds	and	strains	of	mice	
 All mice used in this project were of a mixed geneGc background of C57BL/6 and FVB. 
The strains of geneGcally altered mice are listed in Table M.8 below. 
M.7.2	Maintenance	of	mice	
 All breeding and experimental mice were housed in a Home Office approved facility at 
the CRUK Cambridge InsGtute under licence 70/7586. Day-to-day husbandry and breeding as 
well as most of the experimental treatments such as intraperitoneal injecGon, topical treatment 
of skin, and diet intake of doxycycline were carried out by trained facility staff. Substances 
administered to mice are shown in Table M.9.  
  Ear biopsies were taken from 3 week old pups at weaning. gDNA was extracted from the 
biopsies using Chelex 100 following the manufacturer’s protocol (BioRad, Cat. no. 1421253). 
The genotype was determined by  PCR as described in Sec;on M.1.  
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Table M.8 Strains of gene;cally modified mice used
Strain  (allele altered) Source Purpose Background
Trp53TRE/TRE Created in this project Reversible repression of endogenous Trp53 C57BL/6, 129/SvJ
R26CAG-rtTS/+ Dr. Ivonne Gamper, Evan group Reversible repression of endogenous Trp53 C57BL/6, 129/SvJ
PGK-CreTg/+ Evan group Cre-mediated removal of NeoR from the targeted allele C57BL/6, 129/SvJ
Trp53flox/flox;K14-CreERTg/+ Dr. Michaela Frye DeleGon of endogenous Trp53 gene in chemically induced skin cancer experiment C57BL/6, 129/SvJ
METHODS AND MATERIALS 
M.7.3	Chemical	induction	of	skin	cancer	
 Following the published protocol of chemical inducGon of skin cancer (Abel et al. 2009), 
the shaved dorsal skin of 6 week old mice was topically treated with DMBA once and then 
topically treated with TPA from the age of 7 weeks for up to 20 weeks (three treatments with 
TPA per week) (Table M.9). Mice were shaved weekly at the applicaGon site to assist in 
monitoring the development of skin tumours.  
M.7.4	Collection	and	preparation	of	mouse	tissues	
 Experimental mice were culled by cervical dislocaGon. Small pieces of lung, intesGne, 
liver, pancreas, spleen, thymus and skin were collected in an eppendorf tube and snap-frozen in 
liquid nitrogen and stored at -80oC or fixed in 10% formalin for 24 hours prior to storage in 70% 
ethanol. Formalin fixed Gssues were embedded in paraffin blocks and 4 µm secGons prepared 
on glass slides. 
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Table M.9 Substances administrated to mice
Substances Route of administra;on Concentra;on Amount/treatment
Sucrose water Drinking water 1% (w/v) in water Continuous
Doxycycline Drinking water 2 mg/mL in 1% sucrose water Continuous
Tamoxifen Intraperitoneal injection 10 mg/mL in oil 1 mg per injection
7,12-dimethyl-
benz[a]anthracene (DMBA)
Topical applicaGon on skin 666.7 μg/mL in acetone 100 μg per treatment
12-O-tetradecanoyl-
phorbol-13-acetate (TPA) Topical applicaGon on skin 33.4 μg/mL in acetone 5 μg per treatment
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M.8	Immuno;luorescence	staining	of	mouse	tissues	
 Paraffin embedded secGons of mouse Gssues were de-paraffinized using xylene and 
ethanol (3 x 5 minute wash in xylene; 2 x 5 minutes wash in 100%, 95% and 70% ethanol 
respecGvely; 1 x 5 minutes wash in 50% ethanol and water). The de-paraffinized secGons were 
processed for anGgen retrieval using citric buffer (10 mM Sodium citrate, 0.05% Tween 20, pH 
6.0): the slides were heated in boiling citric buffer in a microwave for 10 minutes. aner cooling 
by equilibraGng in 1x PBS-T (8 mM Na2HPO4, 150 mM NaCl, 2 mM KH2PO4, 3 mM KCl, 0.05% 
Tween 20, pH7.4) for 5 minutes, the slides were blocked with blocking soluGon (2% NGS in 1x 
PBS-T) for 60 minutes. The secGons were then bloged with primary and secondary anGbody (in 
blocking soluGon) overnight at 4 OC and 1 hour at room temperature respecGvely. Finally, the 
secGons were stained with DAPI (4ʹ,6-diamidino-2-phenylindole, ThermoFisher ScienGfic Cat. 
no. 62248) for nuclei and mounted with cover slides. The secGons were then examined under a 
fluorescent microscope. 
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Table M.10 An;bodies used in immunofluorescence staining of mouse ;ssues
An;body Source Target Primary/Secondary
Host 
species Clone
Concentra;on 
used
CM5 Leica Mouse p53 protein 1
O Rabbit Polyclonal 1:200
A11008 Alexa Fluor 488 Rabbit IgG (H+L) 2
O Goat Monoclonal 1:500
METHODS AND MATERIALS 
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Chapter	1:		
A	model	for	reversible	repression	of	endogenous	Trp53	
expression	
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CHAPTER 1 
1.1	Why	is	a	new	switchable	p53	model	needed? 
 The elucida-on of p53 func-on in animals has relied heavily on comparing phenotypes 
between p53 wild type (WT) mice versus mice with germline dele-on of Trp53 (p53 knockout 
mice). Although such knockout mice are viable and fer-le, they exhibit (with variable 
penetrance) certain developmental abnormali-es such as neural tube closure defects 
(Armstrong et al. 1995; Sah et al. 1995). Moreover, as with all germline knockout mice, it is 
unclear to what extent their adult phenotype (or the lack thereof) is a consequence not of the 
direct absence of the targeted gene, but instead of adap-ve developmental compensa-on or 
func-onal redundancy - in the case of p53 dele-on, from the func-onally overlapping p63 and 
p73 genes (Yang & McKeon 2000). For these reasons, gene-c analysis of p53 func-on in adult 
-ssues clearly benefits from more sophis-cated mouse models in which WT p53 func-on is 
retained during development but which may then be switched off (and back on) in adults, either 
systemically or -ssue-by--ssue. For example, such models allow for a more discrimina-ng study 
of p53’s physiological func-ons whilst mi-ga-ng the confounding suscep-bility towards 
spontaneous lymphomas in early adult life. Although previous switchable p53 mouse models 
have been developed, they all suffer from various prac-cal limita-ons that restrict their use in 
inves-ga-ng p53 physiological and tumour suppressing func-ons. Thus, the well-documented 
Cre recombinase-dependent p53flox mouse model was developed to model the acute loss of p53 
func-on that occurs in tumours. In these animals, LoxP sites are inserted to flank exon 2 - 10 of 
the endogenous Trp53 alleles (Jonkers et al. 2001). When combined with a CreERT2 background, 
in which Cre-mediated recombina-on may be acutely triggered by administra-on of the 4-
hydroxytamoxifen (4OHT) ligand, this may be used to inac-vate endogenous Trp53 at will, either 
systemically or in a -ssue-specific manner (Li[lewood et al. 1995; Metzger & Chambon 2001). 
However, this model has profound limita-ons. First, the Trp53 dele-on is irreversible, 
precluding study of subsequent restora-on of p53 func-on in tumours that have evolved a]er 
p53 loss. Second, Cre-dependent recombina-on is not completely penetrant and o]en varies 
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according to condi-ons and contexts, making interpreta-on of results difficult (Bao et al. 2013). 
Finally, Cre recombinase triggers a profound DNA damage response that, in the case of p53, a 
pivotal DNA damage sensor, is an unhelpfully confounding complica-on (Janbandhu et al. 
2014). The other well-characterised switchable p53 in vivo model is the p53ERKI mouse, in which 
endogenous Trp53 is modified to encode a 4OHT-dependent p53ERTAM fusion protein 
(Christophorou et al. 2005). In the absence of 4OHT ligand, p53ERTAM is completely inac-ve and 
mice are effec-vely null for p53 func-ons. However, systemic administra-on of the 4OHT ligand 
rapidly restores p53ERTAM func-ons to the WT state, together with all the same level and 
temporal dynamics as the WT p53 protein that it replaces. Importantly, p53 ac-vity in 4OHT-
treated p53ERKI mice remains completely dependent upon upstream ac-va-ng signals such as 
DNA damage (Christophorou et al. 2005). The p53ERKI model allows for rapid, reversible 
switching of p53 in adult mice without the confounding DNA damage of the p53flox models, 
while its ability to rapidly and reversibly toggle between p53 null and WT state uniquely allows 
for establishing direct cause and effect rela-onships in p53 ac-va-on (Christophorou et al. 
2005; Mar-ns et al. 2006; Christophorou et al. 2006; Junela et al. 2010). Nonetheless, due to 
the potent abor-genic ac-vity of Tamoxifen (Nakamura et al. 2006), p53ERTAM must be 
maintained in its inac-vate state throughout embryonic development, raising the same 
problems of adap-ve compensa-on as in conven-onal p53 knockout mice. 
 To address the inherent limita-ons of the above exis-ng current models, I have 
constructed a novel, reversibly switchable p53 model that allows for precise temporal and 
spa-al analysis of the roles of p53 in normal physiology and in tumourigenesis. Importantly, this 
model allows embryogenesis and neonatal development to proceed in the presence of normal 
p53 func-ons yet retains the key capacity to toggle acutely, reversibly and rapidly p53 status 
from WT to null and back, either systemically or -ssue-by--ssue. This new model relies on 
tetracycline (Tet, or its deriva-ve ligand doxycycline, Dox) ligand-dependent repression of 
endogenous Trp53 expression. A heptad tetracycline response element (TRE) is inserted into the 
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transcrip-onal control region of Trp53 that allows tetracycline-dependent binding of a 
transcrip-onal repressor to the TRE (Fig. 1.1, right panels). This system is very flexible and can 
also be configured as a Tet-off version, as illustrated in le8 panels of Figure 1.1 (Gossen & 
Bujard 1992). The Tet-on model of Trp53 described below is herea]er referred to as TRE-p53 
throughout this thesis. 
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1.2	Designing	and	optimising	the	TRE-p53	repression	system	
 The first step in genera-ng the new switchable p53 model was to decide where to insert 
the TRE cis-regulatory mo-f – specifically, in the promoter or in the first intronic region of the 
endogenous Trp53 gene. Previous work in the Evan group indicated that the careful posi-oning 
of TRE is cri-cal in such models since it can greatly influence the efficacy of repression of the 
target gene and any surrounding genes. For example, inser-on of a TRE in the E2F3 promoter 
mediated almost complete Tet-dependent silencing of the target gene (Gamper et al. 2017); by 
contrast, TRE inser-on in the second intron of c-Myc resulted in only par-al repression of 
expression Myc (unpublished). However, the op-mal TRE inser-on site allowing for the most 
defini-ve Tet-dependent repression of the target gene without disrup-ng that gene’s normal 
regula-on (or that of nearby genes) is probably highly dependent on subtle-es in the local DNA 
landscape and has to be determined empirically. To this end, the promoter and first intronic 
region of the mouse Trp53 locus (chromosome 11 posi-on 69,580,359-69,591873 bp; from 
MGI, updated Jan 2014; h[p://www.informa-cs.jax.org/marker/MGI:98834) were analysed 
using several available algorithms based on different matrices to iden-fy transcrip-on and 
splicing regulatory cis-DNA elements. In addi-on, Trp53 co-locates with an an-sense gene of 
poorly defined func-on called Wrap53. The coding region of the Wrap53 gene, which is located 
upstream of the Transcrip-on start site (TSS) of Trp53, was also ruled out for placing poten-al 
TRE inser-on sites. Based on this informa-on, the final regions chosen for TRE inser-on are 
shown in Table 1.1.: -2161 bp, -57 bp and +356 bp in rela-on to the TSS of endogenous Trp53; 
these sites are herea]er referred to as C3, C4 and C5 respec-vely (Figure 1.2). 
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1.3	Generation	of	Trp53	targeting	vector	
1.3.1	Cloning	of	TRE-LoxP-Neo-LoxP	cassette	into	pL452	
 Cloning of TRE into each of the three selected loca-ons required mul-ple cloning steps. 
First, the TRE sequence and neomycin resistance gene (NeoR) flanked by two LoxP sites were 
cloned into the pL452 plasmid to generate the sequence casse[e TRE-LoxP-Neo-LoxP (Figure 1.3 
shows (a) a schema-c of the casse[e and (b) a map of pL452 a]er inser-on of the casse[e). 
This ini-al cloning step had been previously completed by Dr Ivonne Gamper in the Evan group. 
Inclusion of a NeoR sequence allowed for selec-on of clones targeted with the TRE casse[e in 
the subsequent cloning steps, including E. coli recombineering and mouse embryonic stem cell 
(mESC) targe-ng. The inserted LoxP sites allow for later excision of NeoR to eliminate any 
confounding interference the extra 1.6 kb might have on normal Trp53 expression and func-on. 
1.3.2	Preparation	of	DTA	targeting	vector	to	capture	Trp53	promoter/intron	sequence	
 To accurately target C3, C4 and C5 in the endogenous Trp53 gene by homologous 
recombina-on, the TRE-LoxP-Neo-LoxP casse[e to be inserted into the sites has to be 
embedded in 5 kbp of DNA sequence upstream and downstream of the desired inser-on sites. 
This en-re sequence has to be cloned into the DTA targe-ng vector (Figure 1.4 shows the map 
of the original DTA vector). 
 The 5 kbp sequences upstream and downstream of C3, C4 and C5 (10 kbp in total for 
each) were first captured into the DTA vector. To achieve this, two 200 bp sequences 
homologous to each end of the 10 kbp fragments were generated by PCRs using the bacterial 
ar-ficial chromosome (BAC) bMQ358 as template, which carries at least 20 kbp of sequence 
upstream and downstream of the Trp53 TSS. The 200 bp sequences were then added to the DTA 
vector by restric-on enzyme diges-ons and liga-on of these PCR products and the original DTA 
vector. Figure 1.5 shows a schema-c diagram of this cloning process and the resul-ng DTA 
vectors with the added homologies. 
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Figure 1.4. The original DTA targeOng vector pBSDT-AII. The DTA vector carries the Diphtheria Toxin A gene 
(DTA) that encodes the cytotoxic DTA protein. This allowed nega-ve selec-on of undesired incorpora-on of 
the targe-ng vector backbone into the genome. Restric-on enzymes KpnI and SalI were used to linearise 
the vector for the subsequent cloning step. pBSDT-AII was a gi] from Yoh Wada (Addgene plasmid # 
27179 ; h[p://n2t.net/addgene:27179 ; RRID:Addgene_27179; Aoyama et al. 2005).
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1.3.3	Capturing	Trp53	promoter/intron	sequence	from	BAC	into	DTA	vector	
 The same BAC, bMQ358 was used as a source of the gene promoter and first intron 
sequence in the cloning process. The BAC DNA was freshly prepared from the carrier bacterial 
library and its integrity was verified by PCR amplifica-on and sequencing of several short 
segments across the Trp53 gene (Figure 1.6 and data not shown). The BAC was then 
transformed by electrophora-on into EL350, a specific strain of E. coli that expresses heat-
inducible recombina-on protein at 42OC.  
 The linearised DTA vectors added with the 200 bp homology ends were introduced into 
the pre-heated (at 42OC) BAC-carrying EL350 cells by electrophora-on. Three 10 kbp-fragments 
carrying the promoter or first intron sequence of Trp53 were then captured respec-vely into 
the DTA vector by recombineering in EL350 cells with the corresponding homologous sequence 
at the ends of the linearised DTA fragments. Figure 1.7a illustrates the recombineering scheme 
and Figure 1.7b is a map of the resul-ng DTA-10 kbp vectors formed from recombineering. Each 
of the 10 kbp fragments contained the corresponding TRE inser-on site posi-oned in the 
middle of the 10 kbp sequence so that the TRE-LoxP-Neo-LoxP casse[e, once inserted, would be 
flanked on each end by a 5 kbp sequence of the Trp53 promoter and/or first intron. The three 
resul-ng targe-ng vectors carrying the respec-ve 10 kbp fragments are referred as DTA3, DTA4 
and DTA5, containing the TRE inser-on sites C3, C4 and C5 respec-vely. The vectors were 
verified by diagnos-c restric-on diges-on with KpnI and SalI (Figure 1.8). 
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Figure 1.6. PCRs confirmed the BAC bQM368 carried the correct part of mouse chromosome 11. Five 
colonies were picked from a re-streak plate and four short sequences across the promoter and first intron of 
the Trp53 gene were amplified by colony-PCRs to check the integrity of the sequence in the BAC. Top le]: a 
sequence of 900 bp was amplified (-8.3 kb to -7.4 kb from TSS). Top right: a sequence of 1000 bp was 
amplified (-5.4 kb to -4.4 kb from TSS). Bo[om le]: a sequence of 500 bp was amplified (-2.5 kb to -2 kb from 
TSS). Bo[om right: a sequence of 600 bp was amplified (+0.8 kb to +1.4 kb from TSS). Sequence of primers 
used are detailed in Table M.1c in the Methods and Materials chapter. GeneRuler 1 kb Plus ladder from 
Thermo Scien-fic was used in these gel electrophoresis.
Figure 1.7. Capturing of the 10 kbp homology sequence surrounding the inserOon sites into the DTA vector. (a) The 200 bp-
homologies-added DTA vectors were linearised with BglII and electroporated into 42oC pre-heat-shocked EL350 cells carrying the BAC 
bMQ358. The 10 kbp sequences from the BAC were then captured respec-vely by recombineering to form the DTA-10kbp vectors 
DTA3, DTA4 and DTA5. (b) A map of DTA3 resul-ng from the recombineering process is shown as an example.
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1.3.4	Insertion	of	TRE-LoxP-Neo-LoxP	cassette	into	DTA3/4/5	
 To introduce the TRE-LoxP-Neo-LoxP casse[e into DTA3/4/5 vectors at the selected sites, 
60 bp sequences homologous to the region adjacent to the desired TRE inser-on sites were 
added to both ends of the casse[e by PCR (Figure 1.9). The PCR products generated with each 
of the site-specific homologous 60 bp primers were column-purified and verified by DNA 
sequencing (data not shown). Then, the TRE-LoxP-Neo-LoxP casse[es with the homology arms 
for C3, C4 and C5 were introduced by electropora-on into the pre-heat-shocked EL350 bacteria 
carrying DTA3, DTA4 and DTA5. This generated DTA-TRE3-NeoR, DTA-TRE4-NeoR and DTA-TRE5-
NeoR respec-vely (Figure 1.10). Five individual colonies were selected from each 
transforma-on plate and the presence of the inser-on was confirmed by PCR amplifica-on of 
the junc-ons where the TRE-LoxP-Neo-LoxP sequence was inserted into the middle of the 10 
kbp genomic fragments in the vectors (Figure 1.11). Vectors genera-ng the correct PCR 
fragments were amplified, column purified and analysed by diagnos-c restric-on enzyme 
diges-on (Figure 1.12). All the diges-ons generated profiles that included all the expected 
bands, but with the addi-on of one or two unexpected fragments. This suggested that the 
vectors prepared were probably a mixture of TRE-inserted and non-TRE-inserted vectors, 
possibly due to incomplete and/or non-specific recombineering in EL350 cells.  
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Figure 1.8. DiagnosOc digesOons by KpnI-HK and SalI-HF of the three targeOng vectors that carried the corresponding 
10 kb fragment. Five colonies were picked and cultured overnight, from which plasmids were prepared by miniprep. The 
plasmids were then digested by KpnI-HK and SalI-HF and the products were run on an agarose gel. The expected 
restric-on fragments size for DTA3 are 5.3 kbp, 4.6 kbp, 3.6 kbp and 0.46 kbp; DTA4 are 5.0 kbp, 4.6 kbp, 3.2 kbp, 1.5 kbp 
and 0.46 kbp; DTA5 are 5.0 kbp, 4.6 kbp, 2.8kbp, 1.9kbp and 0.46 kbp. The lanes marked with a -ck indicate clones that 
gave a correct diges-on profile. GeneRuler 1 kb Plus ladder from Thermo Scien-fic was used in these electrophoresis 
(first lane of both panel).
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Figure 1.9. Adding homologies to both ends of the TRE-LoxP-Neo-LoxP casse\e by PCR. (a) A schema-c diagram of the 
60 bp homologies-added casse[e. (b)Three sets of primers were used to add the three different sets of homologies to 
the TRE-LoxP-Neo-LoxP casse[es. Sequence of primers used are detailed in Table M.1c in the Methods and Materials. 
The expected size of the amplicons were around 2.3 kbp (the size of the casse[e was nearly 2.2 kb while each 
homologous sequence was 60 bp). From le] to right: 1 Kb Plus DNA Ladder from Invitrogen, homologies-added TRE-LoxP-
Neo-LoxP casse[es for DTA3, DTA4 and DTA5 respec-vely. 
Figure 1.10. A map of the casse\e-added DTA3 vector, i.e. DTA-TRE3-LoxP-NeoR-LoxP. The TRE-LoxP-Neo-LoxP casse[e 
was added to the inser-on points of DTA3/4/5 respec-vely by recombineering in EL350 cells.
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Figure 1.11. ConfirmaOon of TRE inserOon by PCR across the inserOon juncOons. Five colonies were picked from each of 
the transforma-on plates and tested with colony-PCR using construct-specific primers amplifying the junc-ons of the 
inser-on. (a) PCR amplifying the 5’ junc-on of the inser-on in the plasmid. The expected amplicon sizes for DTA-TRE3-
NeoR, DTA-TRE4-NeoR and DTA-TRE5-NeoR are 600 bp, 700 bp and 700 bp respec-vely. (b) The colonies that gave a 
posi-ve result in the first PCR was then checked further with the PCR amplifying the corresponding 3’ junc-ons. The 
expected amplicon sizes for DTA-TRE3-NeoR, DTA-TRE4-NeoR and DTA-TRE5-NeoR were all 500 bp. Sequence of primers 
used are detailed in Table M.1c in Methods and Materials. GeneRuler 1 kb Plus ladder from Thermo Scien-fic was used in 
all these gel electrophoreses.
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Figure 1.12. First round of TRE-LoxP-Neo-LoxP casse\e recombineering didn’t yield the expected DTA-TRE3/4/5-
NeoR constructs. Top panel: A table summarising the enzymes used in the diagnos-c diges-ons and the expected 
results. Bo[om: Images of diges-on reac-ons a]er electrophoresis by agarose gel. (i) The diges-on of DTA-TRE3-NeoR 
gave two unexpected bands with a size of 5 kbp and 2.5 kbp respec-vely. (ii) A diges-on profile with an unexpected 
band sized around 700 bp was observed for DTA-TRE4-NeoR. (iii) An unexpected band sized around 2 kb was observed 
for diges-on of DTA-TRE5-NeoR. GeneRuler 1 kb Plus ladder from Thermo Scien-fic was used in all these gel 
electrophoreses.
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1.3.5	Isolation	of	DTA-TRE3/4/5-NeoR	vectors	
 Based on the hypothesis that the prepared vectors were a mixture of TRE casse[e-
inserted and non-inserted vectors, several approaches were used to isolate the DTA-TRE3/4/5-
NeoR vectors. First, competent E. coli were transformed with the mixed DTA plasmids (with and 
without TRE) and plasmid DNAs were prepared from the picked colonies. However, subsequent 
screening revealed that all individual clones selected s-ll retained a mixture of plasmids (results 
not shown). It is possible that the mixed plasmids were supercoiled together and therefore not 
taken up separately into cells. Second, the mixed products were digested with two different 
restric-on enzymes, both of which only cut at a single site, and the fragment carrying the TRE-
LoxP-NeoR-LoxP casse[e purified and ligated with the DTA3/4/5 plasmids cut with the same 
restric-on enzymes. The products of these liga-ons were then transformed into competent E. 
coli. However, no colonies were observed, possibly due to a failed liga-on as a result of 
insufficient TRE-LoxP-NeoR-LoxP-carrying DNA fragment (results not shown). Third, Gibson 
Assembly of PCR products was a[empted (Gibson et al. 2009). Using the mixed products as 
templates, the two halves of the TRE-LoxP-NeoR-LoxP casse[e were amplified along with the 
respec-ve adjacent sequences of the Trp53 gene (up to 2.5 kb). Each half of the TRE-LoxP-NeoR-
LoxP casse[e carried half of the NeoR gene, with 30 bp of overlapping sequence at that end of 
the fragment, which was required for Gibson Assembly. Sequences iden-cal to the ends of the 
cut empty DTA vector backbone were introduced by PCR to the other end of the fragments 
respec-vely. Gibson Assembly was then used to assemble the three fragments into complete 
DTA-TRE3/4/5-NeoR constructs. However, following transforma-on of E. coli, selec-on with 
ampicillin and neomycin yielded no colonies. This failure was likely due to the low efficiency of 
Gibson Assembly for large plasmids (12 kb in this case). A final a[empt to isolate pure TRE-
containing plasmids was to digest the mixed plasmids with a restric-on enzyme that cut at 
mul-ple sites, ligate all the cut fragments, and transform the ligated products directly into 
competent E. coli. The ra-onale for this approach was to free any supercoiled DTA3/4/5-TRE-
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NeoR and non-TRE-inserted vectors by cueng them into specific fragments, which would then 
be ligated into separate plasmids and taken up individually by bacteria. All DTA-TRE3/4/5-NeoR 
vectors were successfully isolated with this approach, as indicated by the diagnos-c diges-on 
with the corresponding restric-on enzymes (Figure 1.13). The verified DTA-TRE3/4/5-NeoR 
vectors were then used to target the endogenous Trp53 gene in mESC as described below.  
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Figure 1.13. The final approach to separate the correctly targeted DTA-TRE constructs from the mixture was successful. 
The constructs were verified by diges-on with corresponding restric-on enzymes. DTA-TRE3-NeoR, DTA-TRE4-NeoR and 
DTA-TRE5-NeoR were digested by EcoRI, BstXI and DrdI respec-vely. The lane between DTA-TRE3-NeoR and ladder was 
not shown as it was irrelevant. The expected band sizes are listed in the table in Figure 1.12. GeneRuler 1 kb Plus ladder 
from Thermo Scien-fic was used as size marker.
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1.4	Targeting	Trp53	gene	in	mESC	
 To insert the TRE element into the desired loca-ons in the endogenous mouse Trp53 
locus, two different targe-ng approaches were used - the CRISPR/Cas9 gene edi-ng system and 
the mESC homologous recombina-on targe-ng method. CRISPR/Cas9 gene edi-ng has been 
shown to be highly efficient in modifying the mouse genome, especially when dele-ng or 
trunca-ng target genes. In addi-on, it can be used directly on early stage embryos (e.g. single-
cell stage) without having to first target and select the embryonic stem cells. I a[empted to 
insert the TRE using the CRISPR/Cas9 system but no successfully targeted pups were generated 
a]er mul-ple a[empts. I then tried the second approach of mESC homologous recombina-on. 
The E14 line of mESC, kindly provided by Ken Jones from the Cambridge Stem Cell Ins-tute, was 
cultured in 2I/LIF medium with the established condi-ons and procedures (Silva et al. 2008) 
detailed in the Methods and Materials chapter. The three DTA-TRE3/4/5-NeoR vectors were 
linearised using the restric-on enzyme SalI and introduced into cultured mESC by 
electropora-on. These mESC were then subject to neomycin selec-on for the stable expression 
of NeoR from the casse[e, which supposedly indicated integra-on of the whole casse[e into 
the genome. 96 Neo-resistant clones were picked for each inser-on site, expanded and 
screened for correct inser-on of the casse[e by Southern blots, as detailed below. 
 Correct inser-ons of the casse[e were verified by Southern bloeng rather than PCR 
analysis (because the la[er can only confirm the presence of the TRE-LoxP-NeoR-LoxP casse[e in 
the genome but not the inser-on loca-on, nor the orienta-on of the inser-on). The casse[e 
embedded in the 10 kbp homology region could be integrated randomly at undesired posi-ons 
in the genome, disrup-ng gene func-ons at those loci, informa-on about which a PCR analysis 
would not provide. 
 Two DNA probes (7.8 and 3.3, sequence shown in Methods and Materials), each 
approximately 300 - 500 bp, were designed to anneal to within 5 kbp of 5’ and 3’ sides of the 
inser-on sites respec-vely. Annealing of these two probes to restric-on enzyme-digested 
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genomic DNA (gDNA) from targeted mESC clones would indicate whether the TRE-Lox-NeoR-Lox 
casse[e (embedded in the 10 kbp homology) had been integrated correctly into the desired 
posi-ons. To digest the gDNA, two restric-on enzymes were used - one cueng outside of the 5 
kbp homology on one side while the other inside the 5 kbp homology at the other side proximal 
to the inser-on of the casse[e. In the cases of the 3’ Southern of C4 and C5, XbaI cuts in the 
TRE-LoxP-NeoR-LoxP casse[e in addi-on to cueng inside the 5 kbp homology. As such, a 
diges-on fragment of the expected size would result only from the correct incorpora-on of the 
TRE-LoxP-NeoR-LoxP-embedded 10 kbp homologies into the desired loci of the genome where 
the correct restric-on diges-on sites were present. Figure 1.14 illustrates the design of the 
Southern blots while Table 1.2 gives details of the probes, restric-on enzyme cueng sites and 
the expected results of correct inser-on. 
 gDNA of Neo-resistant mESC clones (96 each for C3, C4 and C5) was prepared from the 
cells, restric-on digested (Table 1.2) and then frac-onated by electrophoresis. Figure 1.15 
shows the restric-on diges-on of the C4-targeted clones by EcoRV and HindIII. Presence of a 
smear instead of visibly discrete bands indicated the gDNA was completely digested. The 
digested gDNA on the gels were then transferred to Hybond C membranes and incubated with 
the radioac-vely labelled probes. The target fragments hybridised with the probes were 
visualised on X-ray films (Figure 1.16). Posi-ve mESC clones (Figure 1.16, coloured boxes), 
herea]er referred to as Trp53TRE3/4/5-NeoR, were thawed and expanded in -ssue culture for 
further analyses (see below). Note that some posi-ve clones displayed significantly different 
band intensi-es in comparison with the wild type band, sugges-ng an increased copy number 
of the targeted allele or a mosaic of targeted and non-targeted cells in the picked colonies. 
These clones were not selected.  
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Figure 1.14. Southern blots were designed to assess whether the endogenous Trp53 allele was correctly 
targeted with the DTA-TRE3/4/5-NeoR casse\es at the desired sites respecOvely. Labels: TSS: Trp53 
transcrip-on start site; Green line: 5 kbps homologies; black line: Trp53/adjacent genomic sequence; red 
short line: probe 3.3; blue short line: probe 7.8; : fragment resul-ng from the restric-on diges-on 
detectable by probe 3.3;  : fragment resul-ng from the restric-on diges-on detectable by probe 
7.8; C3, C4, C5: corresponding TRE inser-on sites.
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Figure 1.15. Agarose gel of separated gDNA of the picked Neo-resistant C4-targeted mESC clones digested by EcoRV 
and HindIII. GeneRuler 1 kb Plus ladder from Thermo Scien-fic was loaded to the first lane from the le] as a size 
marker.
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1.5	Analyses	of	positional	effect	of	TRE	insertion	
 To determine which of the TRE inser-on sites allow for the most efficient and -ght 
repression of Trp53 by the system yet with a minimal impact on normal Trp53 expression in the 
absence of rtTS repressor ac-vity, representa-ve targeted mESC clones verified by the Southern 
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Figure 1.16. Southern blots of correspondingly digested gDNA of the picked Neo-resistant mESC clones targeted at (a) 
C3, (b) C4 and (c) C5. Digested gDNA of each clone was loaded onto one lane of the agarose gel in each Southern blot. 
Details of the diges-ons, probes used and expected target fragment sizes are outlined in Table 1.2. Southern blots of 
both sides were run for all 96 of the C3- and C4-targeted clones, while for the C5-targeted clones the 3’ Southern blot 
was only run on the ones that were posi-ve in the 5’ Southern blot. Blue (C3-targeted), green (C4-targeted) and red 
(C5-targeted) boxes indicate the clones that gave posi-ve results in both Southern blots.
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blots were expanded in culture and had the TRE repression system implemented by addi-on of 
an rtTS-expressing gene into the mESC genome. Prior to addi-on of the rtTS-expressing gene, 
each expanded clone was transiently infected by Lipofectamine with the DNA plasmid pCAG-Cre 
(a gi] from Connie Cepko; Addgene plasmid #13775; h[p://n2t.net/addgene:13775; 
RRID:Addgene_13775; (Matsuda & Cepko 2007)), which drives cons-tu-ve expression of Cre 
recombinase ac-vity inside the cells. This efficiently excised the NeoR sequence (flanked by the 
loxP sites) previously used for selec-ng the targeted mESC. The infected cells were sparsely 
plated on a dish un-l discrete embryoid bodies (a three-dimension aggregates of cells arisen 
from a single cell; here referred to as colonies) were evident. Twelve such colonies were 
selected, expanded and excision of the NeoR sequence confirmed by PCR. Figure 1.17 shows 
the result of the PCRs; the decrease in band size indicates successful Cre-removal of the NeoR 
sequence. The three targeted Trp53 alleles with NeoR removed were henceforth denoted 
Trp53TRE3/4/5 respec-vely. Successful removal of NeoR demonstrated the removability of NeoR 
from the casse[e, a prerequisite for u-lisa-on of the system for experiments in vitro and in 
vivo. Next, the Trp53TRE3/4/5 clones were transfected with the linearised DNA plasmid 
pPCAGIPCAG that expresses the rtTS repressor from a cons-tu-ve CAG promoter (CAG-rtTStg) 
and resistance to puromycin (pPCAGIPCAG was kindly provided by Ken Jones from Cambridge 
Stem Cell Ins-tute). Cells with stable expression of rtTS resul-ng from successful integra-on of 
CAG-rtTStg into the mESC genome were selected in the presence of puromycin. These cells 
harboured a single copy of the Trp53TRE3/4/5 allele and mul-ple copies of the CAG-rtTStg 
transgene. 
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 Any posi-onal effect of the TRE inser-ons on normal expression of Trp53 and efficiency 
of the repression system was assessed by determining the expression of Trp53 RNA in the 
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Figure 1.17. Genotyping PCRs to verify removal of NeoR by Cre from the inserted casse\es in targeted 
mESCs. (a) Le]: schema-c diagram of the casse[e inserted in Trp53. Primers (the pair of purple arrows) 
annealing to the sequence just outside the inserted casse[es were used to assess the removal of NeoR by Cre 
from the transient infec-on of pPCAGIPCAG. Right: a summary of the size of expected PCR products. (b) The 
products of the PCRs on the gDNA of the 12 picked clones of each inser-on sites were separated by gel 
electrophoresis. Red arrow: posi-on of band with NeoR; green arrow: posi-on of band that had NeoR 
removed; black arrow: posi-on of WT band. Nega-ve control: PCR on plasmid carrying the full casse[e 
inserted in WT sequence (plus one with WT sequence). Posi-ve: PCR on plasmid carrying the NeoR-removed 
casse[e embedded in WT sequence (plus one with WT sequence). GeneRuler 1 kb Plus ladder from Thermo 
Scien-fic was used in these gel electrophoresis. Sequence of primers used are detailed in Table M.1c in 
Methods and Materials.
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absence and presence of doxycycline (Dox) in the re-cons-tuted mESC (Figure 1.18). Cells were 
seeded, cultured for 24 hours and then treated with Dox at 1000 μg/mL for 48 hours. This 
concentra-on of Dox was found to give the maximum response in vitro and was used for all in 
vitro experiments in this thesis (Gamper et al. 2017). mRNA was prepared by Trizol extrac-on 
and complementary DNA (cDNA) synthesised by reverse transcrip-on. Quan-ta-ve PCR (qPCR) 
was used to quan-fy Trp53 mRNA levels with Tbp (TATA box binding protein) mRNA as 
reference. Unless otherwise specified, mRNA from in vitro experiments was prepared and 
quan-fied as such. The results of the qPCR of this experiment are plo[ed in Figure 1.18a. 
Comparing WT with the three TRE-targeted lines of mESC in the absence of Dox, it is clear that 
TRE inser-on at C4 and C5 significantly affects Trp53 mRNA expression (p =  0.0035 and < 
0.0001, respec-vely) and addi-on of Dox fails to reduce expression further. This is most 
probably due to the proximity of the TRE inser-on to the Trp53 TSS in C4 and C5, such that it 
disrupts the recruitment of core transcrip-onal factors. It is also possible that the 
computa-onal analyses I undertook in SecOon 1.2 failed to provide a comprehensive list of all 
local cis-elements necessary for Trp53 expression. By contrast, normal Trp53 mRNA expression 
appeared unaffected by TRE inser-on at the C3 posi-on in the absence of Dox (p > 0.9999), and 
this was reduced by about 50% within 48 hours of Dox addi-on. As these cells harbour only a 
single copy of the TRE-modified p53 locus – the other being WT - this is consistent with 
complete repression of the single TRE-targeted Trp53 allele. This is, of course, assuming there is 
no nega-ve impact on expression from the WT Trp53 allele, which is suggested by the lack of 
impact of rtTS (with Dox) in WT mESC with no TRE inser-on (Figure 1.18a). Figure 1.18b shows 
that the CAG-rtTSTg transgene expresses the rtTS mRNA regardless of whether or not Dox is 
present. Also, while the mRNA level expressed did vary across the various cell lines, this did not 
appear to affect the func-onality of the repression system. Hence, in conclusion, these data 
indicate that TRE targeted at C3 has minimal impact on the normal expression of Trp53 mRNA 
78
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but confers effec-ve repressibility of Trp53 expression in the presence of both rtTS expression 
and Dox. 
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CHAPTER 1 
 Next, I determined whether p53 protein expression followed that of Trp53 mRNA 
expression in the C3 targeted mESC cells. Protein lysates were prepared from cells treated as 
described above and analysed by western immunobloeng with an--p53 an-body (Figure 1.19). 
Indeed, the p53 protein level was significantly reduced a]er 48 hours of Dox treatment in 
Trp53TRE3/+;CAG-rtTSTg cells, with the residual expression again a[ributed to the WT allele. By 
contrast, p53 protein levels were unchanged in WT cells whether Dox was present or not. This is 
consistent with the TRE repression system implemented at C3 effec-vely regula-ng Trp53 at the 
transcrip-onal level effec-vely leading to a rapid consequen-al effect on p53 protein level with 
a rapid 48-hour -me frame. 
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Figure 1.19. A western blot showing p53 protein level from WT mESCs expressing rtTS and the 
reconsOtuted targeted mESCs with or without Dox treatment (48 hours). 12 μg of proteins were loaded per 
lane and separated on the 12% acrylamine gel. p53 was detected with the primary an-body 1C12 while β-
Ac-n with AC15 (details of an-bodies are described in SecOon M.6 in the Methods and Materials chapter).
CHAPTER 1 
 Finally, I assessed whether regula-on of Trp53 mRNA and protein expression following 
DNA damage are compromised by the TRE inser-on at C3. C3-targeted and WT mESC cells 
harbouring CAG-rtTSTg were cultured with or without Dox for 48 hrs and then exposed to the 
DNA damage-inducing agent doxorubicin for 8 hours (Doxo; concentra-on used = 1 μg/mL, (Cho 
et al. 2012)). mRNA was harvested from these cells and the rela-ve Trp53 mRNA level was 
determined by qPCR (Figure 1.20). In both WT and C3-targeted cells, levels of Trp53 mRNA 
expression were not measurably altered by Doxo treatment. Importantly, in the presence of Dox 
the TRE repression system was equally efficient in repressing Trp53 mRNA expression with or 
without DNA damage. Consistent with the no-on of DNA damage inducing p53 protein 
stabilisa-on, both WT and C3-targeted mESC demonstrated a significant increase in p53 protein 
level in response to Doxo-induced DNA damage (Figure 1.21). However, this increase was 
significantly repressed in in C3-targeted cells in the presence of Dox, consistent with the 
repression of Trp53 mRNA under the same condi-on (Figure 1.20). In conclusion, the TRE 
inser-on at posi-on C3 in the presence of rtTS and Dox mediates effec-ve repression of both 
Trp53 mRNA and p53 protein expression even in the presence of DNA damage. 
 The above series of experiments clearly demonstrated that, at least in mESC, TRE 
inser-on at certain loca-ons (C4 and C5) in the endogenous Trp53 gene has a significant 
nega-ve impact on both normal Trp53 expression and capacity for Dox-dependent repression of 
Trp53 expression. However, inser-on of TRE at C3 allows for wild type expression of Trp53 
mRNA and protein under physiological condi-ons and for Dox-dependent repression of both 
Trp53 mRNA and protein, even when subjected to the potent pro-stabilising ac-ons of DNA 
damage. Accordingly, TRE inser-on at C3 was chosen for all subsequent in vivo experiments. 
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Figure 1.21. A western blot showing p53 protein level from wild type mESCs expressing rtTS and the 
reconsOtuted C3-targeted mESCs in combinaOons of Dox and Doxo treatment. 12 μg of protein was loaded 
per lane and separated on a 12% acrylamine gel. p53 was detected with the primary an-body 1C12 while β-
Ac-n with AC15 (details of an-bodies described in SecOon M.6 in Methods and Materials).
Figure 1.20. The TRE repression system represses Trp53 mRNA expression in the presence of DNA damage 
inflicted by doxorubicin treatment. Pairs of primers specific to Trp53, rtTS and Tbp mRNA were used in the 
qPCR analysis and their details are listed in Table M.6b in the Methods and Materials chapter). Plo[ed are 
the mean values of samples from cells of 2 different passages and the error bars denote the respec-ve 
standard devia-ons.
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CHAPTER 1 
1.6	Generation	of	TRE-p53	animals	
 Trp53TRE3-NeoR/+ mESC were injected into mouse blastocysts by the Transgenic Unit of the 
Cambridge Stem Cell Ins-tute. The injected blastocysts were then implanted into surrogate 
mothers to produce F0 animals - chimaeric mice comprising mixtures of WT cells from the 
recipient blastocyst and injected Trp53TRE3-NeoR/+ mESC. Germline transmission of theTrp53TRE3-
NeoR/+ allele requires at least one of the Trp53TRE3-NeoR/+ mESC to contribute to the resultant 
embryo’s germ cells, an eventuality assessed by examina-on of the resul-ng progeny. Male 
chimaeric mice (not female mice because the mESC used were generated from a male embryo) 
with a predominantly E14 mouse chinchilla coat colour were mated with black coat colour C57/
Bl6 female mice. Produc-on of F1 mice of chinchilla coat colour indicates germline-transmission 
of the chimaera and of these F1 mice 50% should inherit the Trp53TRE3-NeoR allele. 
 Although several F0 male chimaeras were produced, unfortunately none of them was 
germline-transmi[ed. The reason for this is unclear. While it is formally possible that the TRE-
LoxP-NeoR-LoxP casse[e inser-on in one Trp53 allele caused embryonic lethality, this was 
considered unlikely as mice with a single WT Trp53 allele are viable and exhibited no deleterious 
phenotypes. Moreover, mice with a germline knockout of Trp53 were viable and fer-le. It is 
possible that the targeted mESC were compromised during the targe-ng process, although 
karyotyping did not reveal any major defects of chromosome number (data not shown). To 
expedite genera-on of these mice, gene targe-ng and the genera-on and breeding of 
chimaeras was outsourced to the Transgenic Unit of the Babraham Ins-tute. This resulted in the 
produc-on of germline-transmi[ed chimaeras a]er 6 months. The resul-ng F1 was biopsied 
and genotyped using PCR to amplify the whole inserted TRE-LoxP-NeoR-LoxP casse[e and the 
junc-ons respec-vely (Figure 1.22). Correct inser-on of TRE at C3 of the PCR-posi-ve F1 mice 
was confirmed by Southern blot (Figure 1.23) using the strategy illustrated in Figure 1.13 and 
Table 1.2. The F1 mice confirmed by the Southern blots were used as founder animals. 
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Figure 1.22. Genotyping PCRs to screen for F1 pups that inherited the Trp53TRE3NeoR allele from the 
chimaeras. (a) Le]: schema-c diagram of the Trp53TRE3NeoR allele and the primers (arrows of colours) used in 
the PCRs. Right: details of the PCRs and expected results. (b) PCR products on agarose gel a]er 
electrophoresis. gDNA from each F1 pup was analysed with the three PCRs and only the ones that were 
posi-ve in all three (indicated by light blue boxes) were further analysed with Southern blots. Arrows indicate 
the expected band size of the respec-ve PCR. GeneRuler 1 kb Plus ladder from Thermo Scien-fic was used in 
these gel electrophoresis. Sequences of primers used are detailed in Table M.1c in Methods and Materials.
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1.7	Reconstituting	the	repression	system	in	vivo	
 Removal of the embedded NeoR sequence, to avoid any chance that it interfered with 
na-ve Trp53 expression and regula-on, was achieved by breeding the male founders with Pgk-
Cre female mice that express Cre recombinase ac-vity from the diploid phase of oogenesis 
onwards. Pups born from these breedings were genotyped by PCR to confirm NeoR removal. 
NeoR-excised mice, carrying the Trp53TRE3 allele, were mated with mice carrying the R26CAG-rtTS 
allele that drives expression of rtTS (allele generated by Dr Ivonne Gamper in Evan group). Pups 
from these crosses were genotyped and further bred to generate mice homozygous for 
Trp53TRE3 with R26CAG-rtTS (Trp53TRE/TRE;R26CAG-rtTS/+). The system was further verified in these 
animals and cells derived from them, as described in Chapter 2.  
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Figure 1.23. Southern blots of correspondingly digested gDNA of F1 pups that gave posiOve results in the 
genotyping PCR (see Figure 1.22). Top: Southern blot on the 5’ side of the inser-on site; bo[om: Southern 
blot on the 3’ side of the inser-on site. Digested gDNA of each F1 pup was loaded onto one lane of the 
agarose gel in each blot. Details of the diges-ons, probe used and expected target fragment sizes are outlined 
in Table 1.2. All pups, barring 5.2 b and c which were shown to be WT, gave posi-ve results in the Southern 
blots. The bands on the film of the 3’ Southern blot appeared very faint on the scanned image but were 
visible on the actual film to be indica-ve of the results. The red arrows indicate the posi-ons of the faint 
bands. 
CHAPTER 1 
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The results reported in Chapter 1 indicate efficient repression of Trp53 in the heterozygous 
Trp53TRE3/+ mESCs in which the TRE was targeted to posi=on C3 of the endogenous Trp53 allele. 
In order to further confirm the func=onality of the TRE system, similar experiments were 
conducted in homozygous Trp53TRE3/TRE3 mESCs and targeted mouse embryonic fibroblasts 
(MEFs) as well as in the targeted animals. 
2.1	Validating	the	repression	system	in	mESCs	
2.1.1	Creating	homozygous	Trp53TRE3/TRE3;CAG-rtTStg	mESCs	
 The preliminary results in Chapter 1 suggest that Trp53 expression can be effec=vely 
repressed by the Dox-dependent rtTS without interfering with the na=ve expression and 
regula=on of Trp53 when the TRE was inserted into posi=on C3 in Trp53’s promoter. However, 
since these Trp53TRE3/+ mESCs retained one WT Trp3 allele, it was impossible to discern how 
effec=vely the Trp53TRE3 allele was repressed. To this end, homozygous Trp53TRE3/TRE3 mESCs 
were generated. 
 Trp53TRE3/+ cells were re-infected with the DTA3-TRE-NeoR vector to target the remaining 
WT allele (same strategy as described in Chapter 1 Sec3on 1.4). Of the 43 selected clones, 
genotyping PCR indicated that 8 had the WT allele successfully targeted with the TRE-LoxP-
NeoR-LoxP casseVe (Figure 2.1). These posi=ve clones were further analysed by Southern blots 
as described in Figure 1.13 and Table 1.2 to confirm accurate targe=ng (Figure 2.2). All of the 
eight clones tested with the genotyping PCR were also posi=ve in the Southern blots. These 
clones, of the genotype Trp53TRE3/TRE3-NeoR, were then used to recons=tute the TRE repression 
system. The NeoR sequence from the Trp53TRE3-NeoR allele was first excised and the CAG-rtTStg 
transgene was added to the cells, as described in Chapter 1 sec3on 1.5. 
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Figure 2.1. Genotyping PCR to preliminarily screen for mESCs that had the second allele targeted at C3 with 
the TRE-Lox-NeoR-Lox casseGes. LeZ: a summary of the expected size of PCR products. Right: Products of the 
genotyping PCRs on the gDNA of the 44 picked clones were separated by gel electrophoresis. The red arrow 
indicates posi=on of the band amplified from the Trp53TRE3-NeoR allele on the gel; the green arrow indicates the 
band amplified from the Trp53TRE3 allele; the black arrow indicates the WT band. The eight posi=ve clones are 
indicated by the blue boxes. GeneRuler 1 kb Plus ladder from Thermo Scien=fic was used in these gel 
electrophoresis. The sequences of primers used are detailed in Table M.1c in the Methods and Materials 
chapter.
CHAPTER 2 
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Figure 2.2. Southern blots of the eight PCR-posi3ve clones. (a) A table of expected detectable targeted 
fragment sizes. Details of the diges=ons and the probes used were outlined in Table 1.2. (b) Digested gDNA of 
each clone was loaded onto one lane of the agarose gel in each Southern blot. Top blot: Southern blot on the 
5’ side; boVom blot: Southern blot on the 3’ side.
CHAPTER 2 
2.1.2	Kinetics	of	Trp53	repression	and	de-repression	in	mESCs 
 Both kine=cs of Trp53 mRNA repression by the system upon Dox treatment and its 
recovery aZer removal of Dox were assessed. The system in a heterozygous state (Trp53TRE3/+) 
was included to check if the system would func=on differently than in the homozygous state 
(Trp53TRE3/TRE3) in terms of kine=cs due to, for example, the poten=al influence exerted by the 
WT allele. 
 To assess the repression kine=cs, Trp53TRE3/+;CAG-rtTStg and Trp53TRE3/TRE3;CAG-rtTStg 
mESCs cultured on petri dishes for 24 hours were treated with Dox for various =mes and Trp53 
mRNA expression in these cells was assessed by qPCR (Figure 2.3). 48 hours of Dox treatment 
reduced Trp53 mRNA expression by 50% and 98.5% in Trp53TRE3/+;CAG-rtTStg and Trp53TRE3/
TRE3;CAG-rtTStg cells respec=vely. The 50% reduc=on in the heterozygous Trp53TRE cells is 
consistent with the reten=on of expression from the WT allele. Interes=ngly, it was consistently 
observed that untreated Trp53 mRNA level slightly decreased as the cells were cultured on the 
same dish for a longer period of =me (e.g. 12 hours vs 96 hours of culturing on the same plate). 
The exact reason for this is unclear but it may be due to the increase in cell confluence. 
 To assess the recovery rate of Trp53 mRNA level aZer withdrawal of Dox treatment, the 
mESCs were treated with Dox for 48 hours and then cultured in Dox-free growth medium for 
different periods of =me. mRNA was extracted from the cells and the rela=ve Trp53 mRNA level 
was quan=fied by qPCR (Figure 2.4). In both Trp53TRE3/+;CAG-rtTStg and Trp53TRE3/TRE;CAG-rtTStg 
mESCs, the Trp53 mRNA level recovered to that seen in untreated cells and control cells with or 
without Dox treatment within 48 hours aZer withdrawal of Dox treatment. 
 These data confirm that Trp53 mRNA expression from the Trp53TRE3 allele can be rapidly 
and reversibly repressed even in the heterozygous state, sugges=ng that the remaining wild 
type allele exerts no influence on regula=on of the targeted allele by the TRE system. 
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Figure 2.3. Kine3cs of Dox repression by the TRE system in heterozygous and homozygous mESCs. The rela=ve 
Trp53 mRNA level in each sample was quan=fied with qPCR and then ploVed against length of Dox treatment. 
PloVed are the mean values of samples from cells of 2 different passages and the error bars denote the 
respec=ve standard devia=ons. (a) Heterozygous Trp53TRE3/+;CAG-rtTStg mESCs. (b) Homozygous Trp53TRE3/
TRE3;CAG-rtTStg mESCs. The % mRNA at 48 and 72 hours of Dox treatment was calculated with reference to the 
level at 0 hour with no treatment. Primers specific to Trp53 and Tbp mRNA were used in the qPCR analysis and 
their details are listed in Table M.6b in the Methods and Materials chapter. 
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Figure 2.4. Kine3cs of de-repression of Trp53 mRNA following Dox repression by the TRE system in 
heterozygous and homozygous mESCs. Rela=ve Trp53 mRNA level were quan=fied by qPCR and ploVed 
correspondingly against the Dox-removal =mepoints. Shown are the mean values of samples from cells of 2 
different passages and the error bars denote the respec=ve standard devia=ons. (a) Heterozygous 
Trp53TRE3/+;CAG-rtTStg mESCs. (b) Homozygous Trp53TRE3/TRE3;CAG-rtTStg mESCs. Primers specific to Trp53 and 
Tbp mRNA were used in the qPCR analysis and their details are listed in Table M.6b in the Methods and 
Materials chapter. PloVed were the mean values of samples from cells of 2 different passages and the error 
bars denote the respec=ve standard devia=ons.
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2.2	Repression	of	Trp53	in	primary	MEFs 
 To complement the results in mESCs reported above and in Chapter 1, I determined the 
efficiency and kine=cs of Dox-dependent repression of p53 in MEFs. Despite also being an in 
vitro cell system, the MEFs resemble the in vivo mouse system more than the mESCs in two 
regards. First, the rtTS repressor in MEFs is expressed from the ubiquitous cons=tu=ve Rosa26 
promoter rather than from the poten=ally mul=ple inser=ons of the transgenes in the mESCs. 
Second, primary MEFs of early passages were used to avoid any compensa=on or changes that 
may have occurred during the long-term culture of the mESCs. 
 Whether the TRE inser=on affects normal Trp53 expression in the MEFs system was first 
assessed. Heterozygous Trp53TRE3/+;R26CAG-rtTS/+ E13.5 embryos were harvested and 
disaggregated into MEFs, which were then cultured in vitro. Trp53 mRNA expression of these 
cells in the absence of Dox was compared to WT cells. As shown in Figure 2.5, there was no 
difference in Trp53 mRNA level between the heterozygous and WT cells aZer either 24 hours or 
120 hours in culture, indica=ng that the TRE inser=on itself did not affect Trp53 mRNA 
expression. Similar to the mESCs system (Sec3on 2.1.2 above), a sta=s=cally significant 
reduc=on of Trp53 mRNA expression correla=ng with =me in culture was also observed in the 
MEFs (Figure 2.5; sta=s=cally tested with One-way ANOVA; p values = 0.0352 for WT and 0.0481 
for Trp53TRE3/+ cells).  
 Then, rtTS expression from the endogenous R26 locus in the Trp53TRE3/+;R26CAG-rtTS/+ MEFs 
with or without the Dox treatment was quan=fied with qPCR (Figure 2.6). Robust expression of 
rtTS mRNA was detected in these cells both in the absence and presence of Dox. The slight 
fluctua=on of the expression level observed with longer Dox treatment is apparently irrelevant 
to the efficient repression of Trp53 expression by the TRE system. (Figure 2.7 below). 
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Figure 2.5. TRE inser3on did not affect normal Trp53 mRNA expression in MEFs. Two WT and two Trp53TRE3/+ MEFs 
cell lines were grown on culture dishes for 24 and 120 hours with no treatment and harvested for mRNA extrac=on. 
Rela=ve Trp53 mRNA level of the cells were quan=fied by qPCR and the mean value of 2 cell lines of the same 
genotype were ploVed respec=vely against the corresponding =me point. The error bars denote the respec=ve 
standard devia=ons. A One-way ANOVA test was used to test the significance of the apparent decrease of rela=ve 
mRNA level at 120 hours from 24 hours (WT p = 0.0352; Trp53TRE3/+ p = 0.0481). Primers specific to Trp53 and Tbp 
mRNA were used in the qPCR analysis and their details are listed in Table M.6b in the Methods and Materials 
chapter. 
Figure 2.6. rtTS expression level from the Rosa26 locus is independent of Dox treatment. Two Trp53TRE3/+;R26CAG-rtTS/
+ MEFs cell lines were grown on culture dishes for 24 hours and then treated accordingly with Dox for the indicated 
period of =me and harvested for mRNA extrac=on. Rela=ve rtTS mRNA levels in the cells were quan=fied by qPCR and 
the mean value of the two lines were ploVed against the corresponding =mepoint. The error bars denote the 
respec=ve standard devia=ons. Primers specific to rtTS mRNA were used in the qPCR analysis and their details are 
listed in Table M.6b in the Methods and Materials chapter. 
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 Next, how quickly the TRE system repressed Trp53 expression was determined. 
Heterozygous Trp53TRE3/+;R26CAG-rtTS/+ MEFs were treated with Dox for various periods of =me 
and the rela=ve expression level of Trp53 mRNA quan=fied by qPCR (Figure 2.7). Total Trp53 
mRNA was reduced by approximately 50% within 24 hours of addi=on of Dox to the culture 
medium. Given that expression from the WT allele of p53 was unaffected by the system, this 
result suggests that the Trp53TRE3 allele was completely repressed within 24 hours of Dox 
treatment. To further confirm the degree and kine=cs of repression of the Trp53TRE3 allele by the 
system, homozygous MEFs (Trp53TRE3/TRE3;R26CAG-rtTS/+) derived from mice were also treated with 
Dox for different periods of =me and the Trp53 mRNA expression quan=fied by a qPCR. As 
shown in Figure 2.8, the Trp53 mRNA level was repressed to 1.15% of the untreated level aZer 
12 hours of Dox treatment. This repression rate, like in the heterozygous MEFs, was 
substan=ally faster than in mESCs. For example, it took 48 hours of Dox treatment to reach 
98.5% repression of Trp53 mRNA expression in homozygous mESCs (Figure 2.4). Though the 
exact reasons for such a difference are unknown, it could be a result of the dissimilar cellular 
contexts. For instance, Trp53 is found to be expressed at a higher level in embryonic stem cells 
(Solozobova & BlaVner 2011) and it is possible that such a level was more robustly regulated 
and resilient against repression exerted by the TRE system in mESCs than in MEFs.  
 Lastly, the kine=cs of de-repression was determined. Trp53TRE3/TRE3;R26CAG-rtTS/+ cells were 
first treated with Dox for 48 hours, changed to fresh Dox-free medium and cultured for different 
periods of =me before mRNA was harvested from the cells. Trp53 mRNA from these cells was 
then quan=fied with qPCR (Figure 2.9). Trp53 mRNA level recovered to the untreated level 
within 24 hours aZer Dox removal, again with faster kine=cs than the corresponding mESCs.  
 In conclusion, the TRE system proved to be capable of reversibly repressing Trp53 mRNA 
expression in both mESCs and MEFs, though with slightly different kine=cs of repression and de-
repression. However, the fast repression and de-repression observed in MEFs likely represents 
the baseline, probably maximal, rate at which the system could operate because of the absence 
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of hindrances such as delay by Dox delivery to individual =ssues in vivo and/or a reduced 
stability of Dox due to metabolism aZer intake by the animals. Indeed, the in vivo verifica=ons 
in the following sec=on show the system func=oned in a slightly lower rate than in vitro at 
general. 
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Figure 2.7. Rapid repression of Trp53 mRNA level by Dox in heterozygous Trp53TRE3/+;R26CAG-rtTS/+ MEFs. Three 
Trp53TRE3/+;R26CAG-rtTS/+ MEFs cell lines (and two WT as reference) seeded and cultured for 24 hours were treated with 
Dox with the indicated periods of =me and harvested for mRNA. Rela=ve Trp53 mRNA level of the cells were quan=fied 
by qPCR and the mean value of the cell lines were ploVed against the corresponding =mepoint. The error bars denote 
the respec=ve standard devia=ons. Note that the complete repression of expression from the Trp53TRE3 allele (i.e. 50% 
of untreated or WT level) was reached substan=ally faster than in heterozygous mESCs at 12 - 24 hours. Primers 
specific to Trp53 and Tbp mRNA were used in the qPCR analysis and their details are listed in Table M.6b in the 
Methods and Materials chapter. 
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2.3	Repression	of	Trp53	in	vivo	
2.3.1	Does	TRE	insertion	interfere	with	normal	Trp53	mRNA	expression	in	tissues? 
 To address whether the implementa=on of the system exerted any impact on normal 
Trp53 expression, various =ssues reported to be radio-sensi=ve (intes=ne, spleen and thymus) 
or radio-resistant (lung, liver, pancreas and skin) were harvested from 6-week-old Trp53TRE3/+ 
and Trp53TRE3/TRE3 mice. Both radio-sensi=ve and radio-resistant =ssues were included in all 
experiments in this thesis despite the radio-sensi=ve =ssue-specific p53 expression and 
transcrip=on ac=vi=es speculated by previous reports, because the use of a germline p53-null 
model in these reports could have missed the subtler func=ons of p53 (MacCallum et al. 1996; 
Komarova et al. 1997; Bouvard et al. 2000; Burns et al. 2001; Fei et al. 2002; Fei & El-Deiry 
2003). From the collected =ssues mRNA was extracted and rela=ve Trp53 mRNA expression was 
quan=fied by qPCR (Figure 2.10). From the plot, it is clearly demonstrated that the inser=on of 
TRE at posi=on C3 did not affect mRNA expression of the endogenous Trp53 gene in all the 
=ssues analysed. These data (as are all subsequent mouse qPCR results) are derived from 
several mice (number denoted as n) and the results ploVed as the mean and standard 
devia=ons. 
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Figure 2.10. TRE inser3on at one or both alleles of the endogenous Trp53 gene did not affect normal 
Trp53 mRNA expression in different 3ssues. PloVed are the mean quan=fied rela=ve Trp53 mRNA level of 
the animals in each genotype group (n = number of animals in the group) while error bars denotes the 
standard devia=on. Only results from 3 mice were ploVed for skin of the Trp53+/+ and Trp53TRE3/TRE3 group 
respec=vely because of the poor inefficient mRNA extrac=ons from skin of the other mice. The differences 
in the rela=ve p53 mRNA level amongst the three genotype groups in all =ssues were insignificant, as 
indicated by a One-way ANOVA test. Primers specific to Trp53 and Tbp mRNA were used in the qPCR 
analysis and their details are listed in Table M.6b in the Methods and Materials chapter. 
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2.3.2	Verifying	rtTS	mRNA	expression	in	vivo 
 The in vivo expression of rtTS mRNA from the R26 locus was analysed. Rela=ve mRNA 
levels of rtTS in the =ssues collected from 6-week old Trp53TRE3/TRE3;R26CAG-rtTS/+ and Trp53TRE3/
TRE3;R26CAG-rtTS/CAG-rtTS mice was quan=fied by qPCR and the results are ploVed in Figure 2.11. A 
five-fold varia=on of rtTS mRNA expression levels in different =ssues was observed with a rough 
trend of doubled expression level in homozygous compared to R26CAG-rtTS/+ =ssues. Enriching the 
data set of the homozygous =ssues should increase the significance of the data. The varying rtTS 
mRNA expression across the =ssues did not appear to correlate with the efficiency or the 
kine=cs of repression and de-repression of Trp53 mRNA by the TRE system, as shown in the 
following sec=ons. 
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Figure 2.11. rtTS mRNA expression from one or two copies of the R26CAG-rtTS allele varied across 3ssues. 
PloVed are the mean quan=fied rela=ve rtTS mRNA level of the animals in each genotype group (n = number 
of animals in that group) and the error bars denote the standard devia=ons (**** : p <0.0001; ** : p =0.0019; 
unmarked = non significant). Primers specific to rtTS mRNA were used in the qPCR analysis and their details 
are listed in Table M.6b in the Methods and Materials chapter.
CHAPTER 2 
2.3.3	Repression	of	Trp53	mRNA	expression	by	Dox	in	vivo	
 Having verified the components of the system in vivo, the TRE system’s capacity to 
repress endogenous Trp53 mRNA expression in =ssues upon Dox treatment was assessed. To 
this end, =ssues were collected from Trp53TRE3/TRE3;R26CAG-rtTS/+ mice that had been administered 
with Dox in sucrose-sweetened water for 7 days, a =mepoint at which E2f3 expression was 
>95% repressed from the TRE-Ef3 allele in similar experiments in Gamper et al. (Gamper et al. 
2017). The rela=ve Trp53 mRNA level in the collected =ssues was determined by qPCR (Figure 
2.12). Consistent with Gamper et al., aZer 7 days of Dox treatment the Trp53 mRNA level was 
almost completely eliminated across the panel of =ssues tested. The residual level of Trp53 
mRNA in the pancreas and spleen was 3.39% and 2.56% of the untreated group respec=vely, 
while in the other =ssues it was less than 1%. The sta=s=cal significance of the mRNA levels 
between the treated and untreated group was affirmed by a One-way ANOVA test and the p-
values are indicated in the graph. 
 Note that in all in vivo experiments in this thesis, Dox was administered to mice in 
drinking water at a concentra=on of 2 mg/1 mL of 1% (w/v) sucrose water while the untreated 
control groups were treated with the Dox-free 1% sucrose water. Sucrose was added to the 
drinking water to mask the biVer taste of Dox dissolved in water, which might dissuade the 
animals from drinking. 
2.3.4	Kinetics	of	Trp53	mRNA	repression	by	Dox 
 To u=lise the TRE repression system in in vivo experiments, it is necessary to know how 
quickly the system responds upon Dox treatment. To this end, I set up a =mepoint experiment 
where Trp53TRE3/TRE3;R26CAG-rtTS/+ mice were treated with Dox for 1, 2 or 3 days. Note that =ssues 
were always harvested from 6-week old mice to minimise any possible age-related effects. 
Rela=ve Trp53 mRNA levels in intes=ne, spleen, thymus, lung, liver, pancreas and skin were 
quan=fied by qPCR (Figure 2.13). Results from the 7 days Dox treatment was also included as a 
  103
CHAPTER 2 
=mepoint in the plot. The graphs indicate that for all the tested =ssues, a Dox treatment of 2 
days sufficed to repress Trp53 mRNA expression to a minimal level, though in the pancreas and 
skin more varia=ons were observed at the 2 and 3 day =mepoints. 
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Figure 2.12. Trp53 mRNA expression was almost completely repressed in various 3ssues aXer 7 days of 
Dox treatment. PloVed are the mean quan=fied rela=ve Trp53 mRNA level in the =ssues of the animals in 
each treatment group (n = number of animals in the group) while error bar denotes the standard 
devia=on. The differences between the treated and untreated group in each =ssue was tested for 
significant by a One-way ANOVA test and the p-values are indicated by asterisks (*: p = 0.0101; ***: p = 
0.002; ****: p < 0.0001). Primers specific to Trp53 and Tbp mRNA were used in the qPCR analysis and 
their details are listed in Table M.6b in the Methods and Materials chapter. 
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Kinetics	of	Trp53	mRNA	repression	by	Dox	
in	tissues
Figure 2.13. Kine3cs of Dox repression of Trp53 mRNA in various 3ssues. PloVed are the mean quan=fied rela=ve 
Trp53 mRNA level of the indicated =ssues from the animals at each =mepoint (n = number of animals in that 
=mepoint) while error bar denotes the standard devia=on. Note that the scale of the y-axis represen=ng rela=ve 
Trp53 mRNA levels is not necessarily the same across the =ssues. The sta=s=cal significance shown in the pancreas 
graph resulted from a One-way ANOVA test and the p-values are indicated by asterisk (ns = non-significant; *: p = 
0.0413). Primers specific to Trp53 and Tbp mRNA were used in the qPCR analysis and their details are listed in Table 
M.6b in the Methods and Materials chapter.
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2.3.5	Kinetics	of	Trp53	mRNA	de-repression	following	removal	of	Dox	
 The ability to reversibly suppress Trp53 func=on is essen=al to determine Trp53’s 
temporal func=onality in different processes, such as tumour evolu=on and =ssue regenera=on. 
Therefore it is necessary to determine the kine=cs of Trp53 mRNA level recovery in =ssues aZer 
withdrawal of Dox. In this experiment, Trp53TRE3/TRE3;R26CAG-rtTS/+ mice were first administered 
Dox-added sucrose water for 7 days (where maximum repression was achieved; Figure 2.13) 
and switched to Dox-free fresh water for 1 or 3 days; the animals were euthanised at the 
=mepoints indicated and =ssues were collected by snap-freezing. Rela=ve Trp53 mRNA levels in 
these =ssues were then quan=fied by qPCR (Figure 2.14). With the excep=on of skin where 
insufficient mRNA was isolated, Trp53 mRNA in all =ssues returned to the normal, untreated 
level by 3 days (See Figure 2.20 below for recovery of p53 protein ac=vi=es in skin in three days, 
which is similar to the other =ssues). The uniform rate of Trp53 mRNA recovery across these 
=ssues suggests that inherent Trp53 transcrip=on is not overly influenced by any =ssue-specific 
trans-effects.  
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Figure 2.14. De-repression of Trp53 mRNA following removal of Dox treatment from mice. PloVed were 
the mean quan=fied rela=ve Trp53 mRNA levels in the indicated =ssues of the animals at each =mepoint 
(n = number of animals in that =mepoint) while error bar denotes the standard devia=on. Note that the 
scale of the y-axis represen=ng rela=ve Trp53 mRNA level is not necessarily the same across the =ssues. 
Primers specific to Trp53 and Tbp mRNA were used in the qPCR analysis and their details are listed in Table 
M.6b in the Methods and Materials chapter. 
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2.3.6	Repression	of	p53	protein	levels	by	the	TRE	system 
 Having established the rate at which the system represses and de-represses Trp53 mRNA 
in vivo, repression of p53 protein level by the TRE system in vivo was determined. Trp53TRE3/
TRE3;R26CAG-rtTS/+ mice were treated with Dox for 3, 5 and 7 days and proteins prepared from 
whole cell lysate of frozen =ssues of these mice were analysed by western blots (Figure 2.15). 
p53 protein in spleen, thymus and surprisingly pancreas was shown to be expressed under 
normal condi=ons at a detectable level in the western blots. It also showed that the presence of 
TRE in the Trp53 allele or rtTS expression from the R26 locus did not significantly change p53 
levels in the three =ssues. Upon Dox treatment, p53 was repressed substan=ally in the three 
=ssues, though with slightly varying rates. In spleen, the level reduced to a minimal level by 5 
days whereas it took three days in the thymus and pancreas. Intriguingly, in spite of the 
remaining p53 level in spleen aZer 5 days of Dox treatment, the transcrip=on ac=vity of p53 
was shown to be repressed by three days (see sec=on 2.3.7 below). The blots also show that a 
7-day Dox treatment prevented up-regula=on of p53 protein level in spleen upon DNA damage 
signals (Figure 2.15a lanes 11 - 13). Note that in all the pancreas samples a pep=de species with 
slower mobility was detected but it was absent in the posi=ve control (γ-irradiated thymus) and 
other =ssues tested. 
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Figure 2.15. Repression of p53 protein level in spleen, thymus and pancreas by Dox treatment. (a) Spleen. A 
separate gel was run for GAPDH as there was an air bubble blocking the transfer of the original gel to the membrane 
blot at GAPDH’s posi=on of lane 9 - 13. (b) Thymus (top) and pancreas (boVom). Lane 12 is empty in the thymus blot. 
+ve ctrl: posi=ve control for p53 staining which was lysate from γ-irradiated thymus. For each genotype/treatment 
group, proteins from two mice were analysed. 20 μg of proteins were loaded per lane and separated by 12% 
acrylamine gel. p53 was detected with the primary an=body 1C12 while GAPDH and β-Ac=n with an=bodies D16H11 
and AC15 respec=vely (details of an=bodies described in Sec3on M.6 in the Methods and Materials chapter). Note 
that the spleen Western blot per se in (a) was executed by Ms. Maria-Myrsini Tzioni, a rotatory student in the Evan 
group, under my supervision and used in this thesis with her consent.
CHAPTER 2 
2.3.7	Regulation	of	p53	transcription	activity 
 Although p53 was repressed substan=ally following Dox treatment, in some cases 
residual protein level was present aZer the treatment but the biological relevance was not 
discernible in the western blots. p53 as a transcrip=on factor has been well characterised for 
media=ng stress-induced responses such as transcrip=onal regula=on of its downstream targets 
following DNA damage (Lakin & Jackson 1999). The transcrip=onal ac=vity of p53 upon DNA 
damage could therefore poten=ally be used as a parameter to gauge the repression of p53 
ac=vi=es by the TRE system. 
 Firstly the func=onality of the TRE repression system upon DNA damage in vivo was 
confirmed. In this experiment, 5-week old mice of the genotype Trp53TRE3/TRE3;R26CAG-rtTS/+ were 
treated with either Dox-added or Dox-free sucrose-sweetened water for 3, 5 or 7 days followed 
by whole body 5 Gy γ-radia=on to inflict DNA damage such as DNA single- and double-strand 
breaks in cells of different =ssues. Five hours aZer irradia=on, the mice were euthanised, =ssues 
harvested, RNA extracted and Trp53 mRNA level determined by qPCR (Figure 2.16). As shown in 
the plots, the TRE system repressed Trp53 mRNA expression in the presence of Dox to a similar 
extent with or without the γ-radia=on. On a separate note, Trp53 mRNA expression in the 
irradiated mice was up-regulated in pancreas and thymus, but in lung and liver the level 
decreased comparing to non-irradiated =ssues. While an increase in Trp53 mRNA level would be 
biologically reasonable considering the stabilisa=on of Trp53 mRNA by an=sense Wrap53 mRNA 
in the presence of a DNA damage signal (Mahmoudi et al. 2009), the observed decreases were 
unexpected. However, given the rather small extent of the increases and decreases and the 
nature of varia=on in animal experiments, the dataset will have to be enlarged to draw any 
conclusion confidently.  
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Figure 2.16. Repression of Trp53 mRNA expression in 3ssues by Dox aXer a dose of 5 Gy γ-irradia3on. PloVed were 
the mean quan=fied rela=ve Trp53 mRNA level of the animals in each treatment group (n = number of animals in the 
group) while error bar denotes the standard devia=on. Note that the scale of the y-axis represen=ng rela=ve Trp53 
mRNA level is not necessarily the same across the =ssues. One-way ANOVA test was used to analyse the sta=s=c 
significance of the differences between the treatment groups as exemplified on the Pancreas Plot in which the p-
values are indicated (ns: non-significant; ***: p = 0.0006; ****: p < 0.0001). Primers specific to Trp53 and Tbp mRNA 
were used in the qPCR analysis and their details are listed in Table M.6b in the Methods and Materials chapter. 
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 Having confirmed that Trp53 mRNA was s=ll repressed by the system in the presence of 
DNA damage signals, I next checked whether the p53 transcrip=onal target gene Bax (BCL2-
associated X) could be used as a readout for the transcrip=onal ac=vity of p53. Bax encodes the 
apopto=c ac=vator protein Bax that facilitates apoptosis by permeabilisa=on of the 
mitochondrial outer membrane, releasing pro-apopto=c factors including cytochrome c (Oltvai 
et al. 1993; Finucane et al. 1999) and is up-regulated by p53 upon DNA damage (Miyashita & 
Reed 1995). To assess whether Bax mRNA expression could be used as a reporter of p53 
transcrip=onal ac=vity, rela=ve Bax mRNA level in the =ssues of the mice irradiated with or 
without Dox treatment was quan=fied by qPCR (Figure 2.17). From the plots, it is clear that Bax 
mRNA was expressed at a basal level in all the =ssues even without irradia=on and this 
expression was not dependent on p53 as it remained unchanged aZer 7 days of Dox treatment. 
Upon irradia=on, the rela=ve mRNA level of Bax was up-regulated in all =ssues as expected, 
though to a different extent. This induc=on of Bax by irradia=on was en=rely absent in the 
=ssues of mice treated with Dox for 3 days prior to irradia=on (except the skin where 
unfortunately Bax induc=on could not be determined at the 3 and 5 day =mepoints due to poor 
quality of the extracted mRNA) and hence was p53-dependent. These data demonstrate that 
within 3 days of Dox treatment p53’s transcrip=onal ac=vity was completely repressed.  
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Figure 2.17. p53-dependent γ-irradia3on-induced up-regula3on of Bax expression showed repression of p53 
transcrip3on ac3vity by three days of Dox treatment. PloVed were the mean quan=fied rela=ve Bax mRNA level of the 
animals in each treatment group (n = number of animals in the group) while error bar denotes the standard devia=on. 
Note that the scale of the y-axis represen=ng rela=ve Trp53 mRNA level is not necessarily the same across the =ssues. 
One-way ANOVA test was used to analyse the sta=s=c significance of the differences between the treatment groups/
=mepoints (ns = non significant; **: p = 0.0048; ****: p <0.0001). Primers specific to Bax and Tbp mRNA were used in 
the qPCR analysis and their details are listed in Table M.6b in the Methods and Materials chapter. 
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 To examine whether this induc=on by p53 in all =ssues is specific to Bax or general to 
other p53 target genes as well, the mRNA expression of two other direct p53 targets, namely 
Puma (p53 upregulated modulator of apoptosis) and Cdkn1a, were analysed in the same 
manner. Puma, like Bax, encodes a pro-apopto=c protein Puma that is a member of the Bcl-2 
apopto=c protein family. It func=ons to interact with an=-apopto=c Bcl-2 proteins to free Bax 
and/or Bak to trigger apoptosis via the mitochondrial pathway. Regulated by transcrip=on 
factors, Puma is expressed upon various signals in both p53-dependent and -independent 
manners (Nakano & Vousden 2001; Melino et al. 2004; Matallanas et al. 2007; Ming et al. 
2008). Cdkn1a, on the other hand, connects DNA damage to cell cycle arrest instead of 
apoptosis. This gene expresses a cyclin-dependent kinase inhibitor protein p21Cip1 (alterna=vely 
p21Waf1) that limits cell cycle progression by primarily binding and thus inhibi=ng the ac=vity of 
CDK2 (cyclin-dependent kinase 2) in response to DNA damage signals channeled through p53 
(El-Deiry 1993; Brugarolas et al. 1995). The p21Cip1 protein also interacts with PCNA 
(prolifera=ng cell nuclear an=gen) to regulate S-phase DNA synthesis (Waga et al. 1994). The 
expression of Puma and Cdkn1a mRNA in the same samples as those in Figures 2.16 and 2.17 is 
shown in Figures 2.18 and 2.19, respec=vely. With the excep=on of Puma in the liver where 
unexpectedly high varia=ons were observed, transcrip=on of both Puma and Cdkn1a exhibited 
paVerns of mRNA expression similar to that of Bax. In conclusion, the p53-dependent induc=on 
of Bax, Puma and Cdkn1a upon γ-irradia=on occurred in all tested =ssues (except Puma in liver, 
the irregularity of the data was likely due to poor RNA quality resulted from compromised 
extrac=on) and can all be used as a readout of p53’s ac=vi=es. 
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Figure 2.18. γ-irradia3on induced Puma mRNA up-regula3on is dependent on p53. PloVed are the mean 
quan=fied rela=ve Puma mRNA levels in the indicated =ssues of the animals in each treatment group (n = number 
of animals in the group) while error bar denotes the standard devia=on. Note that the scale of the y-axis 
represen=ng the rela=ve mRNA level is not necessarily the same across the =ssues. One-way ANOVA test was used 
to analyse the sta=s=c significance of the differences between the treatment groups (ns = non significant; *: p = 
0.0470; **: p = 0.0034). Primers specific to Puma and Tbp mRNA were used in the qPCR analysis and their details 
are listed in Table M.6b in the Methods and Materials chapter. 
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Figure 2.19. γ-irradia3on induced Cdkn1a mRNA up-regula3on is dependent on p53. PloVed are the mean 
quan=fied rela=ve Cdkn1a mRNA levels of the indicated =ssues of the animals in each treatment group (n = 
number of animals in the group) while error bar denotes the standard devia=on. Note that the scale of the y-axis 
represen=ng the rela=ve mRNA level is not necessarily the same across the =ssues. One-way ANOVA test was used 
to analyse the sta=s=c significance of the differences between the treatment groups (ns = non significant; *: p = 
0.0186; ***: p = 0.0002). Primers specific to Cdkn1a and Tbp mRNA were used in the qPCR analysis and their 
details are listed in Table M.6b in the Methods and Materials chapter. 
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 Using this approach, the kine=cs of recovery of p53 protein transcrip=onal ac=vity in 
different =ssues aZer removal of Dox treatment was inves=gated. In this experiment, Trp53TRE3/
TRE3;R26CAG-rtTS/+ mice received a 7-day Dox treatment, followed by withdrawal of Dox treatment 
for either 3 or 5 days before whole body, 5 Gy γ-irradia=on. Tissues were collected for mRNA 
quan=fica=on 5 hours aZer irradia=on. In this instance, Bax mRNA expression was used as the 
parameter to gauge p53 protein ac=vi=es and the results are ploVed in Figure 2.20. Consistent 
with the kine=cs of p53 re-expression following Dox withdrawal (Figure 2.14), irradia=on-
dependent Bax expression was clearly seen in all =ssues three days aZer removal of Dox 
treatment and was comparable to the level observed in WT mice (Figure 2.20). 
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Figure 2.20. Recovery of p53 ac3vity aXer removal of Dox treatment. Bax mRNA expression level was used as a 
parameter to assess how fast p53 ac=vi=es recovered from repression aZer Dox treatment removal. PloVed are the 
mean quan=fied rela=ve Bax mRNA levels of the indicated =ssues of the animals in each treatment group (n = number 
of animals in the group) while error bar denotes the standard devia=on. Note that the scale of the y-axis represen=ng 
the rela=ve mRNA level is not necessarily the same across the =ssues. One-way ANOVA test was used to analyse the 
sta=s=c significance of the differences between the treatment groups/=mepoints (ns = non significant). Primers specific 
to Bax and Tbp mRNA were used in the qPCR analysis and their details are listed in Table M.6b in the Methods and 
Materials chapter. 
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2.4	The	antisense	gene	Wrap53	
 Analysis of the gene structure of Trp53 in mouse revealed that the an=sense gene 
Wrap53 is encoded in the promoter region of Trp53. This an=sense gene encodes two 
func=onal mRNAs, namely Wrap53α and Wrap53β which share the first six exons. Wrap53α is 
an an=sense mRNA expressed following DNA damage signals that stabilises Trp53 mRNA by 
complementarily binding to its 5’ UTR (Mahmoudi et al. 2009). The other transcript encodes the 
Wrap53β protein, also named TCAB1, which is involved in the maintenance of nuclear Cajal 
bodies, DNA repair and telomere elonga=on in human cell lines (Venteicher et al. 2009; 
Tycowski et al. 2009; Mahmoudi et al. 2010; Zhong et al. 2011; Henriksson et al. 2014; Freund et 
al. 2014). Figure 2.21 illustrates Wrap53's gene structure in mouse and expression of its gene 
products. In the mouse genome, Trp53 and Wrap53 do not overlap though their transcrip=on 
start sites (TSS) are only 98 bp apart (NCBI). Although the exons of Wrap53 were carefully 
avoided in placing the TRE, it is possible that expression of the gene is affected and/or subject 
to repression imposed by the TRE system. If so, it will be important to dissect the func=onal 
contribu=on of the an=sense gene to results yielded from experiments using the system. To 
determine whether or not this is the case, I conducted some further experiments as described 
below. 
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Figure 2.21. Reported func3ons of the Wrap53 gene. The first mRNA transcript Wrap53α is an=sense to the p53 
mRNA and, once expressed upon DNA damage signals, it binds to the 5’ end of p53 mRNA, stabilising it. The other 
transcript Wrap53β encodes the WD40 protein Wrap53β (or TCAB1), the human analog of which was reported to be 
involved in maintenance of nuclear Cajal bodies, DNA repair and telomere elonga=on, though no commiVed 
inves=ga=ons on the mouse gene have been published. The two transcripts share the first 6 exons. The red pointer 
indicates the TRE inser=on site C3; Deep blue boxes represent exons of Wrap53; Green empty boxes denote the first 
two exons, non-coding, of Trp53. 
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2.4.1	Wrap53	mRNA	expression	in	vivo 
 First, I asked whether Wrap53 was expressed in mouse =ssues and, if so, whether its 
expression was changed by the presence of the TRE alone and in the presence of rtTS and Dox. 
Since no reports have characterised Wrap53 gene func=on in mice and no an=bodies are 
available for the Wrap53β protein, expression of the gene was assessed at the mRNA level by 
qPCR. mRNA was isolated from various =ssues from six-week old WT, and untreated and Dox-
treated Trp53TRE3/TRE3;R26CAG-rtTS/+ mice and total Wrap53α and β mRNA levels were determined 
by qPCR (Figure 2.22). It was not possible to quan=fy the level of the α transcript independent 
of β as the en=rety of transcript α overlaps with the first six exons of transcript β. However, a 
pair of qPCR primers specific for transcript β were designed and used to determine its 
expression in the later part of this sec=on. The plot in Figure 2.22 shows that Wrap53 was 
expressed to comparable levels in all tested =ssues except skin, where the mRNA level was not 
detectable by the primers. It also indicates that the inser=on of TRE in both alleles of the gene 
did not disrupt or reduce Wrap53 mRNA expression in =ssues. Note that in lungs the expression 
was slightly affected by the TRE inser=on, though the reason for that and what it means 
biologically remains unclear. Importantly, this experiment showed that mRNA expression of the 
Wrap53 gene was repressible by the TRE system upon Dox treatment.  
 To determine whether the repression of Wrap53α and Wrap53β both contributed to the 
observed reduc=on in total Wrap53 mRNA, primers specific to Wrap53β (annealing to exon 7 
and 8 respec=vely) were used to quan=fy its expression level (Figure 2.23). It is clear that 
Wrap53β was similarly expressed in the =ssues and its expression was also repressed by the 
TRE system following administra=on of Dox. However, the expression level of Wrap53β 
quan=fied here is not directly comparable to the combined level reported in Figure 2.22 
because the primers used were unlikely to have exactly the same efficiency in the qPCR 
quan=fica=on. Without primers that recognise specifically the α transcript, it cannot be known 
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for certain whether Wrap53α was also expressed and repressed by the system as it is possible 
that the expression detected in Figure 2.22 was solely contributed to by Wrap53β. However, the 
co-repression of Wrap53α by the TRE system, if present, would be of less concern because it 
func=ons solely to regulate the Trp53 mRNA level (Mahmoudi et al. 2009). 
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Figure 2.22. The Wrap53 gene is expressed at mRNA level in all 3ssues except skin and is subject to repression by 
the TRE system upon Dox treatment. n denotes the number of animals in the genotype group. The quan=fica=on 
failed to detect any Wrap53 expression in skin. A One-way ANOVA test was carried out to assess the sta=s=cal 
significance between WT and homozygous TRE lungs (**: p = 0.0080). Note that the primers used in the qPCR 
detected both transcript Wrap53α and β and their details are listed in Table M.6b in the Methods and Materials 
chapter. 
CHAPTER 2 
2.4.2	Strategies	to	address	the	co-repression	of	Wrap53	
 The capacity to rapidly and reversibly repress expression of endogenous Trp53 displayed 
by the TRE-p53 model described in this thesis is undeniably an extremely valuable aid to 
understand when and how p53 exerts its physiological and tumour suppressor roles. It is a 
model far superior to the exis=ng ones. However, co-repression of Wrap53 by the TRE system 
has the poten=al to cloud experimental analyses of at least some of p53’s func=ons and it will 
be important to be able to aVribute experimental results to changes in Trp53 alone. Given the 
circumstances, a feasible solu=on is to add in to the genome an extra copy of the Wrap53β with 
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Figure 2.23. Transcript Wrap53β expressed in 3ssues is also subject to repression by the TRE system upon Dox 
treatment. n denotes the number of animals in the genotype group. The quan=fica=on failed to detect any Wrap53β 
expression in skin. The primers used are listed in Table M.6b in the Methods and Materials chapter. 
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expression matching the WT allele but not regulated by the TRE system. This could compensate 
for the repressed endogenous expression by the TRE system in the presence of Dox. The first 
assump=on here is that the ectopic expression level brought in by the extra copy (in the 
absence of Dox) has no impact cellularly or physiologically. Secondly the designed knock-in of 
the gene expressed in all =ssues in a manner, level-wise and temporally, comparable to the 
endogenous gene. 
 As a preliminary test of the strategy in the future, I will assess in MEFs the replacement 
of the repressed Wrap53β expression by introducing a cons=tu=vely expressed Wrap53β 
transgene by Len=virus. To this end, the coding sequence of Wrap53β transcript was cloned into 
a Len=virus vector under a cons=tu=ve promoter, which was outsourced to be carried out by 
AMSBIO Ltd. Figure 2.24 shows a map of the Len=virus DNA vector carrying the Wrap53β cDNA. 
The original 5’ and 3’ UTR of Wrap53β were included to preserve the post-transcrip=onal 
regula=on of the transcript, if any. The first intron was also retained as other studies indicated 
that reten=on of an intron promoted successful mRNA processing of the ectopic coding 
sequences. Silent point muta=ons were introduced to the annealing sites of the qPCR primers 
used so that mRNA expressed from the Wrap53β transgene could be dis=nguished from the 
endogenous alleles in qPCR quan=fica=on. Finally, a FLAG-tag sequence was also added to the 
5’ end of exon 1 to iden=fy the ectopic Wrap53β protein. 
 This Len=virus construct will be used to introduce the Wrap53β transgene into Trp53TRE3/
TRE3;R26CAG-rtTS/+ MEFs and the expression of ectopic Wrap53β RNA and protein will be 
determined in the presence and absence of Dox. If successful, a similar construct could be used 
to introduce the Wrap53β transgene into Trp53TRE3/TRE3;R26CAG-rtTS/+ mice to compensate for the 
TRE-dependent repression in the presence of Dox. 
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Figure 2.24. Wrap53β cDNA cloned in a Len3virus DNA vector. (a) Map of the Len=virus vector carrying the Wrap53β 
cDNA. mWrap53-beta in the plasmid map denotes the Wrap53β cDNA, which was cloned to carry the first intron and 
silent muta=ons that allow dis=nc=on from the transcript expressed from the endogenous gene following qPCR 
quan=fica=on. A FLAG-tag sequence was also cloned upstream of the 5’ end of Wrap53β cDNA, though it is not shown 
in the map. (b) Details of the plasmid components indicated in the map. Cloning of the plasmid was outsourced to 
AMSBIO Ltd. 
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2.5	Discussion	
2.5.1	The	TRE-p53	model	and	its	applicability		
 The TRE-p53 mouse model allows rapid and reversible switching of endogenous Trp53 
expression and func=on. Administra=on of Dox to TRE-p53 mice led to systemic repression of 
p53 within 2 - 3 days while subsequent withdrawal of Dox treatment allows re-expression of 
Trp53 in the same =meframe. Although not as rapidly as the tamoxifen-dependent switching of 
p53ERTam protein ac=vity (Christophorou et al. 2005), those animals are forced to develop in the 
absence of p53 func=on as tamoxifen causes abor=on. In contrast, the TRE-p53 model allows 
normal p53 func=on during embryogenesis, thus ruling out the poten=al effect of the 
speculated compensatory signalling during embryogenesis (Danilova et al. 2008) but retaining 
the ability to regulate p53 in adult mice. Importantly, the introduc=on of the TRE did not appear 
to have any impact on the normal regula=on of Trp53 expression in the absence of Dox but 
rendered it sensi=ve to rapid repression by rtTS in the presence of Dox. Thus the TRE-p53 
mouse model provides rapid switching of Trp53 expression. Although experiments described 
here are based on systemic toggling of p53 in all =ssues, =ssue-specific expression of rtTS can 
provide analysis of individual =ssues or cell lineages (e.g. =ssue stem cells). 
 However, one caveat with the TRE-p53 model is the co-regula=on of the closely located 
an=sense Wrap53 (see Sec3on 2.4.1). While this might be problema=c for some applica=ons of 
the model, it is unlikely to affect analyses of well defined p53-specific func=ons, including 
ac=va=on of its target genes as demonstrated by the experiments reported in Sec3on 2.3.7. 
 As described in Sec3on 2.4.2 ectopic expression of Wrap53 could be used to 
compensate for any disrup=on of Wrap53 func=ons in the presence of Dox. Alterna=vely, 
replacement of Dox-repressed endogenous Trp53 expression in the TRE-p53 mice by ectopic 
p53 expression can be used to iden=fy any effects of repressing Wrap53 alone. This can be done 
by the use of the Rosa26-p53 mouse model constructed in my host laboratory (unpublished 
data), which has the full coding sequence of a Trp53 transcript (including intron 4) knocked into 
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the cons=tu=vely and ubiquitously expressed Rosa26 locus. The in vivo and in vitro expression 
from this ectopic allele of Trp53 at both mRNA and protein level was comparable to the 
endogenous allele and able to compensate for loss of the endogenous Trp53 allele completely, 
which suggested that the transcrip=onal control and all its isoform variants are largely 
dispensable for the gene’s func=ons, and that the post-transla=onal regula=on is the arbiter of 
its ac=vity.  
2.5.2	SigniPicance	of	the	results	in	this	Chapter	
 While confirming the func=onality of the TRE system to rapidly regulate endogenous p53 
expression and func=on, these TRE-p53 mice have already revealed novel findings regarding 
p53’s expression and transcrip=onal ac=vi=es in radio-sensi=ve and radio-resistant =ssues. For 
example, previous reports using various approaches such as lacZ and eGFP reporter models to 
determine p53’s expression and func=ons in =ssues, (Komarova et al. 1997; Goh et al. 2012; 
Chen et al. 2015; Tanikawa et al. 2017) were largely confined to radio-sensi=ve =ssues, notably 
spleen and thymus. Also, these studies were based on a comparison between WT and germline 
p53-deleted animals that were likely to have exhibited a compensated phenotype resul=ng 
from aberrant expression of the other p53-family proteins p63 and p73 during embryogenesis. 
Therefore, it is not clear whether phenotypes observed in adult germline p53 knockout mice 
accurately reflect acute loss of p53 func=on in adults (that have developed in the presence of 
normal p53). Moreover, the focus on radio-sensi=ve =ssues where no=ceable changes could be 
detected may overlook the more subtle effects of p53 in other =ssues. The reported “=ssue-
specific” expression of p53 target genes including Puma, Bax and Cdkn1a in radio-sensi=ve 
=ssues observed by comparing p53-WT vs germline p53-null animals might not be accurate 
(MacCallum et al. 1996; Komarova et al. 1997; Bouvard et al. 2000; Fei et al. 2002; Fei & El-Deiry 
2003). Whereas some reports suggest p53 “selects to ac=vate” some targets but not the others, 
e.g. Puma vs Cdkn1a, in certain condi=ons and =ssues, others have inferred that p53 and its 
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pathways somehow “dictate” the outcome of DNA damage - apoptosis or growth arrest - and 
thus defining the radio-sensi=vity of individual =ssues. Experiments described in Sec3on 2.3.7 
using the TRE-p53 model cast doubt on these interpreta=ons. First, Trp53 mRNA was expressed 
in all tested =ssues (Figure 2.12, Figure 2.15, and Figure 2.17). Second, p53 was 
transcrip=onally func=onal and capable of inducing Bax, Puma and Cdkn1a, upon DNA damage 
signals in all these =ssues, irrespec=ve of whether they were categorised as radio-sensi=ve or 
not. Induc=on of these genes was p53-dependent. Despite induc=on of the pro-apopto=c genes 
Bax and Puma in all tested =ssues, radio-sensi=ve and radio-resistant alike, not all underwent 
apoptosis (IHC TUNNEL staining carried out on intes=ne, spleen, lungs, liver and skins confirmed 
that; data not shown). This is in agreement with the hypothesis that different cell types, or 
=ssues, exhibit different thresholds for apoptosis and while p53 might shiZ the equilibrium, for 
example in response to DNA damage, it is not the sole determinant of cell fate. Furthermore, as 
both apopto=c and cell cycle arrest genes were induced by p53 upon irradia=on in all =ssues 
alike, the “binary decision” between growth arrest and apoptosis is clearly dependent on cell/
=ssue contexts rather than differen=al p53 ac=vity in such contexts.  
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Although there are over 100,000 publica5ons regarding p53, we are nowhere close to 
understanding even part of its func5ons as a tumour suppressor. How exactly does p53 
dis5nguish tumorous growth from normal physiological process such as regenera5on in wound-
healing? And what is the 5ming of such func5on in tumourigenesis? Moreover, study of p53’s 
physiological func5ons such as metabolism and autophagy have long been overshadowed by 
the overwhelming interests on the tumour suppressive func5on of p53 as well as the highly 
regarded proposed role of “guardian of the genome” (Lane 1992). This is partly due to the 
limita5ons and caveats of exis5ng germline knockout and irreversible switchable mouse models 
of p53 (discussed in Chapter 1). To overcome these limita5ons and refocus to a more complete 
and comprehensive study of p53’s func5ons, the TRE-p53 mouse model that allows rapid, 
reversible and non-invasive repression of p53 was developed. Using this model, I have 
inves5gated the impact of systemic denial of p53 func5ons on normal physiology in adult mice. I 
have also designed experiments to temporally dissect the impact of p53 loss on the genesis of 
skin squamous cells carcinomas.  
 
3.1	Effect	of	systemic	p53	denial	in	adulthood	
3.1.1	Transient	p53	denial	in	adult	mice	has	no	effect	
 The results in Chapter 2 clearly show that administra5on of doxycycline (Dox) for 7 days 
silences p53 expression in Trp53TRE3/TRE3;R26CAG-rtTS/+ mice. These mice exhibited no obvious 
health issues and their body condi5on (BC) scoring and weight tracking were no different to 
untreated Trp53TRE3/TRE3;R26CAG-rtTS/+ and wild type animals. Moreover, careful post-mortem 
examina5on did not reveal any morphological abnormali5es. These results suggest that any 
physiological roles p53 plays in normal unchallenged adult 5ssues, if any, are likely too subtle to 
be revealed from the vantage point of the whole body physiological condi5on. Given majority of 
p53’s func5ons involve its transcrip5on ac5vity, these func5ons may be revealed by comparing 
the transcriptome of 5ssues from the treated and untreated (and WT) animals. 
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3.1.2	Long-term	Trp53	repression	in	adults	results	in	tumour	formation	
 The ques5on I asked here was what the impact would be when Trp53 is repressed for 
the long-term in adulthood and how the observa5ons would compare with germline p53 
knockout mice. Reported by Donehower et al. in 1992, mice with homozygous germline 
dele5on of p53 spontaneously develop tumours, usually lymphomas and thymomas. 74% of 
these mice developed tumours within 20 weeks on average (8 weeks the earliest), while no 
tumours were observed in WT mice a`er 9 months (Donehower et al. 1992). However, these 
mice lacked p53 during embryogenesis and it was unclear whether tumour forma5on results 
from loss of p53 during embryogenesis, during postnatal development or in adulthood or a 
combina5on of all three. Furthermore, any other phenotypes observed would be indica5ve of 
p53’s physiological func5ons including for example cell metabolism, mitochondrial respira5on 
and autophagy (Vousden & Ryan 2009; Matoba et al. 2006; Ryan 2011). 
 To address this ques5on, five-week old Trp53TRE3/TRE3;R26CAG-rtTS/+ and wild type mice 
were administered Dox con5nuously (or not in the case of control animals). By 6.5 months of 
Dox administra5on, five out of twelve Trp53TRE3/TRE3;R26CAG-rtTS/+ mice (Trp53-repressed) 
developed severe symptoms such as a distended abdomen and rapid breathing and were 
euthanised. Three out of these five mice showed spontaneous tumours in the spleen and 
thymus, while no tumours were detected in the other two mice. 
 In addi5on, three apparently healthy experimental Trp53TRE3/TRE3;R26CAG-rtTS/+ mice (and 
two control mice) were sacrificed for analysis a`er 6 months of Dox administra5on. Despite no 
health concerns, two out of these three Trp53TRE3/TRE3;R26CAG-rtTS/+ mice had developed a single 
thymic lymphoma of a substan5al size in their chest cavity (Figure 3.1). No other tumours or 
abnormali5es were detected and all the other organs appeared the same as in the wild type 
control animals (not shown). To confirm that Trp53 was repressed a`er 6 months of Dox 
treatment, mRNA was extracted from various 5ssues of these three mice and Trp53 mRNA 
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quan5fied by qPCR (Figure 3.2). In all 5ssues analysed, including the thymoma, Trp53 RNA 
expression was efficiently repressed. Note that no amplifica5on product of Trp53 mRNA was 
detected by qPCR on skin samples of the Dox-treated mice as the repressed mRNA level was too 
low to be detected (the rela5ve Trp53 mRNA level in skin of the non-treated mice ranged at the 
level of 10-6). 
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Figure 3.1. Autopsies revealed development of thymic lymphoma in two of the experimental mice aDer 6 
months of Dox treatment. Two experimental mice (middle and right panels) developed a single, solid 
thymoma that filled almost the en5re volume of the chest cavity. All other organs in these mice appeared 
normal without any tumour growth, so were all organs of experimental mouse #1. White pointers in the 
lower panel indicate the normal thymus (Expt mouse #1) and thymic lymphoma (Expt mouse #2 and #3). 
CHAPTER 3 
  135
Figure 3.2. Long term repression of Trp53 in Hssues. Plojed were the mean quan5fied rela5ve Trp53 mRNA level 
in 5ssues of animals being treated with Dox for 6 months (n = number of animals in the treatment groups) while 
error bars denote standard devia5on. The scale of the y-axis represen5ng rela5ve Trp53 mRNA level is not 
necessarily the same across the 5ssues. Note that the qPCR failed to detect any Trp53 mRNA in the skin of the Dox-
treated animals, though it picked up signals of Trp53 transcript at a rela5ve level range of 10-6 in the control group. 
Note that 2 out of the 3 mice treated with Dox developed thymic lymphoma, which were analysed instead of 
thymus in these animals. Primers specific to Trp53 and Tbp mRNA were used in the qPCR analysis and their details 
are listed in Table M.6b in the Methods and Materials chapter. 
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 Table 3.1 summarises the post-mortem observa5ons, symptoms and types of 
spontaneous tumours of the eight experimental mice that have been euthanised thus far. Five 
out of these eight mice developed spontaneous tumours, three with thymoma and two with 
splenic tumours. Of the remaining three mice none showed any evidence of tumours, although 
two of these mice exhibited health concerns before euthanasia. The remaining four 
experimental mice were s5ll receiving Dox treatment when this thesis was wrijen and 
appeared healthy and tumour-free. 
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Table 3.1. Summary of the euthanised mice that had received long term Dox treatment to repress Trp53
Animal	count Length	of	treatment Observations
Spontaneous	
tumours
1 16 weeks
- Enlarged/inflated intesHne 
- Otherwise normal 
- Culled sick
- None observed upon autopsy
1 16 weeks
- Moribund  
- Laboured breathing 
- Culled sick
- None observed upon autopsy
1 20 weeks - Enlarged spleen - Culled sick
- Spleen enlargement may be 
malignant
2* 24 weeks
- Appeared healthy  
- Sacrificed for analysis 
- Thymoma
- Thymoma
1* 24 weeks - Appeared healthy - Sacrificed for analysis - None observed upon autopsy
1 28 weeks - Enlarged spleen - Culled sick
- Spleen enlargement may be 
malignant
1 28 weeks
- Laboured breathing 
- InacHve 
- Thymoma  
- Culled sick
- Thymoma
* Had appeared healthy before sacrificed for analyses
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 Several conclusions can be drawn form these experiments. First, Dox was capable of 
long-term repression of p53 expression in Trp53TRE3/TRE3;R26CAG-rtTS/+ mice. This also suggests that 
there is no strong selec5on to restore p53 expression, at least in the 5ssues examined. The 
model can therefore be used in long term experiments such as in tandem with the chemically 
induced skin cancer model (see SecHon 3.3 below) (Hennings et al. 1985). Second, the 
occurrence of spontaneous tumourigenesis appeared to be consistent with observa5ons in 
germline p53 knockout mice (Donehower et al. 1992), though only a limited sample size is 
reported here. Here, five out of twelve Dox-treated mice developed spontaneous tumours in 5 - 
6.5 months, three mice with thymic lymphomas and two with splenic tumours, comparable to 
the latency and tumour spectrum observed by Donehower et al. A larger cohort of animals is 
needed to confirm these ini5al observa5ons. Lastly, that no overt phenotype (other than 
spontaneous tumourigenesis) was observed in these mice suggests that any effect of p53 loss 
on normal physiological processes, if it exists, was too subtle to be discerned from gross 
anatomy. Detailed microscopic analysis will be required to determine such subtle effects. 
Likewise, transcriptomic analysis of 5ssues samples following both short-term and long-term 
Dox treatment may be informa5ve. 
3.2	Assessment	of	Trp53’s	roles	in	early	stage	skin	cancer	
 Despite p53’s undeniable role in tumour suppression, it is s5ll unclear when p53 is lost 
during tumourigenesis. For example, loss of p53 delays the forma5on of carcinogen-induced 
skin papillomas (Kemp et al. 1993). These, perhaps counter-intui5ve, results suggest that 
reten5on of p53 in, at least some, proto- and nascent tumour cells is beneficial and is consistent 
with the observa5on that p53 inac5va5on is o`en associated with late stages of human cancers 
(Vogelstein et al. 1988; Ohue et al. 1994; Leslie et al. 2002). Why is Trp53 not inac5vated from 
the onset of tumourigenesis but in late stages? One possibility is that the oncogenic signals that 
trigger p53 (and would thereby normally engage tumour suppression) arise only at later stages 
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of tumour evolu5on and so there is no selec5ve advantage to inac5vate p53 present in nascent 
tumours. Alterna5vely, perhaps p53 confers some growth and/or survival advantage to early 
cancer cells that are likely to experience considerable stresses, both intracellular and micro-
environmental. This no5on is consistent with emerging roles of p53 in a range of physiological 
func5ons including regula5on of cell metabolism, mitochondrial respira5on and autophagy 
(Vousden & Ryan 2009; Matoba et al. 2006; Ryan 2011). Hence, reten5on of p53 physiological 
func5ons may be beneficial for nascent tumour cells to survive and proliferate amid various 
stresses associated with oncogenesis. Moreover, over half of the p53 pathway-inac5va5ng 
muta5ons in human cancers spare p53 func5on but inac5vate upstream or downstream 
components of the p53 tumour suppression pathway - poten5ally leaving some p53 func5ons 
intact (Junrla & Evan 2009). The ability to rapidly and reversibly regulate expression of 
endogenous p53 in Trp53TRE3/TRE3;R26CAG-rtTS/+ mice provides an ideal experimental plasorm to 
determine when and how p53 (or its inac5va5on) is required for carcinogen-induced skin 
papillomas and their subsequent transi5on to squamous cell carcinoma. 
3.2.1	Temporal	dissection	of	Trp53	function	in	chemically	induced	skin	cancer	
 Pending the genera5on of Trp53TRE3/TRE3;R26CAG-rtTS/+ mice, I inves5gated the role of p53 
in early stage skin cancer using a Cre recombinase-dependent condi5onal p53 knockout mouse 
model, p53flox (Jonkers et al. 2001). The p53flox model has two advantages over germline p53-
null models. First, inac5va5on of the Trp53 gene can be induced at any 5me via tamoxifen-
dependent ac5va5on of CreERT2 recombinase. Second, 5ssue-specific inac5va5on of Trp53 can 
be achieved by restric5ng CreERT2 expression via the K14 promoter to stratum basale of skin 
such as the inter-follicular epidermis (IFE) and the follicle bulge (FB) stem cells where chemically 
induced skin cancer originates (Vasioukhin et al. 1999; Lapouge et al. 2011; Abel et al. 2009). 
The chemically induced skin carcinogenesis model used in conjuga5on with the p53flox model 
allowed visual monitoring of skin cancer development with or without Trp53 inac5va5on. 
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 Prior to the skin cancer experiment, the efficiency and cell type-specificity of Trp53 
inac5va5on by CreERT2 was assessed. Five-week old Trp53flox/flox and Trp53flox/flox;K14-CreERTg/+ 
mice were treated with tamoxifen via Intraperitoneal (IP) injec5on for 5 consecu5ve days (1 mg 
per mouse per day) and then irradiated with 5-Gy of γ-irradia5on. Dorsal skin samples were 
collected in 10% formalin 5 hours post irradia5on and p53 protein expression in these samples 
was determined by immunofluorescence (IF) staining of 5ssue sec5ons (Figure 3.3a). The IF 
staining clearly demonstrates significantly fewer p53-posi5ve IFE and FB stem cells in tamoxifen 
treated animals, sugges5ng that Trp53 had been excised in the majority of these cells (Figure 
3.3b). However, the small number of p53-posi5ve cells in the tamoxifen-treated Trp53flox/
flox;K14-CreERTg/+ animals, indicates incomplete penetrance of CreERT2-mediated p53 excision. 
 I first ajempted to recapitulate the experiments reported by Kemp et al. Thus, five-week 
old Trp53flox/flox;K14-CreERTg/+ and control Trp53flox/flox (Trp53 allele intact) mice received daily IP 
injec5on of tamoxifen for 5 consecu5ve days (1 mg per mouse per day). One week later 100 μg 
of the ini5a5ng agent 7,12-dimethylbenz[a]anthracene (DMBA) was topically administered to 
the shaved dorsal skin of all the mice. One week a`er DMBA administra5on, the promo5ng 
agent 12-O-tetradecanoylphorbol-13-acetate (TPA) was topically applied to the same dorsal 
area of the skin on every Monday, Wednesday and Friday for 18 weeks (5 μg per mouse per 
dose). Figure 3.4a illustrates the 5meline of this experiment. Emergence of lesions on the 
treated dorsal skin was monitored and the total number of tumours a`er 18 weeks of TPA 
treatment is shown in Figure 3.4b.  
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Figure 3.3. InacHvaHon of Trp53 by Tam-acHvated CreERT2 expressed in IFE and FB stem cells. (a) p53 
expression in the nuclei of the IFE and FB cells was probed by IF staining with α-p53 an5body (CM5, Leica) 
and the total nuclei were visualised with Hoechst staining. Red pointers in the bojom panel indicate 
autofluorescence signals (e.g. from hair in follicles). Details of the an5bodies used are listed in Table M.10 in 
the Methods and Materials chapter. (b) Propor5on of p53-posi5ve nuclei post-irradia5on over total nuclei 
was quan5fied in the IF-stained skin sec5ons. Two sec5ons from each animal were counted and the 
percentage averaged. Plojed is the mean value of % of p53-posi5ve nuclei in the sec5ons of the two animal 
and the error bars denote standard devia5on. An unpaired t-test was used to assess the significance of the 
observed difference.
CHAPTER 3 
  141
Figure 3.4. Cell type-specific knockout of Trp53 by inducible CreERT2 hampered chemically induced skin SCC. (a) 
Timeline of the experiment. (b) Each dot represents the number of tumours on the dorsal skin of a mouse a`er 18 
weeks of TPA treatment. p53 status of the skin basal layer (and thus tumours) of Trp53fl/fl and Trp53flox/flox;K14-CreERTg/+ 
was WT and null respec5vely a`er IP injec5on with Tam. The mean values of the genotype groups are shown with the 
standard devia5ons as error bar. A One-way ANOVA test was used to evaluate the sta5s5cal significance between the 
two groups and the p-value is indicated (***: p = 0.0007). 
CHAPTER 3 
 These data clearly demonstrate that mice in which Trp53 was deleted by CreERT2 in cells 
of the stratum basale developed fewer tumours compared to mice that retained intact Trp53 
before chemical induc5on of skin cancer. These findings, in agreement with Kemp CJ et al, 
implied that some func5ons of p53 are advantageous in papilloma genesis. Despite the 
apparent contradic5on to the protein’s prominent role as a tumour suppressor, the implica5on 
is understandable considering p53 tumour suppression was not engaged un5l late stage of 
tumorigenesis by a high level of oncogenic signals (Mar5ns et al. 2006; Xue et al. 2007; Ventura 
et al. 2007; Feldser et al. 2010; Junrla & Evan 2009). Un5l that threshold is reached, other 
func5ons of p53 may promote survival of aberrantly prolifera5ng (pre-)tumour cells by, for 
example, coping with transient metabolic stresses such as oxida5ve stresses and depriva5on of 
nutrient, oxygen or growth factors and thus allowing adapta5on and maintaining homeostasis 
(Humpton & Vousden 2016; Labuschagne et al. 2018). This interes5ng hypothesis had begun to 
gain more ajen5on recently but had not yet been properly inves5gated in a tumorigenesis 
serng. In the following experiments, I further test this hypothesis using the skin carcinogenesis 
model. 
 I first ajempted to pinpoint the period during which reten5on of p53 promotes 
papilloma genesis. This was achieved by delaying the inac5va5on of Trp53 to different 
5mepoints before papilloma emergence. I began with the 5mepoint of inac5va5ng Trp53 
immediately a`er DMBA ini5a5on. In this experiment, five-week old Trp53flox/flox;K14-CreERTg/+ 
and control Trp53flox/flox mice were treated first with DMBA by topical applica5on on the dorsal 
skin, followed by IP injec5ons of Tam 1 week later and then topical administra5on of TPA began 
for 18 weeks. Other than the reverse order of p53 inac5va5on and ini5a5on by DMBA, the dose 
of chemicals used and treatment regime for this cohort of mice remained the same as the 
previous experiment. Figure 3.5a illustrates the 5meline of this experiment. The number of 
papillomas a`er 18 weeks of TPA treatment is shown in Figure 3.5b and it appears that there 
was no difference in tumour emergence rate between the WT and Trp53-inac5vated groups. 
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This result implies that the pro-survival func5ons of p53, whatever they are, only confers the 
survival and/or growth advantage to papilloma genesis in the ini5a5on stage.  
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Figure 3.5. InacHvaHon of Trp53 aDer the iniHaHon by DMBA appeared not to confer a survival and/or growth 
advantage for papilloma development. (a) Timeline of the experiment. (b) Each dot represents the number of tumours 
on the dorsal skin of a mouse a`er 18 weeks of TPA treatment. p53 status of the skin basal layer (and thus tumours) of 
Trp53flox/flox and Trp53flox/flox;K14-CreERTg/+ was WT and null respec5vely a`er IP injec5on with Tam. The mean values of 
the genotype groups are shown with the standard devia5ons as error bar. A One-way ANOVA test was used to evaluate 
the sta5s5cal significance between the two groups and the p-value is indicated (ns = non significant). 
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 Although this serng with the p53flox model proved useful in finding out the star5ng 
point from which reten5on of p53 func5ons are important to skin cancer genesis, its 
irreversibility does not allow assessment of how long these func5ons will remain important 
along the trajectory of skin cancer evolu5on. The excision of Trp53flox alleles by CreERT2 was also 
shown not to be fully penetrant in the target cells. Moreover, the use of a Cre recombinase had 
been proven to inflict significant DNA damage to recipient cells (Janbandhu et al. 2014) and 
would likely introduce noise and varia5ons to analyses of the supposedly subtler and more 
transient func5ons of p53. The TRE-p53 model, on the other hand, can circumvent these issues 
and address the ques5on properly and therefore was used from this stage on. 
3.2.2	ReHined	temporal	dissection	of	Trp53’s	roles	in	chemically	induced	SCC	
 To address the ques5ons with a cleaner and more refined approach, TRE-p53 was used 
in conjunc5on with the chemically induced skin cancer model. The ra5onale of the experiments 
in terms of p53 inac5va5on is the same as with the p53flox model, except the inac5va5on is 
achieved by repression by the TRE system upon Dox treatment and is reversible upon Dox 
withdrawal. Figure 3.6 illustrates the different 5melines in which Trp53 would be repressed by 
Dox to address the ques5ons. Timeline (a) and (b) are the exact analogs of the experiment 
conducted in SecHon 3.2.1 (Figure 3.4 and Figure 3.5 respec5vely) and were included to 
confirm the func5on of the TRE-p53 system behaviour in comparison to the p53flox model. 
Timeline (c) denotes the first of a series of experimental 5melines in which Trp53 is repressed 
specifically at different windows in papilloma genesis. These will unveil the exact period in 
which the pro-survival func5ons of p53 concerned is important for papilloma genesis. Detailed 
analysis of p53 func5on, including transcrip5onal and metabolic responses in lesions and 5ssues 
collected from these animals will be used to determine the “pro-tumour” ac5vity of p53 in early 
lesion development. Depending on the results from 5meline (c), the involvement of these 
func5ons of p53 at more advanced stages of skin cancer development can also be inves5gated 
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Figure 3.6. More flexible repression of Trp53 by the TRE system allows more experiments of various 
Hmelines to address different quesHons. Timelines (a), (b) and (c) are ongoing while (d) will be conducted 
a`er results from Sec5on 3.2.1 and (a) - (c) are analysed.
CHAPTER 3 
by, for example, briefly repressing Trp53 in adenocarcinoma or carcinoma and assessing the 
immediate impact. Timeline (d) illustrates this experiment. This is to assess whether these “pro-
tumour” func5ons of p53, if indeed advantageous for early stage lesions, will con5nue to be 
beneficial throughout tumorigenesis and at which point they will be outweighed by the 
protein’s tumour suppression func5on.  
 At the 5me of wri5ng this thesis, experiments described in Figures 3.6 (a), (b) and (c) are 
ongoing. When the results form these experiments are analysed, further experiments will be 
designed and conducted. 
3.2.3	Does	p53	play	a	similar	role	in	other	cancers?	
 Though frequently mutated in human cancers, the majority of the muta5ons found in 
TP53 are missense muta5ons rather than nonsense or frameshi` muta5ons that are o`en 
found in the other tumour suppressor genes such as RB and APC (Leslie et al. 2002; Soussi 
2005). One possible reason for this is that such missense muta5ons while inac5va5ng p53’s 
tumour suppressor role retains at least some of its stress response ac5vity, for example, in 
nascent tumour cells. However, there is no direct evidence for this, partly since most 
experiments have been focused on the role of p53 in tumour suppression. In the murine 
KrasG12D-driven model of lung cancer, for example, inves5gators modelled the human diseases 
by inac5va5ng Trp53 from the onset (Jackson et al. 2005). Though this yielded tumours of late 
stages that resembled the human disease at an equivalent stage, it likely shortcuts the 
development of the early stage tumour during which p53 might have contributed pro-survival 
and/or growth func5ons and thus is retained. The preliminary data presented in SecHon 3.2 
suggests that p53 does indeed influence the development and progression of early skin 
papillomas. While the p53-dependent “pro-tumour” mechanisms are unclear, it will be 
important to determine whether this is a common feature of early tumours other than those 
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induced by chemical carcinogenesis in the skin. Precise temporal regula5on of p53 expression 
afforded by the TRE-p53 model will be invaluable in this pursuit. 
 Coupled with different mouse tumour models such as the lung KrasG12D model, the TRE-
p53 system can be used to address the ques5on with a similar approach as in SecHon 3.2. 
However, another ini5al parameter is needed to assess the effect of Trp53 inac5va5on in early 
lesions of these tumour models as tumour progression cannot be visually monitored.  
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OVERALL CONCLUSION 
This project was set out to address ques5ons regarding physiological and tumourigenic 
func5ons of p53 that had not been properly addressed due to the limita5ons of the exis5ng in 
vivo model of p53. To achieve such aim, I have built a novel switchable gene5c mouse model of 
p53, TRE-p53, which allows rapidly reversible repression of the gene on transcrip5on level. 
More specifically, when the repression system is not ac5vated, Trp53TRE expression is no 
different from wild type in vivo while repression of Trp53TRE expression to over 98 - 99% is 
efficiently achieved when the repression system is ac5vated through administra5on of Dox. 
 In Chapter 2, the in vivo experiments conducted using the model showed that p53 is 
expressed and func5onal as mediator of DNA damage response, transcrip5onally ac5va5ng Bax, 
Puma and Cdkn1a, in response to whole-body γ-radia5on in different 5ssues.  
 In Chapter 3, short-term systemic repression of p53 using the TRE-p53 model revealed 
no significant impact on the physiology of adult mouse. On the other hand, long-term systemic 
repression of p53 in adult mouse led to suscep5bility towards tumourigenesis, despite no other 
physiological symptoms were observed. The spectrum and latency of tumours developed 
mirrored that of the germline p53-null mice (Donehower et al. 1992). Using the p53Flox model in 
conjunc5on with the chemically induced skin squamous cell carcinoma model, I confirmed that 
the absence of p53 impedes papilloma development triggered by the chemical carcinogen 
DMBA/TPA, in agreement with the Kemp report published in the 90s (Kemp et al. 1993). 
 In the future, the TRE-p53 model will be used to address more ques5ons about the 
biology of p53 such as its less understood role in 5ssue homeostasis, autophagy and metabolic 
regula5on. I also aim to address the fundamental ques5ons regarding p53 in tumourigenesis, 
including in par5cular whether p53 inac5va5on is a driver muta5on in tumorigenesis or a 
merely muta5on-permissive event as well as what p53 ac5va5ng signals, if any, are present in 
tumours that develop without p53. Answers to these ques5ons will provide valuable insights to 
further understanding of p53’s func5ons in normal physiology and carcinogenesis.  
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